10% of people >65 years old; >30% of people >85 years old); anxiety (4%); and depression (lifetime incidence 2%-15%; one year prevalence 3%).
Prospective research is needed to establish (1) the prevalence and severity of chronic symptoms that pre-date the diagnosis of a life-limiting illness in people referred to hospice/palliative care services, comparing this to whole-of-population estimates; and (2) whether this group is disproportionately represented in people with refractory symptoms.
C1 [Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Discipline Serv, Bedford Pk, SA 5042, Australia.
[Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Palliat Serv, Bedford Pk, SA 5042, Australia.
[Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Support Serv, Bedford Pk, SA 5042, Australia.
[Currow, David C.] Repatriat Gen Hosp, Southern Adelaide Palliat Serv, Daw Pk, SA, Australia.
[Clark, Katherine] Calvary Mater Hlth Care, Palliat Care Dept, Waratah, NSW, Australia.
[Clark, Katherine] Univ Newcastle, Callaghan, NSW 2308, Australia.
[Kamal, Arif] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC USA.
[Agar, Meera R.] Braeside Hosp, HammondCare, Braeside, NSW, Australia.
[Lovell, Melanie R.; Phillips, Jane L.] Greenwich Hosp, HammondCare, Greenwich, NSW, Australia.
[Lovell, Melanie R.; Phillips, Jane L.] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia.
[Phillips, Jane L.] Univ Technol Sydney, Ultimo, Sydney, NSW 2007, Australia.
[Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ritchie, Christine] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Currow, DC (reprint author), Flinders Univ S Australia, Palliat & Support Care Dept, Daw Pk, SA 5041, Australia.
EM david.currow@health.sa.gov.au
NR 33
TC 2
Z9 2
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 1
PY 2015
VL 18
IS 6
BP 480
EP 485
DI 10.1089/jpm.2014.0444
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CI2WJ
UT WOS:000354608100003
PM 25859908
ER
PT J
AU Smith, G
Bernacki, R
Block, SD
AF Smith, Grant
Bernacki, Rachelle
Block, Susan D.
TI The Role of Palliative Care in Population Management and Accountable
Care Organizations
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; CODE STATUS DOCUMENTATION; CELL
LUNG-CANCER; QUALITY-OF-LIFE; HEALTH-CARE; ADVANCE DIRECTIVES; SURPRISE
QUESTION; DIALYSIS PATIENTS; PANEL MANAGEMENT; COST SAVINGS
AB By 2021, health care spending is projected to grow to 19.6% of the GDP, likely crowding out spending in other areas. The 2010 Affordable Care Act (ACA) attempts to curb health care spending by incentivizing high-value care through the creation of Accountable Care Organizations (ACOs), which assume financial risk for patient outcomes. With this financial risk, health systems creating ACOs will be motivated to pursue innovative care models that maximize the value of care. Palliative care, as an emerging field with a growing evidence base, is positioned to improve value in ACOs by increasing high-quality care and decreasing costs for the sickest patients. ACO leaders may find palliative care input valuable in optimizing high-quality patient-centered care in the accountable care environment; however, palliative care clinicians will need to adopt new models that extrapolate their direct patient care skills to population management strategies. We propose that palliative care specialists take on responsibilities for working with ACO leaders to broaden their mission for systemwide palliative care for appropriate patients by prospectively identifying patients with a high risk of death, high symptom burden, and/or significant psychosocial dysfunction, and developing targeted, "triggered" interventions to enhance patient-centered, goal-consistent, coordinated care. Developing these new population management competencies is a critical role for palliative care teams in the ACO environment.
C1 [Smith, Grant; Bernacki, Rachelle; Block, Susan D.] Harvard Univ, Sch Med, Boston, MA USA.
[Smith, Grant; Bernacki, Rachelle; Block, Susan D.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
[Bernacki, Rachelle; Block, Susan D.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Block, Susan D.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Smith, Grant; Bernacki, Rachelle; Block, Susan D.] Ariadne Labs, Boston, MA USA.
[Bernacki, Rachelle; Block, Susan D.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA.
RP Bernacki, R (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, D2020 450 Brookline Ave, Boston, MA 02115 USA.
EM rbernacki@partners.org
FU Geriatric Academic Career Award [K01HP20462]
FX The authors have no conflicts of interest to disclose. Dr. Bernacki is
supported by Geriatric Academic Career Award K01HP20462.
NR 72
TC 5
Z9 5
U1 3
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 1
PY 2015
VL 18
IS 6
BP 486
EP 494
DI 10.1089/jpm.2014.0231
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CI2WJ
UT WOS:000354608100004
PM 25723619
ER
PT J
AU Kvale, E
Dionne-Odom, JN
Redden, DT
Bailey, FA
Bakitas, M
Goode, PS
Williams, BR
Haddock, KS
Burgio, KL
AF Kvale, Elizabeth
Dionne-Odom, J. Nicholas
Redden, David T.
Bailey, F. Amos
Bakitas, Marie
Goode, Patricia S.
Williams, Beverly R.
Haddock, Kathlyn Sue
Burgio, Kathryn L.
TI Predictors of Physical Restraint Use in Hospitalized Veterans at End of
Life: An Analysis of Data from the BEACON Trial
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID NURSING-HOME RESIDENTS; SMALL-SAMPLE ADJUSTMENTS; INTENSIVE-CARE-UNIT;
OLDER PATIENTS; ESTIMATOR; SETTINGS; DELIRIUM; HEALTH; ADULTS
AB Background: The use of physical restraints in dying patients may be a source of suffering and loss of dignity. Little is known about the prevalence or predictors for restraint use at end of life in the hospital setting.
Objective: The objective was to determine the prevalence and predictors of physical restraint use at the time of death in hospitalized adults.
Methods: Secondary analysis was performed on data from the "Best Practices for End-of-Life Care for Our Nation's Veterans" (BEACON) trial conducted between 2005 and 2011. Medical record data were abstracted from six Veterans Administration Medical Centers (VAMCs). Data on processes of care in the last seven days of life were abstracted from the medical records of 5476 who died in the six VAMCs. We prospectively identified potential risk factors for restraint use at the time of death from among the variables measured in the parent trial, including location of death, medications administered, nasogastric tube, intravenous (IV) fluids, family presence, and receipt of a palliative care consultation.
Results: Physical restraint use at time of death was documented in 890 decedents (16.3%). Restraint use varied by location of death, with patients in intensive settings being at higher risk. Restraint use was significantly more likely in patients with a nasogastric tube and those receiving IV fluids, benzodiazepines, or antipsychotics.
Conclusions: This is the first study to document that one in six hospitalized veterans were restrained at the time of death and to identify predictors of restraint use. Further research is needed to identify intervention opportunities.
C1 [Kvale, Elizabeth; Redden, David T.; Bailey, F. Amos; Bakitas, Marie; Goode, Patricia S.; Williams, Beverly R.; Burgio, Kathryn L.] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL USA.
[Kvale, Elizabeth; Bailey, F. Amos; Goode, Patricia S.; Williams, Beverly R.; Burgio, Kathryn L.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL 35294 USA.
[Dionne-Odom, J. Nicholas; Bakitas, Marie] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA.
[Redden, David T.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Haddock, Kathlyn Sue] William Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA.
RP Kvale, E (reprint author), Univ Alabama Birmingham, CH19 Suite 301, Birmingham, AL 35294 USA.
EM EKvale@uabmc.edu
OI Bakitas, Marie/0000-0002-2913-2053
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research and Development
Service [IIR 03-126]; VA Birmingham/Atlanta Geriatric Research,
Education and Clinical Center; UAB Cancer Prevention and Control
Training Program [5R25CA047888]
FX This research was supported by a merit review grant from the Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, Health Services Research and Development Service (IIR
03-126 "Intervention to Improve Care at Life's End in VA Medical
Centers;" PI: KL Burgio, Co-PI: FA Bailey) and the VA Birmingham/Atlanta
Geriatric Research, Education and Clinical Center. Dr. Dionne-Odom is a
postdoctoral fellow supported by the UAB Cancer Prevention and Control
Training Program (5R25CA047888).
NR 42
TC 3
Z9 3
U1 3
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 1
PY 2015
VL 18
IS 6
BP 520
EP 526
DI 10.1089/jpm.2014.0354
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CI2WJ
UT WOS:000354608100009
PM 25927909
ER
PT J
AU Kamal, AH
Nipp, RD
Bull, J
Stinson, CS
Abernethy, AP
AF Kamal, Arif H.
Nipp, Ryan D.
Bull, Janet
Stinson, Charles S.
Abernethy, Amy P.
TI Symptom Burden and Performance Status among Community-Dwelling Patients
with Serious Illness
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID PALLIATIVE CARE; ADVANCED CANCER; HOSPICE
AB Background: Predicting when burdensome symptoms will arise or worsen is important to preserving quality of life in patients with serious illness.
Objectives: We explored the relationship between prevalence and severity of symptoms and underlying performance status.
Methods: We performed a retrospective cohort analysis of patients receiving community palliative care, investigating relationships between symptom burden and performance status. Patient data were obtained from the Carolinas Palliative Care Consortium Database, a central registry of community consultation data for research and quality improvement. We measured symptom prevalence and severity using the McCorkle Symptom Distress Scale and performance status using the Palliative Performance Scale.
Results: We analyzed data of 4994 patients, most (90%) with noncancer, serious illnesses. Thirty percent had one or more moderate/severe symptoms. In addition to identifying the high prevalence of fatigue and pain, we found distinct groupings of symptoms with high burden associated with different levels of performance status. This includes high prevalence of fatigue, anorexia, and dyspnea in patients with high performance. Patients with low performance status, however, reported more pain, depression, and constipation.
Conclusion: Bothersome symptoms change as patients' performance status worsens. Using performance status as a common language, both medical professionals and informal caregivers can monitor impending changes in symptom burden. This should inform development of community-based delivery systems to detect and manage distress in patients with palliative care needs.
C1 [Kamal, Arif H.; Abernethy, Amy P.] Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC USA.
[Nipp, Ryan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Bull, Janet] Four Seasons, Flat Rock, NC USA.
[Stinson, Charles S.] Novant Hlth, Forsyth Med Ctr Palliat Care, Winston Salem, NC USA.
RP Kamal, AH (reprint author), Duke Univ, Med Ctr, Box 3436, Durham, NC 27710 USA.
EM arif.kamal@duke.edu
FU AHRQ HHS [R18 HS022763]
NR 9
TC 3
Z9 3
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 1
PY 2015
VL 18
IS 6
BP 542
EP 544
DI 10.1089/jpm.2014.0381
PG 3
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CI2WJ
UT WOS:000354608100012
PM 25789759
ER
PT J
AU Smith, AK
Jain, N
Wallhagen, ML
AF Smith, Alexander K.
Jain, Nelia
Wallhagen, Margaret L.
TI Hearing Loss in Palliative Care
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Editorial Material
ID QUALITY-OF-LIFE; SERVICES TASK-FORCE; OLDER-ADULTS; LONGITUDINAL
ANALYSIS; UNITED-STATES; AID USE; IMPAIRMENT; PREVALENCE; IMPACT; DEAF
AB Background: Age-related hearing loss is remarkably common, affecting more than 60% of adults over the age of 75. Moreover, hearing loss has detrimental effects on quality of life and communication, outcomes that are central to palliative care. Despite its high prevalence, there is remarkably little written on the impact of hearing loss in the palliative care literature.
Objective: The objective was to emphasize its importance and the need for further study. We use a case as a springboard for discussing what is known and unknown about the epidemiology, presentation, screening methodologies, and treatment strategies for age-related hearing loss in palliative care.
Discussion: The case describes a 65-year-old man with acute myelogenous leukemia (AML) that has progressed despite treatment. No concerns are raised about communication challenges during conversations between the palliative care team and the patient in his quiet room. However, in the midst of a family meeting, shortly after discussing prognosis, the patient reports that he cannot hear what anyone is saying.
Conclusion: We describe simple methods of screening patients for hearing loss, and suggest that practical approaches should be used universally in patient encounters. These include facing the patient, pitching one's voice low, using a pocket talker, and creating a hearing-friendly environment when planning a family or group meeting.
C1 [Smith, Alexander K.; Jain, Nelia] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Wallhagen, Margaret L.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Smith, Alexander K.; Jain, Nelia] Vet Affairs Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA.
RP Smith, AK (reprint author), San Francisco VA Med Ctr, UCSF Div Geriatr, 4150 Clement St 181G, San Francisco, CA 94121 USA.
EM aksmith@ucsf.edu
FU NIA NIH HHS [1K23AG040772, K23 AG040772]; NIDCD NIH HHS [R33 DC011510,
R33DC011510]
NR 29
TC 3
Z9 3
U1 3
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 1
PY 2015
VL 18
IS 6
BP 559
EP 562
DI 10.1089/jpm.2014.0367
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CI2WJ
UT WOS:000354608100018
PM 25867966
ER
PT J
AU Zheng, C
Zhou, XH
AF Zheng, Cheng
Zhou, Xiao-Hua
TI Causal mediation analysis in the multilevel intervention and
multicomponent mediator case
SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL
METHODOLOGY
LA English
DT Article
DE Causal inference; Generalized estimating equation; Mediation analysis
ID SENSITIVITY-ANALYSIS; HETEROGENEITY; INVENTORY; MODELS
AB Mediation analysis is an important tool in social and medical sciences as it helps to understand why an intervention works. The commonly used approach, given by Baron and Kenny, requires the strong assumption sequential ignorability' to yield causal interpretation. Ten Have and his colleagues proposed a rank preserving model to relax this assumption. However, the rank preserving model is restricted to the case with binary intervention and single mediator and needs another strong assumption rank preserving'. We propose a new model that can relax this assumption and can handle both multilevel intervention and multicomponent mediators. As an estimating-equation-based method, our model can handle both correlated data with the generalized estimating equation and missing data with inverse probability weighting. Finally, our method can also be used in many other research settings, using mathematical models similar to mediation analysis, such as treatment compliance and post-randomized treatment component analysis. For the causal mediation model proposed, we first show identifiability for the parameters in the model. We then propose a semiparametric method for estimating the model parameters and derive asymptotic results for the estimators proposed. Simulation shows good performance for the proposed estimators in finite sample sizes. Finally, we apply the method proposed to two real world clinical studies: the college student drinking study, and the Improving mood promoting access to collaborative treatment for late life depression' study.
C1 [Zheng, Cheng; Zhou, Xiao-Hua] Univ Washington, Seattle, WA 98195 USA.
[Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, H-655E,Hlth Sci Bldg,1705 North East Pacific St, Seattle, WA 98195 USA.
EM azhou@uw.edu
FU US Department of Veterans Affairs, Veterans Affairs Health
Administration, Research Career Scientist award [RCS 05-196]
FX We thank Jurgen Unutzer and the 'Improving model promoting access to
collaborative treatment' team for providing us with the data set and we
thank David Atkins and the Center for the Study of Health and Risk
Behaviors team for providing us with the college student drinking data
set. The views that are expressed in this paper are those of the authors
and do not neccssarily represent the views of the Department of Veterans
Affairs. Dr Zhou's work was supported in part by a US Department of
Veterans Affairs, Veterans Affairs Health Administration, Research
Career Scientist award (RCS 05-196).
NR 26
TC 2
Z9 2
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1369-7412
EI 1467-9868
J9 J R STAT SOC B
JI J. R. Stat. Soc. Ser. B-Stat. Methodol.
PD JUN
PY 2015
VL 77
IS 3
BP 581
EP 615
DI 10.1111/rssb.12082
PG 35
WC Statistics & Probability
SC Mathematics
GA CI0ES
UT WOS:000354409800002
ER
PT J
AU Franzosa, EA
Hsu, T
Sirota-Madi, A
Shafquat, A
Abu-Ali, G
Morgan, XC
Huttenhower, C
AF Franzosa, Eric A.
Hsu, Tiffany
Sirota-Madi, Alexandra
Shafquat, Afrah
Abu-Ali, Galeb
Morgan, Xochitl C.
Huttenhower, Curtis
TI Sequencing and beyond: integrating molecular 'omics' for microbial
community profiling
SO NATURE REVIEWS MICROBIOLOGY
LA English
DT Review
ID HUMAN GUT; INTESTINAL MICROBIOTA; GENE-EXPRESSION; PATHWAY/GENOME
DATABASES; METAGENOMIC ANALYSIS; FUNCTION PREDICTION; METABOLIC
PATHWAYS; GENOME ANNOTATION; PROTEIN FAMILIES; SARGASSO SEA
AB High-throughput DNA sequencing has proven invaluable for investigating diverse environmental and host-associated microbial communities. In this Review, we discuss emerging strategies for microbial community analysis that complement and expand traditional metagenomic profiling. These include novel DNA sequencing strategies for identifying strain-level microbial variation and community temporal dynamics; measuring multiple 'omic' data types that better capture community functional activity, such as transcriptomics, proteomics and metabolomics; and combining multiple forms of omic data in an integrated framework. We highlight studies in which the 'multi-omics' approach has led to improved mechanistic models of microbial community structure and function.
C1 [Franzosa, Eric A.; Hsu, Tiffany; Shafquat, Afrah; Abu-Ali, Galeb; Morgan, Xochitl C.; Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Franzosa, Eric A.; Hsu, Tiffany; Sirota-Madi, Alexandra; Morgan, Xochitl C.; Huttenhower, Curtis] Broad Inst, Cambridge, MA 02142 USA.
[Sirota-Madi, Alexandra] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Sirota-Madi, Alexandra] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Huttenhower, C (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
EM chuttenh@hsph.harvard.edu
OI Morgan, Xochitl/0000-0002-6264-6961
FU US National Institutes of Health [R01HG005969, U54DK102557]; US National
Science Foundation [DBI-1053486]; US Army Research Office
[W911NF-11-1-0473]; Danone Research grant [PLF-5972-GD]
FX This work was funded in part by US National Institutes of Health grants
R01HG005969 and U54DK102557 (to C. H. and R. J. Xavier); US National
Science Foundation grant DBI-1053486 (to C. H.); US Army Research Office
grant W911NF-11-1-0473 (to C. H.); and Danone Research grant PLF-5972-GD
(to W. S. Garrett).
NR 119
TC 54
Z9 56
U1 30
U2 158
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1740-1526
EI 1740-1534
J9 NAT REV MICROBIOL
JI Nat. Rev. Microbiol.
PD JUN
PY 2015
VL 13
IS 6
BP 360
EP 372
DI 10.1038/nrmicro3451
PG 13
WC Microbiology
SC Microbiology
GA CI1YP
UT WOS:000354541500009
PM 25915636
ER
PT J
AU Wininger, M
Williams, DJ
AF Wininger, Michael
Williams, David J.
TI More with less: A comparative kinematical analysis of Django Reinhardt's
adaptations to hand injury
SO PROSTHETICS AND ORTHOTICS INTERNATIONAL
LA English
DT Article
DE Guitar; kinematics; Django; Django Reinhardt
AB Background: At the age of 18 years, jazz guitarist Django Reinhardt (1910-1953) sustained significant burns to his left-hand ring and little fingers; yet, subsequently, he relearned to play and achieved international fame, despite his injuries.
Case description and methods: Archive film footage and novel motion analysis software were used to compare movements of Django's fretting hand with that of six other guitarists of the same genre.
Findings and outcomes: Django employed greater abduction of index and middle fingers (-9.11 6.52 degrees vs -5.78 2.41 degrees; p < 0.001) and more parallel alignment of fingers to the guitar neck (157.7 +/- 3.37 degrees vs 150.59 +/- 2.67 degrees; p < 0.001) compared to controls.
Conclusion: In response to debilitating hand injury, Django developed quantifiable compensatory adaptation of function of his remaining functional fingers by developing an original playing technique.
Clinical relevance Hand function following injury may be optimized by maximizing latent degrees of freedom in remaining digits, rather than through extensive surgical reconstruction or complex prostheses. Further study of adaptation strategies may inform prosthesis design.
C1 [Wininger, Michael] Univ Hartford, Prosthet & Orthot Program, Hartford, CT 06117 USA.
[Wininger, Michael] US Dept Vet Affairs, VA Cooperat Studies Program, Hartford, CT USA.
[Williams, David J.] Morriston Hosp ABMU NHS Trust, Welsh Ctr Burns, Dept Anaesthet, Swansea, W Glam, Wales.
RP Wininger, M (reprint author), Univ Hartford, 200 Bloomfield Ave, Hartford, CT 06117 USA.
EM wininger@hartford.edu
NR 18
TC 0
Z9 0
U1 6
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0309-3646
EI 1746-1553
J9 PROSTHET ORTHOT INT
JI Prosthet. Orthot. Int.
PD JUN
PY 2015
VL 39
IS 3
BP 238
EP 243
DI 10.1177/0309364614523173
PG 6
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA CI1AT
UT WOS:000354473000009
PM 24570018
ER
PT J
AU Fox, AB
Quinn, DM
AF Fox, Annie B.
Quinn, Diane M.
TI Pregnant Women at Work: The Role of Stigma in Predicting Women's
Intended Exit From the Workforce
SO PSYCHOLOGY OF WOMEN QUARTERLY
LA English
DT Article
DE stigma; employee turnover; job satisfaction; well-being; sex role
attitudes; organizational climate; family-work relationship
ID PERCEIVED ORGANIZATIONAL SUPPORT; CORE SELF-EVALUATIONS;
JOB-SATISFACTION; MATERNAL EMPLOYMENT; SUPERVISOR SUPPORT; SOCIAL
STIGMA; CHILDBIRTH; COMMITMENT; HEALTH; SCALE
AB Research suggests that pregnant women are discriminated against in the workplace and that a significant percentage of new mothers leave the workforce. Few researchers have examined the link between women's discriminatory experiences and workforce attrition, instead of focusing on either individual-level factors (e.g., income) or workplace factors (e.g., workplace support) that predict turnover. We integrate previous findings on individual and workplace factors within a stigma framework that takes into account pregnant women's anticipated and experienced stigma. We hypothesized that pregnant women's anticipated and experienced stigma would mediate the relationships between individual (e.g., gender role attitudes) and workplace factors (e.g., workplace support) and job satisfaction, psychological well-being, and turnover intentions. Using a three-wave longitudinal design, we surveyed 142 pregnant women during and after their pregnancies, and we used path analysis to test mediational models. Results indicated that anticipated stigma partially mediated the relationship between workplace factors and psychological well-being, whereas experienced stigma partially mediated the relationships between workplace factors and job satisfaction, psychological well-being, and turnover intentions. Overall, our study demonstrates both the utility of a stigma framework and the importance of workplace experiences in understanding why women leave their jobs.
C1 [Fox, Annie B.; Quinn, Diane M.] Univ Connecticut, Dept Psychol, Storrs, CT USA.
RP Fox, AB (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.
EM anniebfox@gmail.com
FU Society for the Psychological Study of Social Issues, Psi Chi;
University of Connecticut
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
research was supported, in part, by research grants from the Society for
the Psychological Study of Social Issues, Psi Chi, and the University of
Connecticut.
NR 71
TC 2
Z9 2
U1 6
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0361-6843
EI 1471-6402
J9 PSYCHOL WOMEN QUART
JI Psychol. Women Q.
PD JUN
PY 2015
VL 39
IS 2
BP 226
EP 242
DI 10.1177/0361684314552653
PG 17
WC Psychology, Multidisciplinary; Women's Studies
SC Psychology; Women's Studies
GA CI2IS
UT WOS:000354570500007
ER
PT J
AU Vartiainen, MV
Holm, A
Peltonen, K
Luoto, TM
Iverson, GL
Hokkanen, L
AF Vartiainen, M. V.
Holm, A.
Peltonen, K.
Luoto, T. M.
Iverson, G. L.
Hokkanen, L.
TI King-Devick test normative reference values for professional male ice
hockey players
SO SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
LA English
DT Article
DE sport; concussion; head injury; measurement; neurology
ID VISUAL SCREENING TOOL; CONCUSSION; UTILITY
AB The King-Devick (K-D) test, a measure of processing speed, visual tracking, and saccadic eye movements, has shown promise as a supplemental screening test following concussion. However, limited normative data for this test have been published.The K-D test was administered to 185 professional ice hockey players as a preseason baseline test in seasons 2012-2013 and 2013-2014. Their average age was 23.8 years (median=22.0 years, range=16-40 years). The average K-D score was 40.0s (SD=6.1s, range=24.0-65.7s). K-D test performance showed no association with age, education, or the number of self-reported previous concussions in this sample. The association between trials 1 and 2 of the K-D test was good (ICC=0.92, Pearson=0.93). Normative values of the K-D test for professional male ice hockey players are reported. K-D test performance did not vary by age, education, or concussion history in this study.
C1 [Vartiainen, M. V.; Peltonen, K.; Hokkanen, L.] Univ Helsinki, Inst Behav Sci, Div Cognit Psychol & Neuropsychol, SF-00100 Helsinki, Finland.
[Holm, A.] Satakunta Cent Hosp, Dept Clin Neurophysiol, Pori, Finland.
[Luoto, T. M.] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland.
[Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Iverson, G. L.] Spaulding Rehabil Hosp, Boston, MA USA.
[Iverson, G. L.] Red Sox Fdn, Boston, MA USA.
[Iverson, G. L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
[Iverson, G. L.] Massachusetts Gen Hosp, Sport Concuss Clin, Boston, MA 02114 USA.
RP Vartiainen, MV (reprint author), Univ Helsinki, Inst Behav Sci, Div Cognit Psychol & Neuropsychol, Raisalantie 24, SF-00100 Helsinki, Finland.
EM m.vartiainen@kolumbus.fi
OI Luoto, Teemu/0000-0002-7329-3284; Hokkanen, Laura/0000-0001-8342-9248
NR 11
TC 5
Z9 5
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7188
EI 1600-0838
J9 SCAND J MED SCI SPOR
JI Scand. J. Med. Sci. Sports
PD JUN
PY 2015
VL 25
IS 3
BP e327
EP e330
DI 10.1111/sms.12307
PG 4
WC Sport Sciences
SC Sport Sciences
GA CI2ID
UT WOS:000354568800014
PM 25138698
ER
PT J
AU Xiao, X
Luo, HM
Vanek, KN
Larue, AC
Schulte, BA
Wang, GY
AF Xiao, Xia
Luo, Hongmei
Vanek, Kenneth N.
Larue, Amanda C.
Schulte, Bradley A.
Wang, Gavin Y.
TI Catalase Inhibits Ionizing Radiation-Induced Apoptosis in Hematopoietic
Stem and Progenitor Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID STAT3; INJURY; IRRADIATION; ACTIVATION; REGENERATION; CHEMOTHERAPY;
SENESCENCE; EXPRESSION; PEROXIDE
AB Hematologic toxicity is a major cause of mortality in radiation emergency scenarios and a primary side effect concern in patients undergoing chemo-radiotherapy. Therefore, there is a critical need for the development of novel and more effective approaches to manage this side effect. Catalase is a potent antioxidant enzyme that coverts hydrogen peroxide into hydrogen and water. In this study, we evaluated the efficacy of catalase as a protectant against ionizing radiation (IR)-induced toxicity in hematopoietic stem and progenitor cells (HSPCs). The results revealed that catalase treatment markedly inhibits IR-induced apoptosis in murine hematopoietic stem cells and hematopoietic progenitor cells. Subsequent colony-forming cell and cobble-stone area-forming cell assays showed that catalase-treated HSPCs can not only survive irradiation-induced apoptosis but also have higher clonogenic capacity, compared with vehicle-treated cells. Moreover, transplantation of catalase-treated irradiated HSPCs results in high levels of multi-lineage and long-term engraftments, whereas vehicle-treated irradiated HSPCs exhibit very limited hematopoiesis reconstituting capacity. Mechanistically, catalase treatment attenuates IR-induced DNA double-strand breaks and inhibits reactive oxygen species. Unexpectedly, we found that the radioprotective effect of catalase is associated with activation of the signal transducer and activator of transcription 3 (STAT3) signaling pathway and pharmacological inhibition of STAT3 abolishes the protective activity of catalase, suggesting that catalase may protect HSPCs against IR-induced toxicity via promoting STAT3 activation. Collectively, these results demonstrate a previously unrecognized mechanism by which catalase inhibits IR-induced DNA damage and apoptosis in HSPCs.
C1 [Xiao, Xia; Luo, Hongmei; Larue, Amanda C.; Schulte, Bradley A.; Wang, Gavin Y.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Xiao, Xia] Tianjin First Ctr Hosp, Dept Hematol, Tianjin, Peoples R China.
[Luo, Hongmei] Univ South China, Dept Histol & Embryol, Hengyang City, Hunan, Peoples R China.
[Vanek, Kenneth N.] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Larue, Amanda C.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA.
[Larue, Amanda C.; Wang, Gavin Y.] Med Univ S Carolina, Canc Genes & Mol Regulat Program, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP Wang, GY (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC908, Charleston, SC 29425 USA.
EM wangy@musc.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [HL106451]; Hollings
Cancer Center [P30 CA138313]
FX The authors want to thank Mrs. Aimin Yang for excellent technical
assistance. This study was supported, in part, by a grant from the
National Heart, Lung, and Blood Institute (NHLBI) no. HL106451 (G.Y.W.)
and a pilot grant from the Hollings Cancer Center (G.Y.W.) via P30
CA138313.
NR 35
TC 6
Z9 6
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JUN 1
PY 2015
VL 24
IS 11
BP 1342
EP 1351
DI 10.1089/scd.2014.0402
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
Transplantation
GA CI2XX
UT WOS:000354612600007
PM 25603016
ER
PT J
AU Grabowski, EF
Liu, BH
Gerace, MR
Kushak, RI
Ingelfinger, JR
AF Grabowski, Eric F.
Liu, Bohan
Gerace, Matthew R.
Kushak, Rafail I.
Ingelfinger, Julie R.
TI Shiga toxin-1 Decreases Endothelial Cell Tissue Factor Pathway Inhibitor
Not Co-localized with Tissue Factor on the Cell Membrane
SO THROMBOSIS RESEARCH
LA English
DT Letter
ID HEMOLYTIC-UREMIC SYNDROME; TUMOR-NECROSIS-FACTOR; ALPHA;
ATHEROSCLEROSIS; PATHOGENESIS; EXPRESSION; SECRETION; SURFACE
RP Grabowski, EF (reprint author), Massachusetts Gen Hosp, Pediat Hematol Oncol, Yawkey 8B,55 Fruit St, Boston, MA 02114 USA.
EM Grabowski.Eric@MGH.Harvard.edu
FU NHLBI NIH HHS [R01HL089332]
NR 18
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD JUN
PY 2015
VL 135
IS 6
BP 1214
EP 1217
DI 10.1016/j.thromres.2015.03.018
PG 4
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CI1IN
UT WOS:000354497300030
PM 25864889
ER
PT J
AU Lee, YH
Sun, YP
Gerweck, LE
Glickman, RD
AF Lee, Yuan-Hao
Sun, Youping
Gerweck, Leo E.
Glickman, Randolph D.
TI Regulation of DNA Damage Response by Estrogen Receptor beta-Mediated
Inhibition of Breast Cancer Associated Gene 2
SO BIOMEDICINES
LA English
DT Article
DE BCA2; DNA damage response; Erb-041; Rad51; UVC
ID HOMOLOGOUS RECOMBINATION; NUCLEOPROTEIN FILAMENT; EXPRESSION;
P21(WAF1/CIP1); UBIQUITIN; CELLS; MEDULLOBLASTOMA; STABILITY; TAMOXIFEN;
MIGRATION
AB Accumulating evidence suggests that ubiquitin E3 ligases are involved in cancer development as their mutations correlate with genomic instability and genetic susceptibility to cancer. Despite significant findings of cancer-driving mutations in the BRCA1 gene, estrogen receptor (ER)-positive breast cancers progress upon treatment with DNA damaging-cytotoxic therapies. In order to understand the underlying mechanism by which ER-positive breast cancer cells develop resistance to DNA damaging agents, we employed an estrogen receptor agonist, Erb-041, to increase the activity of ER beta and negatively regulate the expression and function of the estrogen receptor alpha (ER alpha) in MCF-7 breast cancer cells. Upon Erb-041-mediated ERa down-regulation, the transcription of an ERa downstream effector, BCA2 (Breast Cancer Associated gene 2), correspondingly decreased. The ubiquitination of chromatin-bound BCA2 was induced by ultraviolet C (UVC) irradiation but suppressed by Erb-041 pretreatment, resulting in a blunted DNA damage response. Upon BCA2 silencing, DNA double-stranded breaks increased with Rad51 up-regulation and ataxia telangiectasia mutated (ATM) activation. Mechanistically, UV-induced BCA2 ubiquitination and chromatin binding were found to promote DNA damage response and repair via the interaction of BCA2 with ATM, gamma H2AX and Rad51. Taken together, this study suggests that Erb-041 potentiates BCA2 dissociation from chromatin and co-localization with Rad51, resulting in inhibition of homologous recombination repair.
C1 [Lee, Yuan-Hao] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Sun, Youping] Columbia Univ, Dept Radiat Oncol, Ctr Radiol Res, Med Ctr, New York, NY 10032 USA.
[Gerweck, Leo E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Glickman, Randolph D.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, Dept Ophthalmol, San Antonio, TX 78229 USA.
RP Lee, YH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
EM LEEY4@LiveMail.uthscsa.edu; ys2611@cumc.columbia.edu;
lgerweck@mgh.harvard.edu; Glickman@uthscsa.edu
NR 38
TC 1
Z9 1
U1 0
U2 0
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUN
PY 2015
VL 3
IS 2
BP 182
EP 200
DI 10.3390/biomedicines3020182
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DZ2FU
UT WOS:000385658500001
ER
PT J
AU Ionescu, DF
Rosenbaum, JF
Alpert, JE
AF Ionescu, Dawn F.
Rosenbaum, Jerrold F.
Alpert, Jonathan E.
TI Pharmacological approaches to the challenge of treatment-resistant
depression
SO DIALOGUES IN CLINICAL NEUROSCIENCE
LA English
DT Article
DE treatment-resistant depression; optimization; combination; augmentation;
switch therapy; treatment strategy; ketamine; scopolamine
ID STAR-ASTERISK-D; PLACEBO-CONTROLLED TRIAL; SEROTONIN REUPTAKE
INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; D-ASPARTATE ANTAGONIST;
ACETYL-L-CARNITINE; CREATINE MONOHYDRATE AUGMENTATION;
TREATMENT-REFRACTORY DEPRESSION; FAILED MEDICATION TREATMENTS;
CONTROLLED CLINICAL-TRIAL
AB Although monoaminergic antidepressants revolutionized the treatment of Major Depressive Disorder (MDD) over a half-century ago, approximately one third of depressed patients experience treatment-resistant depression (TRD). Such patients account for a disproportionately large burden of disease, as evidenced by increased disability, cost, human suffering, and suicide. This review addresses the definition, causes, evaluation, and treatment of unipolar TRD, as well as the major treatment strategies, including optimization, augmentation, combination, and switch therapies. Evidence for these options, as outlined in this review, is mainly focused on large-scale trials or meta-analyses. Finally, we briefly review emerging targets for antidepressant drug discovery and the novel effects of rapidly acting antidepressants, with a focus on ketamine. (C) 2015, AICH - Servier Research Group
C1 [Ionescu, Dawn F.; Rosenbaum, Jerrold F.; Alpert, Jonathan E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Rosenbaum, JF (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA.
EM jrosenbaum@partners.org
RI Ionescu, Dawn/K-5675-2015;
OI Alpert, Jonathan/0000-0002-4332-908X
NR 133
TC 7
Z9 7
U1 7
U2 10
PU INST CONFERENCE HIPPOCRATE
PI SURESNESS-CEDEX
PA 50 RUE CARNOT, SURESNESS-CEDEX, 92284, FRANCE
SN 1294-8322
EI 1958-5969
J9 DIALOGUES CLIN NEURO
JI Dialogues Clin. Neurosci.
PD JUN
PY 2015
VL 17
IS 2
BP 111
EP 126
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA EF2XV
UT WOS:000390189800002
PM 26246787
ER
PT J
AU Flory, JD
Yehuda, R
AF Flory, Janine D.
Yehuda, Rachel
TI Comorbidity between post-traumatic stress disorder and major depressive
disorder: alternative explanations and treatment considerations
SO DIALOGUES IN CLINICAL NEUROSCIENCE
LA English
DT Article
DE PTSD; MDD; comorbidity; glucocorticoid receptor; FKBP5
ID COMBAT-RELATED PTSD; MENTAL-DISORDERS; DSM-IV; TRAUMA; VULNERABILITY;
METAANALYSIS; REPLICATION; PERSONALITY; PREVALENCE; MECHANISMS
AB Approximately half of people with post-traumatic stress disorder (PTSD) also suffer from Major Depressive Disorder ( MDD). The current paper examines evidence for two explanations of this comorbidity. First, that the comorbidity reflects overlapping symptoms in the two disorders. Second, that the co-occurrence of PTSD and MDD is not an artifact, but represents a trauma-related phenotype, possibly a subtype of PTSD. Support for the latter explanation is inferred from literature that examines risk and biological correlates of PTSD and MDD, including molecular processes. Treatment implications of the comorbidity are considered. (C) 2015, AICH - Servier Research Group
C1 [Flory, Janine D.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Flory, Janine D.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
RP Flory, JD (reprint author), James J Peters Bronx VAMC, Mt Sinai Sch Med, Psychiat, Room 3B-42,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM janine.flory@mssm.edu
FU CSRD VA [I01 CX000952]
NR 58
TC 12
Z9 12
U1 3
U2 3
PU INST CONFERENCE HIPPOCRATE
PI SURESNESS-CEDEX
PA 50 RUE CARNOT, SURESNESS-CEDEX, 92284, FRANCE
SN 1294-8322
EI 1958-5969
J9 DIALOGUES CLIN NEURO
JI Dialogues Clin. Neurosci.
PD JUN
PY 2015
VL 17
IS 2
BP 141
EP 150
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA EF2XV
UT WOS:000390189800004
PM 26246789
ER
PT J
AU Raldow, AC
Zhang, DJ
Chen, MH
Braccioforte, MH
Moran, BJ
D'Amico, AV
AF Raldow, Ann C.
Zhang, Danjie
Chen, Ming-Hui
Braccioforte, Michelle H.
Moran, Brian J.
D'Amico, Anthony V.
TI Risk Group and Death From Prostate Cancer Implications for Active
Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer
SO JAMA ONCOLOGY
LA English
DT Article
ID HAZARDS REGRESSION-MODEL; RADICAL PROSTATECTOMY; COMPETING RISK;
FOLLOW-UP; EXPERIENCE; OUTCOMES; THERAPY; TRIAL; MORTALITY; FAILURE
AB IMPORTANCE Active surveillance (AS), per the National Comprehensive Cancer Network (NCCN) guidelines, is considered for patients with low-risk prostate cancer (PC) and a life expectancy of at least 10 years. However, given the grade migration following the 2005 International Society of Urologic Pathology consensus conference, AS may be appropriate for men presenting with favorable intermediate-risk PC.
OBJECTIVE To estimate and compare the risk of PC-specific mortality (PCSM) and all-cause mortality (ACM) following brachytherapy among men with low and favorable intermediate-risk PC.
DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 5580 consecutively treated men (median age, 68 years) with localized adenocarcinoma of the prostate treated with brachytherapy at the Prostate Cancer Foundation of Chicago between October 16, 1997, and May 28, 2013.
INTERVENTION Standard of practice per the NCCN guidelines.
MAIN OUTCOMES AND MEASURES Fine and Gray competing risks regression and Cox regression analyses were used to assess whether the risks of PCSM and ACM, respectively, were increased in men with favorable intermediate-risk vs low-risk PC. Analyses were adjusted for age at brachytherapy, year of treatment, and known PC prognostic factors.
RESULTS After median follow-up of 7.69 years, 605 men had died (10.84% of total cohort), 34 of PC (5.62% of total deaths). Men with favorable intermediate-risk PC did not have significantly increased risk of PCSM and ACM compared with men with low-risk PC (adjusted hazard ratio [HR], 1.64; 95% CI, 0.76-3.53; P=.21 for PCSM; adjusted HR, 1.11; 95% CI, 0.88-1.39; P=.38 for ACM). Eight-year adjusted point estimates for PCSM were low: 0.48% (95% CI, 0.23%-0.93%) and 0.33%(95% CI, 0.19%-0.56%) for men with favorable intermediate-risk PC and low-risk PC, respectively. The respective estimates for ACM were 10.45%(95% CI, 8.91%-12.12%) and 8.68%(95% CI, 7.80%-9.61%).
CONCLUSIONS AND RELEVANCE Men with low-risk PC and favorable intermediate-risk PC have similarly low estimates of PCSM and ACM during the first decade following brachytherapy. While awaiting the results of ProtecT, the randomized trial of AS vs treatment, our results provide evidence to support AS as an initial approach for men with favorable intermediate-risk PC.
C1 [Raldow, Ann C.] Brigham & Womens Hosp, Harvard Radiat Oncol Program, 75 Francis St, Boston, MA 02115 USA.
[Zhang, Danjie; Chen, Ming-Hui] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA.
[Braccioforte, Michelle H.; Moran, Brian J.] Prostate Canc Fdn Chicago, Westmont, IL USA.
[D'Amico, Anthony V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
RP Raldow, AC (reprint author), Brigham & Womens Hosp, Harvard Radiat Oncol Program, 75 Francis St, Boston, MA 02115 USA.
EM araldow@partners.org
NR 38
TC 13
Z9 13
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN
PY 2015
VL 1
IS 3
BP 334
EP 340
DI 10.1001/jamaoncol.2014.284
PG 7
WC Oncology
SC Oncology
GA DW5FQ
UT WOS:000383669100017
PM 26181182
ER
PT J
AU Partridge, AH
Sepucha, K
O'Neill, A
Miller, KD
Motley, C
Swaby, RF
Schneider, BP
Dang, CT
Northfelt, DW
Sledge, GW
AF Partridge, Ann H.
Sepucha, Karen
O'Neill, Anne
Miller, Kathy D.
Motley, Christine
Swaby, Ramona F.
Schneider, Bryan P.
Dang, Chau T.
Northfelt, Donald W.
Sledge, George W., Jr.
TI Effect of Unblinding on Participants' Perceptions of Risk and Confidence
in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer
SO JAMA ONCOLOGY
LA English
DT Article
ID MEDICAL DECISIONS; SURVIVORS; PLACEBO; BEVACIZUMAB; RECURRENCE;
ADJUSTMENT; ALLOCATION; ONCOLOGY
AB IMPORTANCE Blinding patients to treatment regimen is an important component of high-quality randomized clinical trials, although concern exists about how receipt of a placebo will affect participants' views, particularly among patients with cancer.
OBJECTIVE To determine whether unblinding of random assignment to placebo vs experimental agent in a large adjuvant breast cancer chemotherapy randomized clinical trial was associated with perception of greater chance of cancer recurrence and lower confidence in the decision to participate in the trial in participants who were randomized to placebo compared with those randomized to experimental therapy.
DESIGN, SETTING, AND PARTICIPANTS Serial telephone-based prospective survey substudy of all Eastern Cooperative Oncology Group Protocol 5103 (ECOG5103) participants enrolling between January 5 and June 8, 2010. In ECOG5103, patients were randomized to receive standard adjuvant chemotherapy for breast cancer with either placebo or bevacizumab for either approximately 6 or approximately 12 months. Treatment assignment was unblinded by 24 weeks, and then patients were surveyed.
MAIN OUTCOMES AND MEASURES Trial participants' self-reported perceived risk of recurrence and confidence in study participation.
RESULTS Of 571 patients in this substudy who started protocol therapy, 550 were still in the study at unblinding and 492 (89%) responded to the unblinding survey. At unblinding, 336 of 477 (70%) believed that they had at most a small risk of breast cancer recurrence, and 342 of 480 (71%) reported perceiving at most a small risk of serious problem with therapy; most reported feeling very informed (421 of 483 [87%]) and having high levels of confidence in their study participation (420 of 483 [87%]). The 102 participants who learned that they had been randomized to placebo did not have greater perception of chance of recurrence (P = .48) or fear of recurrence (P = .69), feel less informed (P = .86), or have lower confidence in trial participation (P = .31) compared with the 390 participants who had been randomized to experimental therapy. Patients who learned that they had been randomized to bevacizumab perceived higher risk of having a serious problem caused by treatment (P = .01).
CONCLUSIONS AND RELEVANCE In a placebo-controlled, double-blind randomized clinical trial of chemotherapy for breast cancer, unblinding to randomization allocation did not significantly affect most participants' views except for chance of a serious problem from experimental treatment, regardless of receipt of placebo or experimental anticancer therapy along with standard chemotherapy.
C1 [Partridge, Ann H.; Motley, Christine] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Sepucha, Karen] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[O'Neill, Anne] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Miller, Kathy D.; Schneider, Bryan P.; Sledge, George W., Jr.] Indiana Univ, Dept Med, Ctr Canc, Indianapolis, IN USA.
[Swaby, Ramona F.] Merck, N Wales, PA USA.
[Swaby, Ramona F.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA.
[Dang, Chau T.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA.
[Northfelt, Donald W.] Mayo Clin, Dept Hematol Oncol, Scottsdale, AZ USA.
[Sledge, George W., Jr.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
RP Partridge, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM ahpartridge@partners.org
FU Public Health Service [CA23318, CA66636, CA21115, CA180820, CA180794,
CA27525, CA49883, CA180795, CA77651, CA25224, CA33229, CA180816];
National Cancer Institute; National Institutes of Health; Department of
Health and Human Services; Susan G Komen Promise Award
FX This study was coordinated by the ECOG-ACRIN Cancer Research Group
(Robert L. Comis, MD, and Mitchell D. Schnall, MD, PhD, group cochairs)
and supported in part by Public Health Service grants CA23318, CA66636,
CA21115, CA180820, CA180794, CA27525, CA49883, CA180795, CA77651,
CA25224, CA33229, CA180816 and by grants from the National Cancer
Institute, National Institutes of Health, and the Department of Health
and Human Services. This work has also been supported by a Susan G Komen
Promise Award (primary investigator: Schneider).
NR 33
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN
PY 2015
VL 1
IS 3
BP 369
EP 374
DI 10.1001/jamaoncol.2015.0246
PG 6
WC Oncology
SC Oncology
GA DW5FQ
UT WOS:000383669100023
PM 26114161
ER
PT J
AU Szabatura, AH
Cirrone, F
Harris, C
McDonnell, AM
Feng, Y
Voit, D
Neuberg, D
Butrynski, J
Fisher, DC
AF Szabatura, Audrea H.
Cirrone, Frank
Harris, Christy
McDonnell, Anne M.
Feng, Yang
Voit, Daniel
Neuberg, Donna
Butrynski, James
Fisher, David C.
TI An assessment of risk factors associated with ifosfamide-induced
encephalopathy in a large academic cancer center
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
ID OF-THE-LITERATURE; METHYLENE-BLUE; NEUROTOXICITY; PREVENTION; THIAMINE;
PHARMACOKINETICS; APREPITANT; SARCOMAS; ALBUMIN
AB Purpose Ifosfamide-induced encephalopathy is a neurotoxic adverse effect of ifosfamide chemotherapy. The objective of this study was to determine the incidence of encephalopathy in patients with lymphoma and sarcoma receiving ifosfamide chemotherapy and assess for potential risk factors that influence the incidence of encephalopathy.
Methods A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions. Enrollment began 1 July 2011 and continued chronologically backwards until 100 sarcoma and 100 lymphoma patients were enrolled. Identification of ifosfamide-induced encephalopathy events was performed by reviewing provider documentation of ifosfamide infusions. Logistic regression was employed to determine associations between risk factors and ifosfamide-induced encephalopathy events.
Results Of the 200 patients enrolled, 29 (14.5%) patients experienced encephalopathy. Ifosfamide-induced encephalopathy occurred more frequently in the sarcoma population than the lymphoma population (24 vs. 5 patients, p<0.001). In addition to cancer type, prior use of cisplatin, concomitant opioids, and use of CYP2B6 inhibitors remained as significant variables in the multivariate model conferring a 12.47, 2.81, and 5.17 increased odds of experiencing encephalopathy, respectively. The odds of experiencing encephalopathy were 9.0 and 1.37 times higher for a one-unit increase in serum creatinine and hemoglobin, respectively, and 0.15 times lower for a one-unit increase in albumin.
Conclusions This is the first study to demonstrate that patients with sarcoma experienced ifosfamide-induced encephalopathy more often than those with lymphoma. For all patients, predisposing factors for ifosfamide-induced encephalopathy included previous cisplatin exposure, concomitant opioids and CYP2B6 inhibitors. Laboratory values that increased ifosfamide-induced encephalopathy risk included low serum albumin, increased serum creatinine, and increased hemoglobin.
C1 [Szabatura, Audrea H.; Feng, Yang; Neuberg, Donna; Butrynski, James; Fisher, David C.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Cirrone, Frank] NewYork Presbyterian Hosp, New York, NY USA.
[Harris, Christy] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA.
[McDonnell, Anne M.; Voit, Daniel] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Szabatura, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,YC-542, Boston, MA 02215 USA.
EM audreah_szabatura@dfci.harvard.edu
NR 25
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD JUN
PY 2015
VL 21
IS 3
BP 188
EP 193
DI 10.1177/1078155214527143
PG 6
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA CH4DL
UT WOS:000353982000004
PM 24664476
ER
PT J
AU Gardner, S
Weaver, MJ
Jerabek, S
Rodriguez, E
Vrahas, M
Harris, M
AF Gardner, Stephen
Weaver, Michael J.
Jerabek, Seth
Rodriguez, Edward
Vrahas, Mark
Harris, Mitchel
TI Predictors of early failure in young patients with displaced femoral
neck fractures
SO JOURNAL OF ORTHOPAEDICS
LA English
DT Article
DE Femoral neck fracture; Complications; Predictors of failure; Young
patients
ID INTERNAL-FIXATION; ADULTS; HIP; CLASSIFICATION; METAANALYSIS; REDUCTION;
OUTCOMES; SCREWS; LESS; AGES
AB Introduction: This study compares early failure rates of sliding hip screw (SHS) and cannulated screw (CS) constructs in young patients.
Methods: Patients < 60 years of age, with displaced femoral neck fractures treated with CS or SHS fixation were included. Primary outcome was failure within 6 months.
Results: One patient (3%) with SHS fixation and 6 patients (21%) with CS fixation failed within 6 months (P = 0.04). Regression analysis demonstrated type of fixation (P = 0.005) and reduction quality (P = 0.04) are independent predictors of early failure.
Conclusions: SHS constructs demonstrate a significantly lower short-term failure rate than CS constructs. Copyright (C) 2014, Professor P K Surendran Memorial Education Foundation. Publishing Services by Reed Elsevier India Pvt. Ltd. All rights reserved.
C1 [Gardner, Stephen] Kerlan Jobe Orthopaed Fdn, Kerlan Jobe Orthopaed Clin, Los Angeles, CA USA.
[Weaver, Michael J.; Harris, Mitchel] Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
[Jerabek, Seth] Hosp Special Surg, Dept Orthoped, 535 E 70th St, New York, NY 10021 USA.
[Rodriguez, Edward] Beth Isreal Deaconess Hosp, Dept Orthoped, Boston, MA USA.
[Vrahas, Mark] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA.
RP Gardner, S (reprint author), Kerlan Jobe Orthoped Clin, 4801 Pk Terrace, Los Angeles, CA 90045 USA.
EM stevegardner22@gmail.com
NR 27
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0972-978X
J9 J ORTHOP
JI J. Orthop.
PD JUN
PY 2015
VL 12
IS 2
BP 75
EP 80
DI 10.1016/j.jor.2014.01.001
PG 6
WC Orthopedics
SC Orthopedics
GA DY9EB
UT WOS:000385435300004
PM 25972697
ER
PT J
AU Van Stan, JH
Mehta, DD
Hillman, RE
AF Van Stan, Jarrad H.
Mehta, Daryush D.
Hillman, Robert E.
TI The Effect of Voice Ambulatory Biofeedback on the Daily Performance and
Retention of a Modified Vocal Motor Behavior in Participants With Normal
Voices
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
ID PARKINSONS-DISEASE; KNOWLEDGE; DISORDERS; LOUDNESS; DEVICE;
HYPERFUNCTION; ACCUMULATOR; INTENSITY; ACCURACY; SPEAKERS
AB Purpose: Ambulatory biofeedback has potential to improve carryover of newly established vocal motor behaviors into daily life outside of the clinic and warrants systematic research that is lacking in the literature. This proof-of-concept study was designed to establish an empirical basis for future work in this area by formally assessing whether ambulatory biofeedback reduces daily vocal intensity (performance) and the extent to which this change remains after biofeedback removal (retention).
Method: Six participants with normal voices wore the KayPENTAX Ambulatory Phonation Monitor for 3 baseline days followed by 4 days with biofeedback provided on odd days.
Results: Compared to baseline days, participants exhibited a statistically significant decrease in mean vocal intensity (4.4 dB) and an increase in compliance (16.8 percentage points) when biofeedback was provided above a participant-specific intensity threshold. After biofeedback removal, mean vocal intensity and compliance reverted back to baseline levels.
Conclusions: These findings suggest that although current ambulatory biofeedback approaches have potential to modify a vocal motor behavior, the modified behavior may not be retained after biofeedback removal. Future work calls for the testing of more innovative ambulatory biofeedback approaches on the basis of motor control and learning theories to improve retention of a desired vocal motor behavior.
C1 [Van Stan, Jarrad H.; Mehta, Daryush D.; Hillman, Robert E.] MGH Inst Hlth Profess, Boston, MA 02129 USA.
[Van Stan, Jarrad H.; Mehta, Daryush D.; Hillman, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mehta, Daryush D.; Hillman, Robert E.] Harvard Med Sch, Boston, MA USA.
RP Van Stan, JH (reprint author), MGH Inst Hlth Profess, Boston, MA 02129 USA.
EM jvanstan@mghihp.edu
FU Voice Health Institute; National Institutes of Health (NIH) National
Institute on Deafness and Other Communication Disorders [R33 DC011588,
F31 DC014412]
FX This work was supported by the Voice Health Institute and the National
Institutes of Health (NIH) National Institute on Deafness and Other
Communication Disorders under Grants R33 DC011588 and F31 DC014412. The
article's contents are solely the responsibility of the authors and do
not necessarily represent the official views of the NIH.
NR 33
TC 1
Z9 1
U1 2
U2 2
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA
SN 1092-4388
EI 1558-9102
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN
PY 2015
VL 58
IS 3
BP 713
EP 721
DI 10.1044/2015_JSLHR-S-14-0159
PG 9
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA DX6XE
UT WOS:000384528400013
PM 25765862
ER
PT J
AU Pompon, RH
McNeil, MR
Spencer, KA
Kendall, DL
AF Pompon, Rebecca Hunting
McNeil, Malcolm R.
Spencer, Kristie A.
Kendall, Diane L.
TI Intentional and Reactive Inhibition During Spoken-Word Stroop Task
Performance in People With Aphasia
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
ID FRONTAL-LOBE LESIONS; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; SELECTIVE
ATTENTION; SHORT-TERM; INTERFERENCE; LANGUAGE; COMPREHENSION;
DISTRACTORS; MECHANISMS
AB Purpose: The integrity of selective attention in people with aphasia (PWA) is currently unknown. Selective attention is essential for everyday communication, and inhibition is an important part of selective attention. This study explored components of inhibition-both intentional and reactive inhibition-during spoken-word production in PWA and in controls who were neurologically healthy (HC). Intentional inhibition is the ability to suppress a response to interference, and reactive inhibition is the delayed reactivation of a previously suppressed item.
Method: Nineteen PWA and 20 age-and education-matched HC participated in a Stroop spoken-word production task. This task allowed the examination of intentional and reactive inhibition by evoking and comparing interference, facilitation, and negative priming effects in different contexts.
Results: Although both groups demonstrated intentional inhibition, PWA demonstrated significantly more interference effects. PWA demonstrated no significant facilitation effects. HC demonstrated significant reverse facilitation effects. Neither group showed significant evidence of reactive inhibition, though both groups showed similar individual variability.
Conclusions: These results underscore the challenge interference presents for PWA during spoken-word production, indicating diminished intentional inhibition. Although reactive inhibition was not different between PWA and HC, PWA showed difficulty integrating and adapting to contextual information during language tasks.
C1 [Pompon, Rebecca Hunting; Spencer, Kristie A.; Kendall, Diane L.] Univ Washington, Seattle, WA 98195 USA.
[McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[McNeil, Malcolm R.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Kendall, Diane L.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
RP Pompon, RH (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM rhpompon@uw.edu
FU National Institute on Deafness and Other Communication Disorders Grant
[F31DC012457]
FX This research was supported by National Institute on Deafness and Other
Communication Disorders Grant F31DC012457, awarded to Rebecca Hunting
Pompon. The authors acknowledge Amanda Hendricks, Hallie Mass, Erin
McDonald, Leslie Yoo, and all participants for their contributions to
this study.
NR 72
TC 0
Z9 0
U1 2
U2 2
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA
SN 1092-4388
EI 1558-9102
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN
PY 2015
VL 58
IS 3
BP 767
EP 780
DI 10.1044/2015_JSLHR-L-14-0063
PG 14
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA DX6XE
UT WOS:000384528400018
PM 25674773
ER
PT J
AU Fergadiotis, G
Kellough, S
Hula, WD
AF Fergadiotis, Gerasimos
Kellough, Stacey
Hula, William D.
TI Item Response Theory Modeling of the Philadelphia Naming Test
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
ID LEXICAL ACCESS; SPEECH PRODUCTION; WORD PRODUCTION; FIT STATISTICS;
RASCH MODELS; RETRIEVAL; FREQUENCY; APHASIA; PERFORMANCE; BEHAVIOR
AB Purpose: In this study, we investigated the fit of the Philadelphia Naming Test (PNT; Roach, Schwartz, Martin, Grewal, & Brecher, 1996) to an item-response-theory measurement model, estimated the precision of the resulting scores and item parameters, and provided a theoretical rationale for the interpretation of PNT overall scores by relating explanatory variables to item difficulty. This article describes the statistical model underlying the computer adaptive PNT presented in a companion article (Hula, Kellough, & Fergadiotis, 2015).
Method: Using archival data, we evaluated the fit of the PNT to 1- and 2-parameter logistic models and examined the precision of the resulting parameter estimates. We regressed the item difficulty estimates on three predictor variables: word length, age of acquisition, and contextual diversity.
Results: The 2-parameter logistic model demonstrated marginally better fit, but the fit of the 1-parameter logistic model was adequate. Precision was excellent for both person ability and item difficulty estimates. Word length, age of acquisition, and contextual diversity all independently contributed to variance in item difficulty.
Conclusions: Item-response-theory methods can be productively used to analyze and quantify anomia severity in aphasia. Regression of item difficulty on lexical variables supported the validity of the PNT and interpretation of anomia severity scores in the context of current word-finding models.
C1 [Fergadiotis, Gerasimos] Portland State Univ, Portland, OR 97207 USA.
[Kellough, Stacey; Hula, William D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
RP Fergadiotis, G (reprint author), Portland State Univ, Portland, OR 97207 USA.
EM gfergadiotis@pdx.edu
FU VA Rehabilitation Research and Development Career Development Award
[C7476W]; VA Pittsburgh Healthcare System Geriatric Research Education
and Clinical Center
FX This research was supported by VA Rehabilitation Research and
Development Career Development Award C7476W (awarded to William Hula)
and the VA Pittsburgh Healthcare System Geriatric Research Education and
Clinical Center. The authors would like to acknowledge the helpful
assistance of Daniel Mirman and Myrna Schwartz. The contents of this
article do not represent the views of the Department of Veterans Affairs
or the United States government.
NR 71
TC 2
Z9 2
U1 3
U2 3
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA
SN 1092-4388
EI 1558-9102
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN
PY 2015
VL 58
IS 3
BP 865
EP 877
DI 10.1044/2015_JSLHR-L-14-0249
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA DX6XE
UT WOS:000384528400025
ER
PT J
AU Hula, WD
Kellough, S
Fergadiotis, G
AF Hula, William D.
Kellough, Stacey
Fergadiotis, Gerasimos
TI Development and Simulation Testing of a Computerized Adaptive Version of
the Philadelphia Naming Test
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
ID LEXICAL ACCESS; COMMUNICATIVE PARTICIPATION; APHASIC PERFORMANCE; RASCH
ANALYSIS; SHORT-FORM; ITEM; SYSTEM; COMPREHENSION; CALIBRATION;
FREQUENCY
AB Purpose: The purpose of this study was to develop a computerized adaptive test (CAT) version of the Philadelphia Naming Test (PNT; Roach, Schwartz, Martin, Grewal, & Brecher, 1996), to reduce test length while maximizing measurement precision. This article is a direct extension of a companion article (Fergadiotis, Kellough, & Hula, 2015), in which we fitted the PNT to a 1-parameter logistic item-response-theory model and examined the validity and precision of the resulting item parameter and ability score estimates.
Method: Using archival data collected from participants with aphasia, we simulated two PNT-CAT versions and two previously published static PNT short forms, and compared the resulting ability score estimates to estimates obtained from the full 175-item PNT. We used a jackknife procedure to maintain independence of the samples used for item estimation and CAT simulation.
Results: The PNT-CAT recovered full PNT scores with equal or better accuracy than the static short forms. Measurement precision was also greater for the PNT-CAT than the static short forms, though comparison of adaptive and static nonoverlapping alternate forms showed minimal differences between the two approaches.
Conclusion: These results suggest that CAT assessment of naming in aphasia has the potential to reduce test burden while maximizing the accuracy and precision of score estimates.
C1 [Hula, William D.; Kellough, Stacey] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
[Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Fergadiotis, Gerasimos] Portland State Univ, Portland, OR 97207 USA.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
EM william.hula@va.gov
FU VA Rehabilitation Research & Development Career Development Award
[C7476W]; VA Pittsburgh Healthcare System Geriatric Research Education
and Clinical Center
FX This research was supported by VA Rehabilitation Research & Development
Career Development Award C7476W, and the VA Pittsburgh Healthcare System
Geriatric Research Education and Clinical Center. The contents of this
paper do not represent the views of the Department of Veterans Affairs
or the United States Government.
NR 56
TC 3
Z9 3
U1 2
U2 2
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA
SN 1092-4388
EI 1558-9102
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN
PY 2015
VL 58
IS 3
BP 878
EP 890
DI 10.1044/2015_JSLHR-L-14-0297
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA DX6XE
UT WOS:000384528400026
ER
PT J
AU Hula, WD
Doyle, PJ
Stone, CA
Hula, SNA
Kellough, S
Wambaugh, JL
Ross, KB
Schumacher, JG
Jacque, AS
AF Hula, William D.
Doyle, Patrick J.
Stone, Clement A.
Hula, Shannon N. Austermann
Kellough, Stacey
Wambaugh, Julie L.
Ross, Katherine B.
Schumacher, James G.
Jacque, Ann St.
TI The Aphasia Communication Outcome Measure (ACOM): Dimensionality, Item
Bank Calibration, and Initial Validation
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
ID QUALITY-OF-LIFE; RESPONSE THEORY; PSYCHOMETRIC EVALUATION; COGNITIVE
IMPAIRMENT; BIFACTOR ANALYSIS; STROKE SURVIVORS; SCALE; MODELS;
RELIABILITY; BURDEN
AB Purpose: The purpose of this study is to investigate the structure and measurement properties of the Aphasia Communication Outcome Measure (ACOM), a patient-reported outcome measure of communicative functioning for persons with aphasia.
Method: Three hundred twenty-nine participants with aphasia responded to 177 items asking about communicative functioning. The data were analyzed using a categorical item factor analysis approach. Validity of ACOM scores on the basis of their convergence with performance-based, clinician-reported, and surrogate-reported assessments of communication was also assessed.
Results: Fifty-nine items that obtained adequate fit to a modified bifactor measurement model and functioned similarly across several demographic and clinical subgroupings were identified. The factor model estimates were transformed to item response theory graded response model parameters, and the resulting score estimates showed good precision and moderately strong convergence with other measures of communicative ability and functioning. A free software application for administration and scoring of the ACOM item bank is available from the first author.
Conclusions: The ACOM provides reliable measurement of patient-reported communicative functioning in aphasia. The results supported the validity of ACOM scores insofar as (a) factor analyses provided support for a coherent measurement model, (b) items functioned similarly across demographic and clinical subgroups, and (c) scores showed good convergence with measures of related constructs.
C1 [Hula, William D.; Doyle, Patrick J.; Hula, Shannon N. Austermann; Kellough, Stacey; Schumacher, James G.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
[Hula, William D.; Doyle, Patrick J.; Stone, Clement A.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Wambaugh, Julie L.] VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA.
[Wambaugh, Julie L.] Univ Utah, Salt Lake City, UT USA.
[Ross, Katherine B.] Phoenix VA Healthcare Syst, Phoenix, AZ USA.
[Jacque, Ann St.] Minneapolis VA Healthcare Syst, Minneapolis, MN USA.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
EM william.hula@va.gov
FU VA Rehabilitation Research & Development Merit Review Award [6098R]; VA
Rehabilitation Research & Development Career Development Award [C7476W];
VA Pittsburgh Healthcare System Geriatric Research Education and
Clinical Center
FX This work was supported by VA Rehabilitation Research & Development
Merit Review Award 6098R (principal investigator: Patrick Doyle), Career
Development Award C7476W (principal investigator: William Hula), and the
VA Pittsburgh Healthcare System Geriatric Research Education and
Clinical Center. The authors would like to thank Beth Friedman, Janet
Malotky, Martha Manthie, Christina Nessler, Rebecca Owens, Jessica
Rapier, Mary Sullivan, Brooke Swoyer, Neil Szuminsky, and Sandra Wright
for their assistance with data collection and management. We would also
like to thank the aforementioned along with Michael Dickey, Malcolm
McNeil, Christine Matthews, Ronda Winans-Mitrik, and Gerasimos
Fergadiotis for helpful discussions during the development and execution
of this project. The contents of this article do not represent the views
of the Department of Veterans Affairs or the United States government.
NR 71
TC 1
Z9 1
U1 8
U2 8
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA
SN 1092-4388
EI 1558-9102
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN
PY 2015
VL 58
IS 3
BP 906
EP 919
DI 10.1044/2015_JSLHR-L-14-0235
PG 14
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA DX6XE
UT WOS:000384528400028
PM 25812178
ER
PT J
AU Ionescu, DF
Nugent, AC
Luckenbaugh, DA
Niciu, MJ
Richards, EM
Zarate, CA
Furey, ML
AF Ionescu, Dawn F.
Nugent, Allison C.
Luckenbaugh, David A.
Niciu, Mark J.
Richards, Erica M.
Zarate, Carlos A., Jr.
Furey, Maura L.
TI Baseline working memory activation deficits in dimensional anxious
depression as detected by magnetoencephalography
SO ACTA NEUROPSYCHIATRICA
LA English
DT Article
DE anxious depression; magnetoencephalography (MEG); major depressive
disorder; N-back task; neurobiology
ID STAR-ASTERISK-D; NONANXIOUS DEPRESSION; UNIPOLAR DEPRESSION; COGNITIVE
THERAPY; MAJOR DEPRESSION; DISORDER; BRAIN; OUTPATIENTS; TASK;
IMPROVEMENT
AB Objective Anxiety often co-occurs with major depressive disorder (MDD). This preliminary study sought to ascertain the extent to which anxious depression drives group neurobiological differences between patients with MDD and healthy volunteers (HVs).
Methods Magnetoencephalography beta-band frequency was used to compare differences in brain response during the N-back working memory task between 30 medication-free patients with treatment-resistant MDD (anxious depression=18; nonanxious depression=12) and 28 HVs.
Results Compared to HVs, patients with anxious depression had significantly reduced desynchronisation (less activation) in the left precuneus, right cuneus, and left insula extending into the inferior and middle frontal cortex during the 2-back condition compared with the 1-back condition of the N-back working memory task - indicating less activation of these neural networks in patients with anxious depression during the condition with the highest level of task demands. No other significant group differences were found during the working memory conditions.
Conclusion This preliminary study suggests that a subset of patients - those with anxious depression - may be driving observed group differences between patients with MDD and HVs. Further neurobiological studies and replication experiments are necessary to determine the extent to which this subgroup has preferentially influenced our understanding of the underlying neurobiology of depression.
C1 [Ionescu, Dawn F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Ionescu, Dawn F.] Harvard Univ, Sch Med, Boston, MA USA.
[Nugent, Allison C.; Luckenbaugh, David A.; Niciu, Mark J.; Richards, Erica M.; Zarate, Carlos A., Jr.; Furey, Maura L.] NIMH, Expt Therapeut & Pathophysiol Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
RP Ionescu, DF (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,Floor 6, Boston, MA 02114 USA.
EM dionescu@mgh.harvard.edu
RI Niciu, Mark/J-1766-2014; Ionescu, Dawn/K-5675-2015;
OI Niciu, Mark/0000-0002-5612-3021; Nugent, Allison/0000-0003-2569-2480
FU Intramural Research Program at the National Institute of Mental Health,
National Institutes of Health (IRP-NIMH-NIH); NARSAD; Brain & Behavior
Mood Disorders Research Award
FX Funding for this work was supported by the Intramural Research Program
at the National Institute of Mental Health, National Institutes of
Health (IRP-NIMH-NIH), by a NARSAD Independent Investigator to C.A.Z.,
and by the Brain & Behavior Mood Disorders Research Award to C.A.Z. Dr.
Zarate is listed as a co-inventor on a patent application for the use of
ketamine and its metabolites in major depression. Dr. Zarate has
assigned his rights in the patent to the US government but will share a
percentage of any royalties that may be received by the government. Dr.
Furey is listed as a co-inventor on a patent application for the use of
scopolamine in psychiatric disorders. Dr. Furey has assigned his rights
in the patent to the US government but will share a percentage of any
royalties that may be received by the government. The remaining authors
have no conflicts of interest to disclose, financial, or otherwise.
NR 40
TC 0
Z9 0
U1 1
U2 7
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1601-5215
J9 ACTA NEUROPSYCHIATR
JI Acta Neuropsychiatr.
PD JUN
PY 2015
VL 27
IS 3
BP 143
EP 152
DI 10.1017/neu.2014.46
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CH9YC
UT WOS:000354391600002
PM 25600154
ER
PT J
AU Pourjabbar, S
Singh, S
Kulkarni, N
Muse, V
Digumarthy, SR
Deedar, R
Khawaja, A
Padole, A
Do, S
Kalra, MK
AF Pourjabbar, Sarvenaz
Singh, Sarabjeet
Kulkarni, Naveen
Muse, Victorine
Digumarthy, Subba R.
Deedar, Ranish
Khawaja, Ali
Padole, Atul
Do, Synho
Kalra, Mannudeep K.
TI Dose reduction for chest CT: comparison of two iterative reconstruction
techniques
SO ACTA RADIOLOGICA
LA English
DT Article
DE Image manipulation/reconstruction; CT spiral; thorax; physics; radiation
safety
ID FILTERED BACK-PROJECTION; IMAGE QUALITY ASSESSMENT; COMPUTED-TOMOGRAPHY;
POWER SPECTRA; MODULATION
AB Background: Lowering radiation dose in computed tomography (CT) scan results in low quality noisy images. Iterative reconstruction techniques are used currently to lower image noise and improve the quality of images.
Purpose: To evaluate lesion detection and diagnostic acceptability of chest CT images acquired at CTDIvol of 1.8 mGy and processed with two different iterative reconstruction techniques.
Material and Methods: Twenty-two patients (mean age, 60 +/- 14 years; men, 13; women, 9; body mass index, 27.4 +/- 6.5 kg/m(2)) gave informed consent for acquisition of low dose (LD) series in addition to the standard dose (SD) chest CTon a 128 -multidetector CT (MDCT). LD images were reconstructed with SafeCT C-4, L-1, and L-2 settings, and Safire S-1, S-2, and S-3 settings. Three thoracic radiologists assessed LD image series (S-1, S-2, S-3, C-4, L-1, and L-2) for lesion detection and comparison of lesion margin, visibility of normal structures, and diagnostic confidence with SD chest CT. Inter-observer agreement (kappa) was calculated.
Results: Average CTDIvol was 6.4 +/- 2.7 mGy and 1.8 +/- 0.2 mGy for SD and LD series, respectively. No additional lesion was found in SD as compared to LD images. Visibility of ground-glass opacities and lesion margins, as well as normal structures visibility were not affected on LD. CT image visibility of major fissure and pericardium was not optimal in some cases (n = 5). Objective image noise in some low dose images processed with SafeCT and Safire was similar to SD images (P value > 0.5).
Conclusion: Routine LD chest CTreconstructed with iterative reconstruction technique can provide similar diagnostic information in terms of lesion detection, margin, and diagnostic confidence as compared to SD, regardless of the iterative reconstruction settings.
C1 [Pourjabbar, Sarvenaz; Singh, Sarabjeet; Kulkarni, Naveen; Muse, Victorine; Digumarthy, Subba R.; Deedar, Ranish; Khawaja, Ali; Padole, Atul; Do, Synho; Kalra, Mannudeep K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thorac Div,Dept Imaging, Boston, MA 02114 USA.
RP Pourjabbar, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thorac Div,Dept Imaging, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM spourjabbar@partners.org
FU Society of Thoracic Radiologists; GE Healthcare; Philips Healthcare
FX Sarabjeet Singh has received a research funding from Society of Thoracic
Radiologists, GE Healthcare and Philips Healthcare.
NR 22
TC 5
Z9 6
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0284-1851
EI 1600-0455
J9 ACTA RADIOL
JI Acta Radiol.
PD JUN
PY 2015
VL 56
IS 6
BP 688
EP 695
DI 10.1177/0284185114537256
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CH9AJ
UT WOS:000354328100008
PM 24948790
ER
PT J
AU Schure, MB
Goins, RT
AF Schure, Marc B.
Goins, R. Turner
TI Association of Depressive Symptomatology with Receipt of Informal
Caregiving Among Older American Indians: The Native Elder Care Study
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE American Indians; depressive symptomatology; informal caregiving
ID MENTAL-HEALTH-SERVICES; SELF-REPORTED USE; QUALITY-OF-LIFE;
LONG-TERM-CARE; ADMINISTRATIVE RECORDS; UNITED-STATES; DISABILITY;
SYMPTOMS; ADULTS; PREVALENCE
AB Objective: Our study objectives were to identify the primary sources of informal caregiving and to examine the association of depressive symptomatology with receipt of informal caregiving among a sample of community-dwelling older American Indians. Design: We conducted a cross-sectional study of older American Indians. Participants: Community-dwelling adults aged 55 years and older who are members of a federally recognized American Indian tribe in the Southeast United States. Measurements: We collected information on the participant's primary caregiver, number of informal care hours received in the past week, depressive symptomatology, demographic characteristics, physical health status, and assistance need. Results: Daughters, spouses, and sons were the most common informal primary caregivers with distinct differences by sex of those receiving care. Compared with participants with lower levels, those with a high level of depressive symptomatology received substantially greater hours of informal care (33.4 versus 11.5 hours per week). Conclusion: Older American Indians with higher levels of depressive symptomatology received more informal caregiving than those with lower depressive symptomatology. The burden of caregiving of older adults is primarily shouldered by spouses and children with those who care for older adults with depressive symptomatology likely experiencing an even greater burden of care.
C1 [Schure, Marc B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Goins, R. Turner] Western Carolina Univ, Dept Social Work, Coll Hlth & Human Sci, Cullowhee, NC 28723 USA.
Mt Area Hlth Educ Ctr, Ctr Hlth Aging, Asheville, NC USA.
RP Schure, MB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA.
EM Mark.Schure@va.gov
FU National Institute of Aging, NIH [AG022336]; Oregon State University's
College of Public Health and Human Sciences
FX This study was funded in part from the National Institute of Aging, NIH
(# AG022336) and from Oregon State University's College of Public Health
and Human Sciences. We would like to thank Drs. Adam Branscum and Alan
Acock for providing analytic recommendations.
NR 58
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2015
VL 23
IS 6
BP 579
EP 588
DI 10.1016/j.jagp.2014.03.013
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA CH9EF
UT WOS:000354338100005
PM 24801609
ER
PT J
AU Phillips, KL
Copeland, LA
Zeber, JE
Stock, EM
Tsan, JY
MacCarthy, AA
AF Phillips, Karon L.
Copeland, Laurel A.
Zeber, John E.
Stock, Eileen M.
Tsan, Jack Y.
MacCarthy, Andrea A.
TI Racial/Ethnic Disparities in Monitoring Metabolic Parameters for
Patients with Schizophrenia Receiving Antipsychotic Medications
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE African Americans; healthcare quality assessment; Hispanic; metabolic
syndrome; schizophrenia; veterans
ID HEALTH-CARE; CARDIOVASCULAR-DISEASE; RACIAL DISPARITIES;
AFRICAN-AMERICANS; EXCESS MORTALITY; VETERANS; PATTERNS; CATIE; TRIAL;
INTERVENTION
AB Objective: Patients with schizophrenia experience risks for metabolic dysregulation from medications and lifestyle behaviors. Although most patients with schizophrenia in the Veterans Health Administration (VA) receive antipsychotics, variation in monitoring metabolic dysregulation by race/ethnicity has not been assessed. This study analyzed differential monitoring of metabolic parameters by minority status. Methods: This retrospective study approximated the five components of metabolic syndrome (fasting glucose, high-density-lipoprotein cholesterol, triglycerides, blood pressure, and large waistline) using archival data, substituting body mass index for waistline. VA patients with schizophrenia age 50 or older were followed from October 1, 2001 through September 2009 (N = 30,258). Covariates included age, gender, race (white, black), Hispanic ethnicity, region, marital status, VA priority status, comorbidity, and antipsychotic type. Repeated-measures analysis assessed the association of race/ethnicity with metabolic monitoring. Results: Average patients age was 59 years (standard deviation: 9; range: 50-101), 97% were men, 70% white, 30% black, and 8% Hispanic. At baseline, 6% were monitored on all five metabolic components; this increased to 29% by 2005. In adjusted models, blacks were less likely to be monitored on all parameters, whereas Hispanics were less likely to have glucose and high-density-lipoprotein cholesterol monitored but more likely to have triglycerides tested. By 2009, lab assays were similar across race and ethnicity. Conclusion: Guideline-concordant monitoring metabolic parameters appear to be equitable but low and somewhat at odds with racial/ethnic risk among older patients with schizophrenia. Physicians should discuss lipids, weight, and glucose with patients at risk for developing heart disease, diabetes, and other sequelae of the metabolic syndrome.
C1 [Phillips, Karon L.] IMPAQ Int, Columbia, MD USA.
[Copeland, Laurel A.; Zeber, John E.; Stock, Eileen M.] Scott & White Healthcare, Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA.
[Tsan, Jack Y.] Cent Texas Vet Hlth Care Syst, Temple, TX USA.
[MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Copeland, LA (reprint author), Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA.
EM LaurelACopeland@gmail.com
OI Copeland, Laurel/0000-0002-9478-0209
FU Department of Veterans Affairs [IIR-05-326]; Center for Applied Health
Research; Central Texas Veterans Health Care System; Scott & White
Healthcare; Texas A&M Health Science Center
FX Supported by the Department of Veterans Affairs (grant IIR-05-326;
Copeland, PI) with additional support from the Center for Applied Health
Research, Central Texas Veterans Health Care System, Scott & White
Healthcare, and Texas A&M Health Science Center. The views expressed in
this article are those of the authors and do not necessarily represent
the views of the Department of Veterans Affairs. The authors have no
disclosures to report.
NR 43
TC 2
Z9 2
U1 4
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2015
VL 23
IS 6
BP 596
EP 606
DI 10.1016/j.jagp.2014.07.007
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA CH9EF
UT WOS:000354338100007
PM 25154537
ER
PT J
AU Kim, IA
Long, J
AF Kim, Irene A.
Long, Jennifer
TI Laryngotracheal Stenosis as a Complication of Photodynamic Therapy
SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
LA English
DT Article
DE photodynamic; cancer; photosensitizer; laryngotracheal; stenosis;
laryngeal
ID HEAD; MANAGEMENT; CANCER
AB Objective: Photodynamic therapy (PDT) has been proposed as an effective treatment for mucosal carcinomas such as early-stage laryngeal squamous cell carcinoma. Its advantage over other conventional modalities (surgery and chemoradiation) lies in its ability to treat disease while preserving the function and structure of the larynx. While not FDA-approved in the United States, it is used in some countries as a treatment for laryngeal cancer and is an area of active investigation. This report documents a severe complication of tracheostomy-dependent laryngotracheal stenosis resulting from PDT.
Methods: Methods include a case report and review of the literature.
Results: A 65-year-old male presented with severe stenosis of the supraglottic, glottic, and subglottic larynx following successful treatment of his laryngeal carcinoma with PDT. His presentation, staged airway reconstruction, and outcome are detailed.
Conclusion: PDT is a minimally invasive technique which in early clinical trials has matched the effectiveness of conventional therapies for treating early head and neck squamous cell cancers. It uses a photosensitizing agent that is retained by tumor cells, allowing for the selective destruction of neoplastic cells. Permanent sequelae following treatment have rarely been reported; the most commonly described adverse effects include pain, hoarseness, and phototoxicity. However, our case report discusses the potential for significant laryngotracheal stenosis requiring airway reconstruction following PDT.
C1 [Kim, Irene A.; Long, Jennifer] UCLA David Geffen Sch Med Head & Neck Surg, Los Angeles, CA 90095 USA.
[Long, Jennifer] Greater Los Angeles VAMC, Los Angeles, CA USA.
RP Kim, IA (reprint author), UCLA David Geffen Sch Med Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA.
EM iakim@mednet.ucla.edu
OI Long, Jennifer/0000-0002-4185-2328
NR 12
TC 0
Z9 0
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-4894
EI 1943-572X
J9 ANN OTO RHINOL LARYN
JI Ann. Otol. Rhinol. Laryngol.
PD JUN
PY 2015
VL 124
IS 6
BP 495
EP 498
DI 10.1177/0003489415570930
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CH6GR
UT WOS:000354135100012
PM 25667216
ER
PT J
AU Dickstein, BD
Weathers, FW
Angkaw, AC
Nievergelt, CM
Yurgil, K
Nash, WP
Baker, DG
Litz, BT
AF Dickstein, Benjamin D.
Weathers, Frank W.
Angkaw, Abigail C.
Nievergelt, Caroline M.
Yurgil, Kate
Nash, William P.
Baker, Dewleen G.
Litz, Brett T.
CA Marine Resiliency Study Team
TI Diagnostic Utility of the Posttraumatic Stress Disorder (PTSD) Checklist
for Identifying Full and Partial PTSD in Active-Duty Military
SO ASSESSMENT
LA English
DT Article
DE PCL; CAPS; PTSD; military; Marines; Sailors; subthreshold
ID BECK ANXIETY INVENTORY; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS;
PSYCHOMETRIC PROPERTIES; COMBAT; SCALE; IRAQ; SUBTHRESHOLD; AFGHANISTAN;
IMPAIRMENT
AB The aim of this study was to determine optimally efficient cutoff scores on the Posttraumatic Stress Disorder Checklist (PCL) for identifying full posttraumatic stress disorder (PTSD) and partial PTSD (P-PTSD) in active-duty Marines and Sailors. Participants were 1,016 Marines and Sailors who were administered the PCL and Clinician-Administered PTSD Scale (CAPS) 3 months after returning from Operations Iraqi and Enduring Freedom. PCL cutoffs were tested against three CAPS-based classifications: full PTSD, stringent P-PTSD, and lenient P-PTSD. A PCL score of 39 was found to be optimally efficient for identifying full PTSD. Scores of 38 and 33 were found to be optimally efficient for identifying stringent and lenient P-PTSD, respectively. Findings suggest that the PCL cutoff that is optimally efficient for detecting PTSD in active-duty Marines and Sailors is substantially lower than the score of 50 commonly used by researchers. In addition, findings provide scores useful for identifying P-PTSD in returning service members.
C1 [Dickstein, Benjamin D.] Cincinnati VA Med Ctr, Cincinnati, OH USA.
[Weathers, Frank W.] Auburn Univ, Auburn, AL 36849 USA.
[Angkaw, Abigail C.; Nievergelt, Caroline M.; Yurgil, Kate; Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Angkaw, Abigail C.; Nievergelt, Caroline M.; Baker, Dewleen G.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Nash, William P.] Def Ctr Excellence Psychol Hlth Traumat Brain Inj, Washington, DC USA.
[Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA USA.
[Litz, Brett T.] Boston Univ, Boston, MA 02215 USA.
RP Dickstein, BD (reprint author), Cincinnati VA Med Ctr, Ft Thomas Div, 1000 South Ft Thomas Ave, Ft Thomas, KY 41075 USA.
EM benjamin.dickstein@va.gov
OI Nievergelt, Caroline/0000-0001-5766-8923
FU VA Health Service Research and Development Project [SDR 09-0128]; Marine
Corps; Navy Bureau of Medicine and Surgery
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was
funded by the VA Health Service Research and Development Project No. SDR
09-0128 and by the Marine Corps and the Navy Bureau of Medicine and
Surgery.
NR 44
TC 6
Z9 6
U1 1
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-1911
EI 1552-3489
J9 ASSESSMENT
JI Assessment
PD JUN
PY 2015
VL 22
IS 3
BP 289
EP 297
DI 10.1177/1073191114548683
PG 9
WC Psychology, Clinical
SC Psychology
GA CI0FZ
UT WOS:000354413600003
PM 25178804
ER
PT J
AU MacDonald, ML
Ding, Y
Newman, J
Hemby, S
Penzes, P
Lewis, DA
Yates, NA
Sweet, RA
AF MacDonald, Matthew L.
Ding, Ying
Newman, Jason
Hemby, Scott
Penzes, Peter
Lewis, David A.
Yates, Nathan A.
Sweet, Robert A.
TI Altered Glutamate Protein Co-Expression Network Topology Linked to Spine
Loss in the Auditory Cortex of Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Auditory cortex; Glutamate; Postmortem; Proteomics; Schizophrenia; Spine
ID MISMATCH NEGATIVITY GENERATION; ONSET DYSTONIA-PARKINSONISM; CORTICAL
PYRAMIDAL NEURONS; AMPA RECEPTOR TRAFFICKING; PREFRONTAL CORTEX;
DENDRITIC SPINES; COGNITIVE IMPAIRMENT; PSYCHIATRIC-DISORDERS;
SYNAPTIC-TRANSMISSION; UBIQUITIN-PROTEASOME
AB BACKGROUND: Impaired glutamatergic signaling is believed to underlie auditory cortex pyramidal neuron dendritic spine loss and auditory symptoms in schizophrenia. Many schizophrenia risk loci converge on the synaptic glutamate signaling network. We therefore hypothesized that alterations in glutamate signaling protein expression and co-expression network features are present in schizophrenia.
METHODS: Gray matter homogenates were prepared from auditory cortex gray matter of 22 schizophrenia and 23 matched control subjects, a subset of whom had been previously assessed for dendritic spine density. One hundred fifty-five selected synaptic proteins were quantified by targeted mass spectrometry. Protein co-expression networks were constructed using weighted gene co-expression network analysis.
RESULTS: Proteins with evidence for altered expression in schizophrenia were significantly enriched for glutamate signaling pathway proteins (GRIA4, GRIA3, ATP1A3, and GNAQ). Synaptic protein co-expression was significantly decreased in schizophrenia with the exception of a small group of postsynaptic density proteins, whose co-expression increased and inversely correlated with spine density in schizophrenia subjects.
CONCLUSIONS: We observed alterations in the expression of glutamate signaling pathway proteins. Among these, the novel observation of reduced ATP1A3 expression is supported by strong genetic evidence indicating it may contribute to psychosis and cognitive impairment phenotypes. The observations of altered protein network topology further highlight the complexity of glutamate signaling network pathology in schizophrenia and provide a framework for evaluating future experiments to model the contribution of genetic risk to disease pathology.
C1 [MacDonald, Matthew L.; Newman, Jason; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Yates, Nathan A.] Univ Pittsburgh, Biomed Mass Spectrometry Ctr, Pittsburgh, PA 15213 USA.
[Hemby, Scott] Wake Forest Univ, Sch Med, Neurosci Program, Winston Salem, NC 27109 USA.
[Hemby, Scott] Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27109 USA.
[Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA.
[Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Educ & Clin Ctr, Vet Integrated Serv Network Mental Illness Res 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Biomed Sci Tower,3811 OHara St,BST W1645, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Penzes, Peter/L-3987-2016;
OI Penzes, Peter/0000-0001-5449-1640; Ding, Ying/0000-0003-1352-1000
FU National Institutes of Health [MH 071533, T32 MH 16804]; Biomedical Mass
Spectrometry Center; University of Pittsburgh Cancer Institute Cancer
Biomarker Facility [P30CA047904]; Bristol-Myers Squibb Foundation;
Bristol-Myers Squibb; Curridium Ltd; Pfizer
FX This work was funded by National Institutes of Health Grants MH 071533
and T32 MH 16804. The Biomedical Mass Spectrometry Center and University
of Pittsburgh Cancer Institute Cancer Biomarker Facility are supported
in part by award P30CA047904.; DAL currently receives
investigator-initiated research support from the Bristol-Myers Squibb
Foundation, Bristol-Myers Squibb, Curridium Ltd, and Pfizer and in 2007
to 2010 served as a consultant in the areas of target identification and
validation and new compound development to AstraZeneca, BioLine RX,
Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life
Science. MLM, YD, JN, SH, PP, NY, and RAS report no biomedical financial
interests or potential conflicts of interest.
NR 94
TC 12
Z9 12
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JUN 1
PY 2015
VL 77
IS 11
BP 959
EP 968
DI 10.1016/j.biopsych.2014.09.006
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CH6ZM
UT WOS:000354185300010
PM 25433904
ER
PT J
AU Pagani, O
Ruggeri, M
Manunta, S
Saunders, C
Peccatori, F
Cardoso, F
Kaufman, B
Paluch-Shimon, S
Gewefel, H
Gallerani, E
Abulkhair, O
Pistilli, B
Warner, E
Saloustros, E
Perey, L
Zaman, K
Rabaglio, M
Gelber, S
Gelber, RD
Goldhirsch, A
Korde, L
Azim, HA
Partridge, AH
AF Pagani, Olivia
Ruggeri, Monica
Manunta, Silvia
Saunders, Christobel
Peccatori, Fedro
Cardoso, Fatima
Kaufman, Bella
Paluch-Shimon, Shani
Gewefel, Hanan
Gallerani, Elisa
Abulkhair, OMalkahi
Pistilli, Barbara
Warner, Ellen
Saloustros, Emmanouil
Perey, Lucien
Zaman, Khalil
Rabaglio, Manuela
Gelber, Shari
Gelber, Richard D.
Goldhirsch, Aron
Korde, Larissa
Azim, Hatem A., Jr.
Partridge, Ann H.
TI Pregnancy after breast cancer: Are young patients willing to participate
in clinical studies?
SO BREAST
LA English
DT Article
DE Breast cancer; Young patients; Pregnancy; Estrogen receptor; Endocrine
treatment
ID FERTILITY CONCERNS; ADJUVANT TAMOXIFEN; WOMEN; METAANALYSIS; DIAGNOSIS;
SURVIVORS; AGE; PERSPECTIVES; STATISTICS; CARCINOMA
AB Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/MiddleEast/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (<= 30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for <= 30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Pagani, Olivia; Manunta, Silvia] Oncol Inst Southern Switzerland IOSI, CH-6500 Bellinzona, Switzerland.
[Saunders, Christobel] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia.
[Peccatori, Fedro] IEO, Div Gynecol Oncol, Fertil & Procreat Unit, I-20141 Milan, Italy.
[Cardoso, Fatima] Champalimaud Canc Ctr, Breast Unit, P-1400038 Lisbon, Portugal.
[Kaufman, Bella; Paluch-Shimon, Shani] Sheba Med Ctr, Inst Oncol, Breast Canc Serv Young Women, IL-52621 Tel Hashomer, Israel.
[Gewefel, Hanan] Woman & Fetal Imaging Clin WAFI, Cairo, Egypt.
[Gallerani, Elisa] Osped Multimed, Castellanza, VA, Italy.
[Abulkhair, OMalkahi] King Abdul Aziz Med City Natl Guard, Dept Oncol, Riyadh, Saudi Arabia.
[Pistilli, Barbara] Macerata Hosp, Dept Oncol, I-62100 Macerata, Italy.
[Warner, Ellen] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Med Oncol, Toronto, ON M4N 3M5, Canada.
[Saloustros, Emmanouil] Univ Hosp Heraklion, Dept Med Oncol, Hereditary Canc Clin, Iraklion 71110, Greece.
[Perey, Lucien] CHU Vaudois, Hop Morges, Ensemble Hosp Cote, Greeceo Unite Oncol, Lausanne, Switzerland.
[Zaman, Khalil] CHU Vaudois, Ctr Pluridisciplinaire Oncol CePO, Lausanne, Switzerland.
[Zaman, Khalil] CHU Vaudois, Ctr Oncol, CH-1011 Lausanne, Switzerland.
[Rabaglio, Manuela] Inselspital Bern, Brust & Tumor Zentrum Frauenklin, Univ Klin & Poliklin Med Onkol, CH-3010 Bern, Switzerland.
[Pagani, Olivia; Ruggeri, Monica; Goldhirsch, Aron] IBCSG, CH-3008 Bern, Switzerland.
[Gelber, Shari; Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA USA.
[Goldhirsch, Aron] IEO, Program Breast Hlth, I-20141 Milan, Italy.
[Korde, Larissa] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.
[Azim, Hatem A., Jr.] Univ Libre Bruxelles, Inst Jules Bordet, BrEAST Data Ctr, Dept Med, Brussels, Belgium.
[Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Pagani, O (reprint author), IBCSG, Effingerstr 40, CH-3008 Bern, Switzerland.
EM olivia.pagani@ibcsg.org
RI Saunders, Christobel/H-5779-2014;
OI Saunders, Christobel/0000-0003-2281-9829; Gallerani,
Elisa/0000-0003-4051-0315; Saloustros, Emmanouil /0000-0002-0485-0120;
Cardoso, Fatima/0000-0002-6692-2249
NR 28
TC 12
Z9 14
U1 1
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD JUN
PY 2015
VL 24
IS 3
BP 201
EP 207
DI 10.1016/j.breast.2015.01.005
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CG9HC
UT WOS:000353624600005
PM 25662412
ER
PT J
AU Heapy, AA
Higgins, DM
Cervone, D
Wandner, L
Fenton, BT
Kerns, RD
AF Heapy, Alicia A.
Higgins, Diana M.
Cervone, Dana
Wandner, Laura
Fenton, Brenda T.
Kerns, Robert D.
TI A Systematic Review of Technology-assisted Self-Management Interventions
for Chronic Pain Looking Across Treatment Modalities
SO CLINICAL JOURNAL OF PAIN
LA English
DT Review
DE chronic pain; Internet; review; technology; interactive voice response;
telephone; self-management
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; INTERACTIVE
VOICE RESPONSE; CHRONIC WIDESPREAD PAIN; CHRONIC BACK-PAIN;
PHYSICAL-ACTIVITY INTERVENTION; SMARTPHONE-BASED INTERVENTION; AND/OR
HIP OSTEOARTHRITIS; PRIMARY-CARE PATIENTS; PSYCHOLOGICAL TREATMENTS
AB Objectives: The use of technology to provide chronic pain self-management interventions has increased in the recent years. Individual studies have primarily focused on a single technology-assisted modality and direct comparisons of different technology-assisted modalities are rare. Thus, little is known about the relative strengths and weaknesses of each technology-assisted modality.
Materials and Methods: This article is a systematic review of technology-assisted self-management interventions for chronic nonheadache, noncancer pain in adults. We examined 3 treatment modalities: telephone, interactive voice response, and Internet. Electronic searches of OVID MEDLINE, OVID PsychINFO, and the Cochrane Database of Systematic Reviews were conducted. Forty-four articles including 9890 participants were reviewed.
Results: Across modalities, the existing evidence suggests that technology-assisted psychological interventions are efficacious for improving self-management of chronic pain in adults. All modalities have been shown to provide benefit and no clearly superior modality has emerged. The primary gaps in the literature are lack of in-person comparison groups, lack of direct comparison among technology-assisted modalities, and heterogeneity of methods and interventions that limit comparability across studies and modalities.
Discussion: Future trials should focus on direct comparisons of technology-assisted interventions with in-person treatment and head to head comparisons of different technology-assisted modalities. Additional areas of focus include quantifying the cost of technology-assisted interventions, examining the effect of treatment "dose" on outcomes, and establishing guidelines for developing treatments for the technology-assisted environment.
C1 [Heapy, Alicia A.; Cervone, Dana; Wandner, Laura; Fenton, Brenda T.; Kerns, Robert D.] VA Connecticut Healthcare Syst Pain Res Informat, Ctr Innovat, West Haven, CT 06516 USA.
[Heapy, Alicia A.; Wandner, Laura; Fenton, Brenda T.; Kerns, Robert D.] Yale Univ, Sch Med, New Haven, CT USA.
[Higgins, Diana M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Higgins, Diana M.] VA Boston Healthcare Syst, Boston, MA USA.
RP Heapy, AA (reprint author), VA Connecticut Healthcare Syst Pain Res Informat, Ctr Innovat, 950 Campbell Ave 11ACLGS, West Haven, CT 06516 USA.
EM alicia.heapy@va.gov
RI Emchi, Karma/Q-1952-2016;
OI Higgins, Diana/0000-0002-6885-266X
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research, West Haven, CT;
Development Center of Innovation [CIN-13-407]; Investigator Initiated
Research [IIR 09-058]
FX Supported by Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research, West Haven, CT and Development Center of Innovation
(CIN-13-407), and Investigator Initiated Research (IIR 09-058). The
authors declare no conflict of interest.
NR 67
TC 9
Z9 9
U1 5
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0749-8047
EI 1536-5409
J9 CLIN J PAIN
JI Clin. J. Pain
PD JUN
PY 2015
VL 31
IS 6
BP 470
EP 492
DI 10.1097/AJP.0000000000000185
PG 23
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CH5VK
UT WOS:000354103300002
PM 25411862
ER
PT J
AU Suri, P
Carlson, MJ
Rainville, J
AF Suri, Pradeep
Carlson, M. Jake
Rainville, James
TI Nonoperative Treatment for Lumbosacral Radiculopathy: What Factors
Predict Treatment Failure?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID LUMBAR DISC HERNIATION; RESEARCH TRIAL SPORT; LOW-BACK-PAIN;
PROGNOSTIC-FACTORS; DISABILITY COMPENSATION; CONSERVATIVE TREATMENT;
NONSURGICAL TREATMENT; PHYSICAL-EXAMINATION; TREATMENT OUTCOMES;
FOLLOW-UP
AB Prior studies of nonoperative treatment for lumbosacral radiculopathy have identified potential predictors of treatment failure, defined by persistent pain, persistent disability, lack of recovery, or subsequent surgery. However, few predictors have been replicated, with the exception of higher leg pain intensity, as a predictor of subsequent surgery.
We asked two research questions: (1) Does higher baseline leg pain intensity predict subsequent lumbar surgery? (2) Can other previously identified "candidate" predictors of nonoperative treatment failure be replicated?
Between January 2008 and March 2009, 154 participants with acute lumbosacral radicular pain were enrolled in a prospective database; 128 participants (83%) received nonoperative treatment and 26 (17%) received surgery over 2-year followup. Ninety-four nonoperative participants (73%) responded to followup questionnaires. We examined associations between previously identified "candidate" predictors and treatment failure defined as (1) subsequent surgery; (2) persistent leg pain on a visual analog scale; (3) persistent disability on the Oswestry Disability Index; or (4) participant-reported lack of recovery over 2-year followup. Confounding variables including sociodemographics, clinical factors, and imaging characteristics were evaluated using an exploratory bivariate analysis followed by a multivariate analysis.
With the numbers available, higher baseline leg pain intensity was not an independent predictor of subsequent surgery (adjusted odds ratio [aOR], 1.22 per point of baseline leg pain; 95% confidence interval [CI], 0.98-1.53; p = 0.08). Prior low back pain (aOR, 4.79; 95% CI, 1.01-22.7; p = 0.05) and a positive straight leg raise test (aOR, 4.38; 95% CI, 1.60-11.9; p = 0.004) predicted subsequent surgery. Workers compensation claims predicted persistent leg pain (aOR, 9.04; 95% CI, 1.01-81; p = 0.05) and disability (aOR, 5.99; 95% CI, 1.09-32.7; p = 0.04). Female sex predicted persistent disability (aOR, 3.16; 95% CI, 1.03-9.69; p = 0.05) and perceived lack of recovery (aOR, 2.44; 95% CI, 1.02-5.84; p = 0.05).
Higher baseline leg pain intensity was not confirmed as a predictor of subsequent surgery. However, the directionality of the association seen was consistent with prior reports, suggesting Type II error as a possible explanation; larger studies are needed to further examine this relationship. Clinicians should be aware of potential factors that may predict nonoperative treatment failure, including prior low back pain or a positive straight leg raise test as predictors of subsequent surgery, workers compensation claims as predictors of persistent leg pain and disability, and female sex as a predictor of persistent disability and lack of recovery.
Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
C1 [Suri, Pradeep] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA.
[Suri, Pradeep; Carlson, M. Jake] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.
[Rainville, James] New England Baptist Hosp, Boston, MA USA.
[Rainville, James] Harvard Univ, Sch Med, Boston, MA USA.
RP Suri, P (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,RCS 117, Seattle, WA 98108 USA.
EM pradeep.suriyaarachchi@va.gov
FU Rehabilitation Medicine Scientist Training K12 Program (RMSTP); National
Institutes of Health [K12 HD 01097]
FX VA Puget Sound provided support for one of the author's (PS)
participation in this research. A portion of this research was conducted
while this author was funded by the Rehabilitation Medicine Scientist
Training K12 Program (RMSTP) and the National Institutes of Health (K12
HD 01097).
NR 35
TC 3
Z9 3
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2015
VL 473
IS 6
BP 1931
EP 1939
DI 10.1007/s11999-014-3677-8
PG 9
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CH6FX
UT WOS:000354133000013
PM 24832829
ER
PT J
AU Manchikanti, L
Benyamin, RM
Falco, FJE
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Benyamin, Ramsin M.
Falco, Frank J. E.
Kaye, Alan D.
Hirsch, Joshua A.
TI Do Epidural Injections Provide Short- and Long-term Relief for Lumbar
Disc Herniation? A Systematic Review
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; 2-YEAR
FOLLOW-UP; CENTRAL SPINAL STENOSIS; MANAGING CHRONIC PAIN;
CLINICAL-PRACTICE GUIDELINE; NERVE ROOT COMPRESSION; ACTIVE-CONTROL
TRIAL; RADICULAR PAIN
AB As part of a comprehensive nonsurgical approach, epidural injections often are used in the management of lumbar disc herniation. Recent guidelines and systematic reviews have reached different conclusions about the efficacy of epidural injections in managing lumbar disc herniation.
In this systematic review, we determined the efficacy (pain relief and functional improvement) of the three anatomic approaches (caudal, lumbar interlaminar, and transforaminal) for epidural injections in the treatment of disc herniation.
We performed a literature search from 1966 to June 2013 in PubMed, Cochrane library, US National Guideline Clearinghouse, previous systematic reviews, and cross-references for trials studying all types of epidural injections in managing chronic or chronic and subacute lumbar disc herniation. We wanted only randomized controlled trials (RCTs) (either placebo or active controlled) to be included in our analysis, and 66 studies found in our search fulfilled these criteria. We then assessed the methodologic quality of these 66 studies using the Cochrane review criteria for RCTs. Thirty-nine studies were excluded, leaving 23 RCTs of high and moderate methodologic quality for analysis. Evidence for the efficacy of all three approaches for epidural injection under fluoroscopy was strong for short-term (< 6 months) and moderate for long-term (a parts per thousand yen 6 months) based on the Cochrane rating system with five levels of evidence (best evidence synthesis), with strong evidence denoting consistent findings among multiple high-quality RCTs and moderate evidence denoting consistent findings among multiple low-quality RCTs or one high-quality RCT. The primary outcome measure was pain relief, defined as at least 50% improvement in pain or 3-point improvement in pain scores in at least 50% of the patients. The secondary outcome measure was functional improvement, defined as 50% reduction in disability or 30% reduction in the disability scores.
Based on strong evidence for short-term efficacy from multiple high-quality trials and moderate evidence for long-term efficacy from at least one high quality trial, we found that fluoroscopic caudal, lumbar interlaminar, and transforaminal epidural injections were efficacious at managing lumbar disc herniation in terms of pain relief and functional improvement.
The available evidence suggests that epidural injections performed under fluoroscopy by trained physicians offer improvement in pain and function in well-selected patients with lumbar disc herniation.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA.
[Manchikanti, Laxmaiah] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Benyamin, Ramsin M.] Millennium Pain Ctr, Bloomington, IL USA.
[Benyamin, Ramsin M.] Univ Illinois, Coll Med, Dept Surg, Urbana, IL 61801 USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Pain Med Fellowship Program, Philadelphia, PA 19140 USA.
[Falco, Frank J. E.] Temple Univ, Dept Phys Med & Rehabil, Sch Med, Philadelphia, PA 19122 USA.
[Kaye, Alan D.] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Intervent Care Minimally Invas Spine Surg Interve, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), Pain Management Ctr Paducah, 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
FU Boston Scientific (Natick, MA, USA); Kimberly Clark (Dallas, TX, USA);
St Jude Medical, Inc (St Paul, MN, USA); Joimax Inc (Irvine, CA, USA);
Depomed, Inc (Newark, CA, USA)
FX One of the authors (RMB) certifies that he or she, or a member of his or
her immediate family, has received or may receive payments or benefits,
during the study period, an amount of less than USD 10,000 from Boston
Scientific (Natick, MA, USA) and Kimberly Clark (Dallas, TX, USA). One
of the authors (FJEF) certifies that he or she, or a member of his or
her immediate family, has received or may receive payments or benefits,
during the study period, an amount of less than USD 10,000, from St Jude
Medical, Inc (St Paul, MN, USA) and Joimax Inc (Irvine, CA, USA). One of
the authors (ADK) certifies that he or she, or a member of his or her
immediate family, has received or may receive payments or benefits,
during the study period, an amount of less than USD 10,000, from
Depomed, Inc (Newark, CA, USA).
NR 130
TC 33
Z9 34
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2015
VL 473
IS 6
BP 1940
EP 1956
DI 10.1007/s11999-014-3490-4
PG 17
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CH6FX
UT WOS:000354133000014
PM 24515404
ER
PT J
AU Bozic, KJ
Kamath, AF
Ong, K
Lau, E
Kurtz, S
Chan, V
Vail, TP
Rubash, H
Berry, DJ
AF Bozic, Kevin J.
Kamath, Atul F.
Ong, Kevin
Lau, Edmund
Kurtz, Steve
Chan, Vanessa
Vail, Thomas P.
Rubash, Harry
Berry, Daniel J.
TI Comparative Epidemiology of Revision Arthroplasty: Failed THA Poses
Greater Clinical and Economic Burdens Than Failed TKA
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; TOTAL JOINT
ARTHROPLASTY; UNITED-STATES; COST-EFFECTIVENESS; RISK-FACTORS; 2-STAGE
REIMPLANTATION; HOSPITAL READMISSION; MEDICARE PATIENTS; FOLLOW-UP
AB Revision THA and TKA are growing and important clinical and economic challenges. Healthcare systems tend to combine revision joint replacement procedures into a single service line, and differences between revision THA and revision TKA remain incompletely characterized. These differences carry implications for guiding care and resource allocation. We therefore evaluated epidemiologic trends associated with revision THAs and TKAs.
We sought to determine differences in (1) the number of patients undergoing revision TKA and THA and respective demographic trends; (2) differences in the indications for and types of revision TKA and THA; (3) differences in patient severity of illness scoring between THA and TKA; and (4) differences in resource utilization (including cost and length of stay [LOS]) between revision THA and TKA.
The Nationwide Inpatient Sample (NIS) was used to evaluate 235,857 revision THAs and 301,718 revision TKAs between October 1, 2005 and December 31, 2010. Patient characteristics, procedure information, and resource utilization were compared across revision THAs and TKAs. A revision burden (ratio of number of revisions to total number of revision and primary surgeries) was calculated for hip and knee procedures. Severity of illness scoring and cost calculations were derived from the NIS. As our study was principally descriptive, statistical analyses generally were not performed; however, owing to the large sample size available to us through this NIS analysis, even small observed differences presented are likely to be highly statistically significant.
Revision TKAs increased by 39% (revision burden, 9.1%-9.6%) and THAs increased by 23% (revision burden, 15.4%-14.6%). Revision THAs were performed more often in older patients compared with revision TKAs. Periprosthetic joint infection (25%) and mechanical loosening (19%) were the most common reasons for revision TKA compared with dislocation (22%) and mechanical loosening (20%) for revision THA. Full (all-component) revision was more common in revision THAs (43%) than in TKAs (37%). Patients who underwent revision THA generally were sicker (> 50% major severity of illness score) than patients who underwent revision TKA (65% moderate severity of illness score). Mean LOS was longer for revision THAs than for TKAs. Mean hospitalization costs were slightly higher for revision THA (USD 24,697 +/- USD 40,489 [SD]) than revision TKA (USD 23,130 +/- USD 36,643 [SD]). Periprosthetic joint infection and periprosthetic fracture were associated with the greatest LOS and costs for revision THAs and TKAs.
These data could prove important for healthcare systems to appropriately allocate resources to hip and knee procedures: the revision burden for THA is 52% greater than for TKA, but revision TKAs are increasing at a faster rate. Likewise, the treating clinician should understand that while both revision THAs and TKAs bear significant clinical and economic costs, patients undergoing revision THA tend to be older, sicker, and have greater costs of care.
C1 [Bozic, Kevin J.; Chan, Vanessa; Vail, Thomas P.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
[Bozic, Kevin J.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
[Kamath, Atul F.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
[Ong, Kevin; Kurtz, Steve] Exponent Inc, Philadelphia, PA USA.
[Lau, Edmund] Exponent Inc, Menlo Pk, CA USA.
[Rubash, Harry] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Berry, Daniel J.] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA.
RP Bozic, KJ (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 500 Parnassus Ave,MU 320W, San Francisco, CA 94143 USA.
EM kevin.bozic@ucsf.edu
FU DePuy Orthopaedics, Inc (Warsaw, IN, USA); Zimmer, Inc (Warsaw, IN, USA)
FX One or more of the authors (SMK, KO, EL) are employees of Exponent, Inc,
Menlo Park, CA, USA, and Philadelphia, PA, USA. One of the authors
certifies that he (DJB), or a member of his or her immediate family, has
received or may receive payments or benefits, during the study period,
an amount in excess of USD 100,001-USD 1,000,000, from DePuy
Orthopaedics, Inc (Warsaw, IN, USA). One of the authors (TPV) certifies
that he has received or may receive payments or benefits, during the
study period, an amount in excess of USD 10,001-USD 100,000 from DePuy
Orthopaedics, Inc (Warsaw, IN, USA).; One of the authors (HER) certifies
that he has received or may receive payments or benefits, during the
study period, an amount in excess of USD 100,001-USD 1,000,000, from
Zimmer, Inc (Warsaw, IN, USA).
NR 61
TC 21
Z9 22
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2015
VL 473
IS 6
BP 2131
EP 2138
DI 10.1007/s11999-014-4078-8
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CH6FX
UT WOS:000354133000042
PM 25467789
ER
PT J
AU Brown, DL
Cowdery, JE
Jones, TS
Langford, A
Gammage, C
Jacobs, TL
AF Brown, Devin L.
Cowdery, Joan E.
Jones, Toni Stokes
Langford, Aisha
Gammage, Catherine
Jacobs, Teresa L.
TI Adolescent knowledge and attitudes related to clinical trials
SO CLINICAL TRIALS
LA English
DT Article
DE Adolescent; knowledge; attitude; biomedical research; clinical trials
ID CANCER; PARTICIPATION; RACE
AB Background or aims Poor enrollment plagues most clinical trials. Furthermore, despite mandates to improve minority representation in clinical trial participation, little progress has been made. We investigated the knowledge and attitudes of adolescents related to clinical trials and made race/ethnicity comparisons in an attempt to identify a possible educational intervention target.
Methods Students aged 13-18 years in southeast Michigan were offered participation through a class at one high school or two academic summer enrichment programs that drew from multiple high schools (73% response). Questionnaires previously validated in adults were administered. Non-Hispanic whites were compared with minorities using Wilcoxon rank-sum tests.
Results Of the 82 respondents, the median age was 16 years (interquartile range: 15-17 years); 22 (28%) were white, 41 (51%) were African American, 11 (14%) were multiracial, 2 (2%) were American Indian or Alaska Native, 1 (1%) was Asian, 3 (4%) were Native Hawaiian or other Pacific Islander, and 2 respondents did not report a race (but did report Hispanic ethnicity). Nine (12%) were Hispanic. Only 27 (33%) had ever heard of a clinical trial. On a scale from 1 (most receptive) to 5 (least receptive) for learning more about a clinical trial for a relevant medical condition, the median score was 2 (interquartile range: 1-3) and for participating in a clinical trial for a relevant medical condition was 2 (interquartile range: 2-3). Overall knowledge was poor, with a median of 46% (interquartile range: 23%-62%) of knowledge answers correct. Knowledge was reduced (p=0.0006) and attitudes were more negative (p=0.05) in minorities than non-Hispanic whites, while minorities also endorsed more substantial barriers to trial participation (p=0.0002). Distrust was similar between minority students and non-Hispanic whites (p=0.15), and self-efficacy was greater in non-Hispanic whites (p=0.05).
Conclusion Educational interventions directed toward adolescents that address knowledge, attitudes, and distrust in order to improve clinical trial awareness and receptivity overall are needed and may represent a tool to address disparities in minority enrollment in clinical trials.
C1 [Brown, Devin L.; Jacobs, Teresa L.] Univ Michigan, Stroke Program, Cardiovasc Ctr, Ann Arbor, MI 48109 USA.
[Cowdery, Joan E.] Eastern Michigan Univ, Sch Hlth Promot & Human Performance, Ypsilanti, MI 48197 USA.
[Jones, Toni Stokes] Eastern Michigan Univ, Dept Teacher Educ, Ypsilanti, MI 48197 USA.
[Langford, Aisha] US Dept Vet Affairs, Ctr Clin Management Res, Washington, DC USA.
[Langford, Aisha] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA.
[Gammage, Catherine] Melvindale High Sch, Dept Sci, Melvindale, MI USA.
[Jacobs, Teresa L.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Brown, DL (reprint author), Univ Michigan, Stroke Program, Cardiovasc Ctr, 1500 East Med Ctr Dr,SPC 5855, Ann Arbor, MI 48109 USA.
EM devinb@umich.edu
OI Langford, Aisha/0000-0003-1758-691X
NR 12
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD JUN
PY 2015
VL 12
IS 3
BP 212
EP 214
DI 10.1177/1740774515571443
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CH4EC
UT WOS:000353984100004
PM 25673637
ER
PT J
AU Cote, CJ
AF Cote, Charles J.
TI Anesthesiological considerations for children with obstructive sleep
apnea
SO CURRENT OPINION IN ANESTHESIOLOGY
LA English
DT Review
DE adverse events; obstructive sleep apnea; opioid sensitivity; OSA;
perioperative
ID PERIOPERATIVE MANAGEMENT; PEDIATRIC POPULATION; RECURRENT HYPOXEMIA;
OPIOID RECEPTOR; YOUNG-CHILDREN; STEEP APNEA; TONSILLECTOMY;
ADENOTONSILLECTOMY; OBESITY; CODEINE
AB Purpose of review
To summarize recent evidence-based data regarding outcomes associated with children who have obstructive sleep apnea (OSA).
Recent findings
Internet surveys conducted by pediatric otolaryngologists and pediatric anesthesiologists have reported a disturbing number of deaths within 24 h of tonsillectomy attributed to postsurgical/anesthesia apnea. Several occurred in the post anesthesia care unit after routine monitors had been removed. In addition, a number of deaths also have been attributed to children who have duplicated cytochromes allowing the rapid conversion of codeine to morphine, thus producing a relative drug overdose. Finally, there is some human and animal evidence suggesting that repeated episodes of hypoxemia result in altered opioid receptors causing relative opioid sensitivity. These factors have important clinical implications.
Summary
Perioperative deaths in children with OSA occur at a low frequency. Hypoxia-induced opioid sensitivity combined with an approximate 1-2% incidence of rapid conversion of codeine to morphine suggest the need for new approaches for providing preoperative assessment of risk, extended postoperative observation and the need for alternative opioids to codeine. Additionally, new less painful surgical approaches may help to reduce postoperative opioid requirements and therefore perhaps less risk for opiate-induced apnea in this vulnerable population.
C1 Harvard Univ, Massachusetts Gen Hosp, Mass Gen Hosp Children,Sch Med, Dept Anesthesia Crit Care & Pain Management,Div P, Boston, MA 02114 USA.
RP Cote, CJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Mass Gen Hosp Children,Sch Med, Dept Anesthesia Crit Care & Pain Management,Div P, 55 Fruit St, Boston, MA 02114 USA.
EM cjcote@partners.org
NR 43
TC 4
Z9 4
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0952-7907
EI 1473-6500
J9 CURR OPIN ANESTHESIO
JI Curr. Opin. Anesthesiol.
PD JUN
PY 2015
VL 28
IS 3
BP 327
EP 332
DI 10.1097/ACO.0000000000000187
PG 6
WC Anesthesiology
SC Anesthesiology
GA CH2GP
UT WOS:000353844000016
PM 25827276
ER
PT J
AU del Carmen, C
Andrades, MG
Oruezabal, RI
Cuende, N
AF del Carmen, C.
Andrades, M. G.
Oruezabal, R. I.
Cuende, N.
TI ARTIFICIAL CORNEAS: A TRANSLATIONAL PROCESS GENERAL VIEW
SO CYTOTHERAPY
LA English
DT Meeting Abstract
C1 [del Carmen, C.; Oruezabal, R. I.; Cuende, N.] Andalusian Initiat Adv Therapies, Seville, Spain.
[Andrades, M. G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston Keratoprosthesis Lab, Boston, MA USA.
[Andrades, M. G.] Schepens Eye Res Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465-3249
EI 1477-2566
J9 CYTOTHERAPY
JI Cytotherapy
PD JUN
PY 2015
VL 17
IS 6
SU S
MA 275
BP S80
EP S80
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology; Hematology; Medicine, Research & Experimental
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
& Experimental Medicine
GA CH6JK
UT WOS:000354142700254
ER
PT J
AU Telo, GH
Volkening, LK
Butler, DA
Laffel, LM
AF Telo, Gabriela H.
Volkening, Lisa K.
Butler, Deborah A.
Laffel, Lori M.
TI Salient Characteristics of Youth with Type 1 Diabetes Initiating
Continuous Glucose Monitoring
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID EXCHANGE CLINIC REGISTRY; INSULIN-PUMP THERAPY; GENERIC CORE SCALES;
FAMILY CONFLICT; CHILDREN; TRIAL; QUALITY; ASSOCIATION; TECHNOLOGY;
MANAGEMENT
AB Objective: Consistent continuous glucose monitoring (CGM) use is a challenge in youth with type 1 diabetes. This study aimed to investigate patient and family behavioral and clinical characteristics associated with interest in implementing CGM.
Research Design and Methods: In a cross-sectional study, we compared 120 youth interested in starting CGM (the CGM group) with a general sample of 238 youth with type 1 diabetes (the Standard group). Youth and their parents completed validated surveys assessing adherence to diabetes management, diabetes-specific family conflict, parent involvement in diabetes management, and youth quality of life. Demographic and clinical data were obtained from chart review and interview.
Results: Youth participants had a mean age of 13.0 +/- 2.8 years, diabetes duration of 6.3 +/- 3.4 years, and hemoglobin A1c (HbA1c) level of 8.2 +/- 1.0% (66 +/- 11 mmol/mol). Youth in the CGM group performed more frequent blood glucose monitoring, had lower HbA1c levels, and were more likely to be treated by continuous subcutaneous insulin infusion (CSII) and to be living in two-parent homes than youth in the Standard group. Compared with the Standard group, youth interested in wearing a CGM device and their parents reported greater adherence to diabetes management, less diabetes-specific family conflict, and higher youth quality of life. No differences were found between groups with respect to parent involvement in diabetes management by both youth and parent reports.
Conclusions: In efforts to enhance CGM uptake, it is important to address factors such as blood glucose monitoring frequency, CSII use, adherence, and diabetes-specific family conflict when considering youth with type 1 diabetes for CGM implementation.
C1 [Telo, Gabriela H.; Volkening, Lisa K.; Butler, Deborah A.; Laffel, Lori M.] Harvard Univ, Sch Med, Pediat Adolescent & Young Adult Sect, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Telo, Gabriela H.; Volkening, Lisa K.; Butler, Deborah A.; Laffel, Lori M.] Harvard Univ, Sch Med, Genet & Epidemiol Sect, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Telo, Gabriela H.] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Telo, Gabriela H.] Minist Educ, CAPES Fdn, Brasilia, DF, Brazil.
RP Laffel, LM (reprint author), Harvard Univ, Sch Med, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect,Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM lori.laffel@joslin.harvard.edu
FU National Institutes of Health [R01DK089349, P30DK036836]; CAPES/CNPq
[0596-13-2]; Katherine Adler Astrove Youth Education Fund; Maria Griffin
Drury Pediatric Fund; Eleanor Chesterman Beatson Fund
FX This research was supported by funding from the National Institutes of
Health (grants R01DK089349 and P30DK036836), the CAPES/CNPq (grant
0596-13-2), the Katherine Adler Astrove Youth Education Fund, the Maria
Griffin Drury Pediatric Fund, and the Eleanor Chesterman Beatson Fund.
NR 30
TC 4
Z9 4
U1 4
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUN 1
PY 2015
VL 17
IS 6
BP 373
EP 378
DI 10.1089/dia.2014.0290
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CH6TF
UT WOS:000354168400003
PM 25749206
ER
PT J
AU Rockette-Wagner, B
Edelstein, S
Venditti, EM
Reddy, D
Bray, GA
Carrion-Petersen, ML
Dabelea, D
Delahanty, LM
Florez, H
Franks, PW
Montez, MG
Rubin, R
Kriska, AM
AF Rockette-Wagner, Bonny
Edelstein, Sharon
Venditti, Elizabeth M.
Reddy, Deepti
Bray, George A.
Carrion-Petersen, Mary Lou
Dabelea, Dana
Delahanty, Linda M.
Florez, Hermes
Franks, Paul W.
Montez, Maria G.
Rubin, Richard
Kriska, Andrea M.
CA Diabet Prevention Program Res Grp
TI The impact of lifestyle intervention on sedentary time in individuals at
high risk of diabetes
SO DIABETOLOGIA
LA English
DT Article
DE Diabetes Prevention Program; Sedentary behaviour; Television watching;
Type 2 diabetes
ID MODIFIABLE ACTIVITY QUESTIONNAIRE; PHYSICAL-ACTIVITY;
PREVENTION-PROGRAM; ADULTS; RELIABILITY; POPULATION; BEHAVIORS;
MELLITUS; VALIDITY; OBESITY
AB Aims/hypothesis The Diabetes Prevention Program (DPP) lifestyle intervention successfully achieved its goal of increasing leisure physical activity levels. This current study examines whether the lifestyle intervention also changed time spent being sedentary and the impact of sedentary time on diabetes development in this cohort.
Methods 3,232 DPP participants provided baseline data. Sedentary behaviour was assessed via an interviewer-administered questionnaire and reported as time spent watching television specifically (or combined with sitting at work). Mean change in sedentary time was examined using repeated measures ANCOVA. The relationship between sedentary time and diabetes incidence was determined using Cox proportional hazards models.
Results During the DPP follow-up (mean: 3.2 years), sedentary time declined more in the lifestyle than the metformin or placebo participants (p < 0.05). For the lifestyle group, the decrease in reported mean television watching time (22 [95% CI 26, 17] min/day) was greater than in the metformin or placebo groups (p < 0.001). Combining all participants together, there was a significantly increased risk of developing diabetes with increased television watching (3.4% per hour spent watching television), after controlling for age, sex, treatment arm and leisure physical activity (p < 0.01), which was attenuated when time-dependent weight was added to the model.
Conclusions/interpretation In the DPP, the lifestyle intervention was effective at reducing sedentary time, which was not a primary goal. In addition, in all treatment arms, individuals with lower levels of sedentary time had a lower risk of developing diabetes. Future lifestyle intervention programmes should emphasise reducing television watching and other sedentary behaviours in addition to increasing physical activity.
C1 [Rockette-Wagner, Bonny; Venditti, Elizabeth M.; Kriska, Andrea M.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Edelstein, Sharon; Reddy, Deepti] George Washington Univ, Washington, DC USA.
[Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
[Carrion-Petersen, Mary Lou] Univ Calif San Diego, San Diego, CA 92103 USA.
[Dabelea, Dana] Univ Colorado, Denver, CO 80202 USA.
[Delahanty, Linda M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Florez, Hermes] Univ Miami, Miami, FL USA.
[Franks, Paul W.] Lund Univ, Genet & Mol Epidemiol Unit, Dept Clin Sci, Malmo, Sweden.
[Franks, Paul W.] Harvard Univ, Dept Nutr, Boston, MA 02115 USA.
[Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Rubin, Richard] Johns Hopkins Sch Med, Baltimore, MD USA.
[Kriska, Andrea M.] George Washington Univ, Ctr Biostat, DPP Coordinating Ctr, Rockville, MD 20852 USA.
[Dabelea, Dana] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA.
[Delahanty, Linda M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Florez, Hermes] Univ Miami, VA GRECC, Miami, FL USA.
RP Kriska, AM (reprint author), Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
EM dppmail@bsc.gwu.edu
OI Kriska, Andrea/0000-0002-3522-0869
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
of the National Institutes of Health [U01 DK048489]; NIDDK; Intramural
Research Program; Indian Health Service; National Institute of Child
Health and Human Development; National Institute on Aging; National Eye
Institute; National Heart Lung and Blood Institute; Office of Research
on Women's Health; National Institute on Minority Health and Health
Disparities; Centers for Disease Control and Prevention; ADA;
Bristol-Myers Squibb; Parke-Davis
FX During the DPPOS, the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) of the National Institutes of Health provided
funding to the clinical centres and the Coordinating Center for the
design and conduct of the study, and collection, management, analysis
and interpretation of the data (U01 DK048489). The Southwestern American
Indian Centers were supported directly by the NIDDK, including its
Intramural Research Program, and the Indian Health Service. The General
Clinical Research Center Program, National Center for Research Resources
and the Department of Veterans Affairs supported data collection at many
of the clinical centres. Funding was also provided by the National
Institute of Child Health and Human Development, the National Institute
on Aging, the National Eye Institute, the National Heart Lung and Blood
Institute, the Office of Research on Women's Health, the National
Institute on Minority Health and Health Disparities, the Centers for
Disease Control and Prevention and the ADA. Bristol-Myers Squibb and
Parke-Davis provided additional funding and material support during the
DPP, Lipha (Merck-Sante) provided medication and LifeScan Inc. donated
materials during the DPP and DPPOS. The opinions expressed are those of
the investigators and do not necessarily reflect the views of the
funding agencies.
NR 18
TC 2
Z9 2
U1 6
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2015
VL 58
IS 6
BP 1198
EP 1202
DI 10.1007/s00125-015-3565-0
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CH2YX
UT WOS:000353893000009
PM 25851102
ER
PT J
AU Schroder, PM
Khattar, M
Baum, CE
Miyahara, Y
Chen, WH
Vyas, R
Muralidharan, S
Mierzejewska, B
Stepkowski, SM
AF Schroder, Paul M.
Khattar, Mithun
Baum, Caitlin E.
Miyahara, Yoshihiro
Chen, Wenhao
Vyas, Rohit
Muralidharan, Shravan
Mierzejewska, Beata
Stepkowski, Stanislaw M.
TI PD-1-dependent restoration of self-tolerance in the NOD mouse model of
diabetes after transient anti-TCR beta mAb therapy
SO DIABETOLOGIA
LA English
DT Article
DE Antibody; Autoimmunity; Immunotherapy; NOD mice; PD-1; Self-tolerance; T
cell receptor.; T cells; Type 1 diabetes
ID PLACEBO-CONTROLLED TRIAL; INDUCED CYTOKINE-RELEASE; T-CELL-RECEPTOR;
MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CD3 ANTIBODY; MICE; AUTOIMMUNITY;
MULTICENTER; REMISSION
AB Aims/hypothesis T cells play a major role in the pathogenesis of type 1 diabetes, and there is great interest in developing curative immunotherapies targeting these cells. In this study, a monoclonal antibody (mAb) targeting the T cell receptor beta-chain (TCR beta) was investigated for its ability to prevent and reverse disease in mouse models of diabetes.
Methods RIP-OVA(hi) (C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ) mice adoptively transferred with ovalbumin-specific T cells (an induced model of diabetes) and NOD mice (a spontaneous model of diabetes) were used to test anti-TCR beta mAb therapy as a means of preventing and reversing type 1 diabetes.
Results A single dose of anti-TCR beta completely prevented disease in RIP-OVA(hi) mice without inducing the release of inflammatory cytokines. Transient anti-TCR beta therapy prevented diabetes in 90% of NOD mice and reversed the disease after its onset in 73% of NOD mice. Long after the remission of type 1 diabetes, the anti-TCR beta treated mice were able to reject BALB/c skin allografts with normal kinetics while maintaining normoglycaemia. Treatment did not cause significant reductions in lymphocyte numbers in the spleen or pancreatic lymph nodes, but did result in a decreased percentage of chemokine receptor 9 (CCR9) positive, CD8(+) T cells. Notably, anti-TCR beta therapy increased the expression of programmed death 1 (PD-1) on the surface of the T cells; PD-1 expression is important for maintaining anti-TCR beta-induced self-tolerance, as type 1 diabetes recurs in mice following a blockade of PD-1 signalling.
Conclusions/interpretation Anti-TCR beta mAb is a safe and effective immunotherapy that results in reduced numbers of CCR9(+) T cells, an increased expression of PD-1 on T cells and the restoration of self-tolerance in NOD mice.
C1 [Schroder, Paul M.; Khattar, Mithun; Baum, Caitlin E.; Miyahara, Yoshihiro; Chen, Wenhao; Vyas, Rohit; Muralidharan, Shravan; Mierzejewska, Beata; Stepkowski, Stanislaw M.] Univ Toledo, Coll Med, Dept Med Microbiol & Immunol, Toledo, OH 43614 USA.
[Khattar, Mithun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Chen, Wenhao] Houston Methodist Hosp, Houston Methodist Res Inst, Immunobiol Res Ctr, Transplant Immunol Res Program, Houston, TX USA.
RP Stepkowski, SM (reprint author), Univ Toledo, Coll Med, Dept Med Microbiol & Immunol, 3000 Arlington Ave,HEB 263A, Toledo, OH 43614 USA.
EM stanislaw.stepkowski@utoledo.edu
FU National Institutes of Health [5RO1AI090244]; UT-Biomedical Science
Innovation Award
FX This work was supported by funds from the National Institutes of Health
(grant number 5RO1AI090244 to SMS) and the UT-Biomedical Science
Innovation Award (to SMS). The funders had no role in the study design,
data collection and analysis, decision to publish or preparation of the
manuscript.
NR 44
TC 1
Z9 1
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2015
VL 58
IS 6
BP 1309
EP 1318
DI 10.1007/s00125-015-3564-1
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CH2YX
UT WOS:000353893000021
PM 25794782
ER
PT J
AU Bentley-Lewis, R
Huynh, J
Xiong, G
Lee, H
Wenger, J
Clish, C
Nathan, D
Thadhani, R
Gerszten, R
AF Bentley-Lewis, Rhonda
Huynh, Jennifer
Xiong, Grace
Lee, Hang
Wenger, Julia
Clish, Clary
Nathan, David
Thadhani, Ravi
Gerszten, Robert
TI Metabolomic profiling in the prediction of gestational diabetes mellitus
SO DIABETOLOGIA
LA English
DT Article
DE Amino acids; Gestational diabetes mellitus; Metabolite profiling;
Metabolites; Metabolomics
ID RISK
AB Aims/hypothesis Metabolomic profiling in populations with impaired glucose tolerance has revealed that branched chain and aromatic amino acids (BCAAs) are predictive of type 2 diabetes. Because gestational diabetes mellitus (GDM) shares pathophysiological similarities with type 2 diabetes, the metabolite profile predictive of type 2 diabetes could potentially identify women who will develop GDM.
Methods We conducted a nested case-control study of 18- to 40-year-old women who participated in the Massachusetts General Hospital Obstetrical Maternal Study between 1998 and 2007. Participants were enrolled during their first trimester of a singleton pregnancy and fasting serum samples were collected. The women were followed throughout pregnancy and identified as having GDM or normal glucose tolerance (NGT) in the third trimester. Women with GDM (n = 96) were matched to women with NGT (n = 96) by age, BMI, gravidity and parity. Liquid chromatography-mass spectrometry was used to measure the levels of 91 metabolites.
Results Data analyses revealed the following characteristics (mean +/- SD): age 32.8 +/- 4.4 years, BMI 28.3 +/- 5.6 kg/m(2), gravidity 2 +/- 1 and parity 1 +/- 1. Six metabolites (anthranilic acid, alanine, glutamate, creatinine, allantoin and serine) were identified as having significantly different levels between the two groups in conditional logistic regression analyses (p < 0.05). The levels of the BCAAs did not differ significantly between GDM and NGT.
Conclusions/interpretation Metabolic markers identified as being predictive of type 2 diabetes may not have the same predictive power for GDM. However, further study in a racially/ethnically diverse population-based cohort is necessary.
C1 [Bentley-Lewis, Rhonda; Huynh, Jennifer; Xiong, Grace; Nathan, David] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med Nephrol, Boston, MA 02114 USA.
[Clish, Clary] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Gerszten, Robert] Massachusetts Gen Hosp, Dept Med Cardiol, Boston, MA 02114 USA.
RP Bentley-Lewis, R (reprint author), Massachusetts Gen Hosp, Dept Med, Diabet Unit, 55 Fruit St,Bulfinch 4-415, Boston, MA 02114 USA.
EM rbentleylewis@mgh.harvard.edu
FU National Institutes of Health [R03 DK096152, K24 DK094872]; Robert Wood
Johnson Foundation Harold Amos Medical Faculty Development Program;
Massachusetts General Hospital Executive Committee on
Research/Multicultural Affairs Office Physician Scientist Development
Award
FX This study was supported in part by the following grants: National
Institutes of Health R03 DK096152 awarded to RB-L and K24 DK094872
awarded to RT and the Robert Wood Johnson Foundation Harold Amos Medical
Faculty Development Program and Massachusetts General Hospital Executive
Committee on Research/Multicultural Affairs Office Physician Scientist
Development Award awarded to RB-L.
NR 10
TC 7
Z9 7
U1 5
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2015
VL 58
IS 6
BP 1329
EP 1332
DI 10.1007/s00125-015-3553-4
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CH2YX
UT WOS:000353893000023
PM 25748329
ER
PT J
AU Astin, F
Carroll, DL
Ruppar, T
Uchmanowicz, I
Hinterbuchner, L
Kletsiou, E
Serafin, A
Ketchell, A
AF Astin, Felicity
Carroll, Diane L.
Ruppar, Todd
Uchmanowicz, Izabella
Hinterbuchner, Lynne
Kletsiou, Eleni
Serafin, Agnieszka
Ketchell, Alison
CA Council Cardiovasc Nursing Allied
TI A core curriculum for the continuing professional development of nurses:
Developed by the Education Committee on behalf of the Council on
Cardiovascular Nursing and Allied Professions of the ESC
SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Review
DE Cardiovascular nurses; continuing professional education; syllabus; core
curriculum
ID DISEASE; COUNTRIES; HEALTH
AB Background: The European Society of Cardiology and the Council on Cardiovascular Nursing and Allied Professions share a vision; to decrease the burden of cardiovascular disease in Europe. Nurses represent the largest sector of the health professional workforce and have a significant contribution to make, which has not yet been fully realised. Recent evidence highlights an association between the level of nurse education and inpatient mortality making this an important topic, particularly as the provision of nurse education in Europe is variable.
Aim: To develop a core curriculum to inform the education of nurses following initial qualification for work in cardiovascular settings.
Method: A syllabus was developed using published literature, policy documents and existing curricula with expert input from service users, specialist nurses, cardiologists, educationalists and academics. The syllabus formed the framework for the development of the core curriculum.
Results: Eight key themes characterise the core curriculum which are presented together with an account of the development process. While the curriculum is not intended to cover all aspects of the highly complex role of the cardiovascular nurse, the themes do exemplify the science and art of nursing and are transferable across different levels of clinical practice and settings. The curriculum functions both as a map', which identifies key themes to include in nurse education, and as a tool' to inform educational provision that bridges' the gap between initial nurse education and advanced specialist practice. Content can be adapted for use to fit the national context and reflects the specific needs, health priorities, legislative and regulatory standards that govern safe nursing practice across different countries.
Conclusion: The core curriculum can be used as a learning framework to guide nurse education, in particular the continuing professional education of post-qualifying nurses working in cardiovascular settings. This represents a significant step towards streamlining cardiovascular nurse education in Europe.
C1 [Astin, Felicity] Univ Huddersfield, Huddersfield HD1 3DH, W Yorkshire, England.
[Astin, Felicity] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield HD1 3DH, W Yorkshire, England.
[Carroll, Diane L.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA.
[Ruppar, Todd] Univ Missouri, Columbia, MO 65211 USA.
[Uchmanowicz, Izabella] Wroclaw Med Univ, Wroclaw, Poland.
[Hinterbuchner, Lynne] Salzburg Univ Hosp, Dept Internal Med & Cardiol, Salzburg, Austria.
[Kletsiou, Eleni] Univ Gen Hosp Attikon, Athens, Greece.
[Serafin, Agnieszka] Med Univ Warsaw, Dept Cardiol 1, Warsaw, Poland.
[Ketchell, Alison] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.
RP Astin, F (reprint author), Univ Huddersfield, Nursing & Appl Hlth Res, Huddersfield HD1 3DH, W Yorkshire, England.
EM f.astin@hud.ac.uk
OI Astin, Felicity/0000-0002-8055-3072
FU European Society of Cardiology
FX The work was supported by the European Society of Cardiology.
NR 29
TC 6
Z9 6
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1474-5151
EI 1873-1953
J9 EUR J CARDIOVASC NUR
JI Eur. J. Cardiovasc. Nurs.
PD JUN
PY 2015
VL 14
IS 3
BP 190
EP 197
DI 10.1177/1474515115572048
PG 8
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA CH6AB
UT WOS:000354116400002
PM 25711215
ER
PT J
AU de Brito, LCN
Teles, FR
Teles, RP
Nogueira, PM
Vieira, LQ
Sobrinho, APR
AF de Brito, L. C. N.
Teles, F. R.
Teles, R. P.
Nogueira, P. M.
Vieira, L. Q.
Ribeiro Sobrinho, A. P.
TI Immunological profile of periapical endodontic infections from HIV- and
HIV plus patients
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Article
DE chemokines; cytokines; human immunodeficiency virus (HIV); periapical
lesion; T-cell expression
ID CHEMOKINE RECEPTORS; CELL-DIFFERENTIATION; IMMUNE-RESPONSES; RADICULAR
CYSTS; T-LYMPHOCYTES; DENTAL-PULP; CYTOKINE; EXPRESSION; GRANULOMAS;
LESIONS
AB AimTo evaluate CD4(+)CD28(+) and CD8(+) T-cell genes and the gene expression of IFN-, TNF-, IL-1-, IL-17A, IL-10, CCL-2/MCP-1, CCL-4, CCL-5 (RANTES), CXCR4, CCR5 and RANKL from cells in the periapical interstitial fluid from root canal infections in healthy patients (HIV-) and HIV-positive individuals (HIV+).
MethodologySubjects included 20 HIV- and 23 HIV+ patients referred to the School of Dentistry at the Universidade Federal de Minas Gerais (Belo Horizonte, MG, Brazil). Almost all HIV+ patients were undergoing highly active antiretroviral therapy (HAART). Clinical samples were taken from teeth with pulp necrosis, and no patients had acute periapical symptoms at the time of the appointments. After cleaning and drying, 3 paper points were introduced into the root canal, passing passively through the root apex (2mm) into the periapical tissues for 1min. The samples were collected immediately after root canal cleaning and 7days later (restrained root canal bacterial load) to characterize those gene expressions using real-time PCR.
ResultsSignificantly higher levels of CD4(+)CD28(+) and CD8(+) T cells in teeth with restrained bacterial loads (second collection) compared with the first collection were observed in both HIV- and HIV+ samples. In HIV- patients, an increase in IL-10 and CXCR4 expression was demonstrated as well as a decrease in pro-inflammatory cytokines such as RANKL, IFN-, IL1- and CCL5. However, in HIV+ patients an increase in cytokines IFN-, IL-1-, TNF- and IL-17A, and chemokines CCL-2, CXCR4 and CCR5 were observed. The chemokine CCL-5 was not detected in HIV+ individuals.
ConclusionsThese findings suggest that after reducing the root canal bacterial load in HIV- individuals an anti-inflammatory response is generated whilst in HIV+ patients a pro-inflammatory response is sustained in the periapical area.
C1 [de Brito, L. C. N.] Univ Itauna, Fac Odontol, Itauna, Brazil.
[Teles, F. R.; Teles, R. P.] Forsyth Inst, Dept Appl Oral Sci, Boston, MA USA.
[Teles, F. R.; Teles, R. P.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Nogueira, P. M.; Ribeiro Sobrinho, A. P.] Univ Fed Minas Gerais, Fac Odontol, Dept Odontol Restauradora, BR-31270901 Belo Horizonte, MG, Brazil.
[Vieira, L. Q.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
[Vieira, L. Q.] Univ Fed Ouro Preto, Nucleo Pesquisa Ciencias Biol, Ouro Preto, Brazil.
RP Sobrinho, APR (reprint author), Univ Fed Minas Gerais, Fac Odontol, Dept Odontol Restauradora, BR-31270901 Belo Horizonte, MG, Brazil.
EM sobrinho.bhz@terra.com.br
FU FAPEMIG; CAPES; CNPq
FX This work was supported by FAPEMIG, CAPES and CNPq. The authors wish to
thank the postgraduate programme at the School of Dentistry of UFMG.
LCNB is CAPES fellow. APRS and LQV are CNPq fellows. The authors declare
no potential conflict of interest with respect to the authorship and/or
publication of this article.
NR 37
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0143-2885
EI 1365-2591
J9 INT ENDOD J
JI Int. Endod. J.
PD JUN
PY 2015
VL 48
IS 6
BP 533
EP 541
DI 10.1111/iej.12345
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CH8NY
UT WOS:000354294300005
PM 25069888
ER
PT J
AU Zietman, AL
AF Zietman, Anthony L.
TI The Red Journal's Outstanding Reviewer Awards for 2014
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Editorial Material
ID PHYSICS
C1 [Zietman, Anthony L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Zietman, AL (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA.
EM azietman@partners.org
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 204
EP 205
DI 10.1016/j.ijrobp.2015.02.036
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000004
PM 25968818
ER
PT J
AU Wallner, PE
Steinberg, ML
McBride, WH
Hahn, SM
Zietman, AL
AF Wallner, Paul E.
Steinberg, Michael L.
McBride, William H.
Hahn, Stephen M.
Zietman, Anthony L.
TI A Fork in the Road: Choosing the Path of Relevance
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Editorial Material
ID RADIATION ONCOLOGY; CANCER
C1 [Wallner, Paul E.] 21st Century Oncol Inc, Bethesda, MD USA.
[Steinberg, Michael L.; McBride, William H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Hahn, Stephen M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zietman, Anthony L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Wallner, PE (reprint author), 5013 Cedar Croft La, Bethesda, MD 20814 USA.
EM Paul.wallner@21co.com
NR 16
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 214
EP 216
DI 10.1016/j.ijrobp.2015.01.010
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000007
PM 25968821
ER
PT J
AU Ye, JC
Mohindra, P
Spektor, A
Krishnan, MS
Chmura, SJ
Howard, AR
Viswanathan, AN
MacDonald, SM
Thaker, NG
Das, P
Mancini, BR
Higgins, SA
Braunstein, S
Haas-Kogan, D
Bradley, KA
Hung, AY
Thomas, CR
Kharofa, J
Wheatley, M
Currey, A
Parashar, B
Du, K
Jimenez, RB
Golden, DW
AF Ye, Jason C.
Mohindra, Pranshu
Spektor, Alexander
Krishnan, Monica S.
Chmura, Steven J.
Howard, Andrew R.
Viswanathan, Akila N.
MacDonald, Shannon M.
Thaker, Nikhil G.
Das, Prajnan
Mancini, Brandon R.
Higgins, Susan A.
Braunstein, Steve
Haas-Kogan, Daphne
Bradley, Kristin A.
Hung, Arthur Y.
Thomas, Charles R., Jr.
Kharofa, Jordan
Wheatley, Matt
Currey, Adam
Parashar, Bhupesh
Du, Kevin
Jimenez, Rachel B.
Golden, Daniel W.
TI Medical Student Perspectives on a Multi-institutional Clerkship
Curriculum: A Report From the Radiation Oncology Education Collaborative
Study Group
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Editorial Material
C1 [Ye, Jason C.; Parashar, Bhupesh] New York Presbyterian Hosp, Weill Cornell Med Coll, Weill Cornell Med Ctr, Stich Radiat Oncol Ctr,Dept Radiat Oncol, New York, NY USA.
[Mohindra, Pranshu] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.
[Spektor, Alexander; Krishnan, Monica S.; Viswanathan, Akila N.; Jimenez, Rachel B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
[Spektor, Alexander; Krishnan, Monica S.; Viswanathan, Akila N.; Jimenez, Rachel B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chmura, Steven J.; Howard, Andrew R.; Golden, Daniel W.] Univ Chicago, Pritzker Sch Med, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.
[MacDonald, Shannon M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Thaker, Nikhil G.; Das, Prajnan] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Mancini, Brandon R.; Higgins, Susan A.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA.
[Braunstein, Steve; Haas-Kogan, Daphne] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
[Bradley, Kristin A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI USA.
[Hung, Arthur Y.; Thomas, Charles R., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Radiat Med, Portland, OR 97201 USA.
[Kharofa, Jordan] Univ Cincinnati, Dept Radiat Oncol, Cincinnati, OH USA.
[Wheatley, Matt; Currey, Adam] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
[Du, Kevin] NYU, Perlmutter Canc Ctr, Dept Radiat Oncol, New York, NY USA.
RP Golden, DW (reprint author), Univ Chicago, Pritzker Sch Med, Dept Radiat & Cellular Oncol, 5758 South Maryland Ave,Mail Code 9006, Chicago, IL 60637 USA.
EM dgolden@radonc.uchicago.edu
FU NCATS NIH HHS [UL1 TR000430]; NCRR NIH HHS [UL1 RR024999]
NR 5
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 217
EP 219
DI 10.1016/j.ijrobp.2015.01.043
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000008
PM 25968822
ER
PT J
AU Cho, E
Mostaghel, EA
Russell, KJ
Liao, JJ
Konodi, MA
Kurland, BF
Marck, BT
Matsumoto, AM
Dalkin, BL
Montgomery, RB
AF Cho, Eunpi
Mostaghel, Elahe A.
Russell, Kenneth J.
Liao, Jay J.
Konodi, Mark A.
Kurland, Brenda F.
Marck, Brett T.
Matsumoto, Alvin M.
Dalkin, Bruce L.
Montgomery, R. Bruce
TI External Beam Radiation Therapy and Abiraterone in Men With Localized
Prostate Cancer: Safety and Effect on Tissue Androgens
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID GROUP PROTOCOL 92-02; PHASE-III TRIAL; DEPRIVATION THERAPY; DNA-REPAIR;
RADIOTHERAPY; SUPPRESSION; NEOADJUVANT; SURVIVAL; TOXICITY; ACETATE
AB Purpose: Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining androgen deprivation therapy with definitive radiation therapy in men with locally advanced or high-grade disease. Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression.
Methods and Materials: A prospective, phase 2 study was conducted in men with localized PCa treated with 6 months of neoadjuvant and concurrent abiraterone with LHRHa and radiation. Duration of adjuvant LHRHa was at the discretion of the treating clinician. Prostate biopsy assays were obtained prior to the start of therapy and prior to radiation. Sera and tissue androgen levels were measured by liquid chromatography-tandem mass spectrometry.
Results: A total of 22 men with intermediate- (n=3) and high-risk PCa (n=19) received study therapy. Sixteen men completed the intended course of abiraterone, and 19 men completed planned radiation to 77.4 to 81 Gy. Radiation to pelvic nodes was administered in 20 men. The following grade 3 toxicities were reported: lymphopenia (14 patients), fatigue (1 patient), transaminitis (2 patients), hypertension (2 patients), and hypokalemia (1 patient). There were no grade 4 toxicities. All 21 men who complied with at least 3 months of abiraterone therapy had a preradiation prostate-specific antigen (PSA) concentration nadir of < 0.3 ng/mL. Median levels of tissue androgen downstream of CYP17A were significantly suppressed after treatment with abiraterone, and upstream steroids were increased. At median follow-up of 21 months (range: 3-37 months), only 1 patient (who had discontinued abiraterone at 3 months) had biochemical relapse.
Conclusions: Addition of abiraterone to LHRHa with radiation is safe and achieves effective prostatic androgen suppression. Preliminary analysis of the clinical data is also promising, with excellent PSA nadir and no relapse to date in this high-risk population. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Cho, Eunpi; Russell, Kenneth J.; Liao, Jay J.; Konodi, Mark A.; Matsumoto, Alvin M.; Dalkin, Bruce L.; Montgomery, R. Bruce] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Cho, Eunpi; Mostaghel, Elahe A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Kurland, Brenda F.] Univ Pittsburgh, Pittsburgh, PA USA.
[Marck, Brett T.; Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Montgomery, RB (reprint author), Univ Washington, Dept Med, Div Oncol, 1959 NE Pacific St,Box 356158, Seattle, WA 98195 USA.
EM rbmontgo@uw.edu
OI Cho, Eunpi/0000-0002-7441-6311; Kurland, Brenda/0000-0002-5669-0595
FU Pacific Northwest Prostate Cancer SPORE [P50CA097186]; Prostate Cancer
Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Johnson Johnson,
Inc.; National Institutes of Health [UL1TR000423]; National Cancer
Institute [T32 CA009515]
FX This work was supported by the Pacific Northwest Prostate Cancer SPORE
P50CA097186, the Prostate Cancer Foundation, the Wayne D. Kuni and Joan
E. Kuni Foundation, Johnson & Johnson, Inc., National Institutes of
Health UL1TR000423, and National Cancer Institute grant T32 CA009515.
NR 30
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 236
EP 243
DI 10.1016/j.ijrobp.2015.01.020
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000011
PM 25772183
ER
PT J
AU Ladra, MM
Mandeville, HC
Niemierko, A
Padera, TP
Friedmann, AM
MacDonald, SM
Ebb, D
Chen, YL
Tarbell, NJ
Yock, TI
AF Ladra, Matthew M.
Mandeville, Henry C.
Niemierko, Andrzej
Padera, Timothy P.
Friedmann, Alison M.
MacDonald, Shannon M.
Ebb, David
Chen, Yen-Lin
Tarbell, Nancy J.
Yock, Torunn I.
TI Local Failure in Parameningeal Rhabdomyosarcoma Correlates With Poor
Response to Induction Chemotherapy
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID SOFT-TISSUE SARCOMA; CHILDRENS ONCOLOGY GROUP; IV RANDOMIZED TRIAL;
RADIATION-THERAPY; INTERGROUP RHABDOMYOSARCOMA; PROTON RADIOTHERAPY;
CLINICAL-OUTCOMES; TUMOR VOLUME; IRS-IV; HYPERFRACTIONATED RADIOTHERAPY
AB Background: Local control remains a challenge in pediatric parameningeal rhabdomyosarcoma (PM-RMS), and survival after local failure (LF) is poor. Identifying patients with a high risk of LF is of great interest to clinicians. In this study, we examined whether tumor response to induction chemotherapy (CT) could predict LF in embryonal PM-RMS.
Methods: We identified 24 patients with embryonal PM-RMS, age 2 to 18 years, with complete magnetic resonance imaging and gross residual disease after surgical resection. All patients received proton radiation therapy (RT), median dose 50.4 Gy(RBE) (50.4-55.8 Gy(RBE)). Tumor size was measured before initial CT and before RT.
Results: With a median follow-up time of 4.1 years for survivors, LF was seen in 9 patients (37.5%). The median time from the initiation of CT to the start of RT was 4.8 weeks. Patients with LF had a similar initial (pre-CT) tumor volume compared with patients with local controlled (LC) (54 cm(3) vs 43 cm(3), P=.9) but a greater median volume before RT (pre-RT) (40 cm(3) vs 7 cm(3), PZ=.009) and a smaller median relative percent volume reduction (RPVR) in tumor size (0.4% vs 78%, P<.001). Older age (PZ=.05), larger pre-RT tumor volume (PZ=.03), and smaller RPVR (P=.003) were significantly associated with actuarial LF on univariate Cox analysis.
Conclusions: Poor response to induction CTappears to be associated with an increased risk of LF in pediatric embryonal PM-RMS. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Ladra, Matthew M.; Niemierko, Andrzej; Padera, Timothy P.; Friedmann, Alison M.; MacDonald, Shannon M.; Ebb, David; Chen, Yen-Lin; Tarbell, Nancy J.; Yock, Torunn I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Mandeville, Henry C.] Royal Marsden Hosp, London SW3 6JJ, England.
RP Yock, TI (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM tyock@partners.org
OI Mandeville, Henry/0000-0001-6820-8578; Padera,
Timothy/0000-0002-3453-9384
FU Federal Share of program income earned by Massachusetts General
Hospital, Proton Therapy Research and Treatment Center [C06 CA059267]
FX Supported by the Federal Share of program income earned by Massachusetts
General Hospital on C06 CA059267, Proton Therapy Research and Treatment
Center.
NR 31
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 358
EP 367
DI 10.1016/j.ijrobp.2015.01.049
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000026
PM 25864172
ER
PT J
AU Arvold, ND
Tanguturi, SK
Aizer, AA
Wen, PY
Reardon, DA
Lee, EQ
Nayak, L
Christianson, LW
Horvath, MC
Dunn, IF
Golby, AJ
Johnson, MD
Claus, EB
Chiocca, EA
Ligon, KL
Alexander, BM
AF Arvold, Nils D.
Tanguturi, Shyam K.
Aizer, Ayal A.
Wen, Patrick Y.
Reardon, David A.
Lee, Eudocia Q.
Nayak, Lakshmi
Christianson, Laura W.
Horvath, Margaret C.
Dunn, Ian F.
Golby, Alexandra J.
Johnson, Mark D.
Claus, Elizabeth B.
Chiocca, E. Antonio
Ligon, Keith L.
Alexander, Brian M.
TI Hypofractionated Versus Standard Radiation Therapy With or Without
Temozolomide for Older Glioblastoma Patients
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article; Proceedings Paper
CT 56th Annual Meeting of the American-Society-for-Radiation-Oncology
CY SEP 14-17, 2014
CL San Francisco, CA
SP Amer Soc Radiat Oncol
ID ELDERLY-PATIENTS; CONCURRENT TEMOZOLOMIDE; ABBREVIATED COURSE; PHASE-3
TRIAL; PRIMARY BRAIN; RADIOTHERAPY; MULTIFORME; CHEMOTHERAPY; GLIOMA;
TUMORS
AB Purpose: Older patients with newly diagnosed glioblastoma have poor outcomes, and optimal treatment is controversial. Hypofractionated radiation therapy (HRT) is frequently used but has not been compared to patients receiving standard fractionated radiation therapy (SRT) and temozolomide (TMZ).
Methods and Materials: We conducted a retrospective analysis of patients >= 65 years of age who received radiation for the treatment of newly diagnosed glioblastoma from 1994 to 2013. The distribution of clinical covariates across various radiation regimens was analyzed for possible selection bias. Survival was calculated using the Kaplan-Meier method. Comparison of hypofractionated radiation (typically, 40 Gy/15 fractions) versus standard fractionation (typically, 60 Gy/30 fractions) in the setting of temozolomide was conducted using Cox regression and propensity score analysis.
Results: Patients received SRT + TMZ (n=57), SRT (n=35), HRT + TMZ (n=34), or HRT (n=9). Patients receiving HRT were significantly older (median: 79 vs 69 years of age; P<.001) and had worse baseline performance status (P<.001) than those receiving SRT. On multivariate analysis, older age (adjusted hazard ratio [AHR]: 1.06; 95% confidence interval [CI]: 1.01-1.10, P=.01), lower Karnofsky performance status (AHR: 1.02; 95% CI: 1.01-1.03; P=.01), multifocal disease (AHR: 2.11; 95% CI: 1.23-3.61, P=.007), and radiation alone (vs SRT vertical bar TMZ; SRT: AHR: 1.72; 95% CI: 1.06-2.79; P=.03; HRT: AHR: 3.92; 95% CI: 1.44-10.60, P=.007) were associated with decreased overall survival. After propensity score adjustment, patients receiving HRT with TMZ had similar overall survival compared with those receiving SRT with TMZ (AHR: 1.10, 95% CI: 0.50-2.4, P=.82).
Conclusions: With no randomized data demonstrating equivalence between HRT and SRT in the setting of TMZ for glioblastoma, significant selection bias exists in the implementation of HRT. Controlling for this bias, we observed similar overall survival for HRT and SRT with concurrent TMZ among elderly patients, suggesting the need for a randomized trial to compare these regimens directly. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Arvold, Nils D.; Aizer, Ayal A.; Christianson, Laura W.; Horvath, Margaret C.; Alexander, Brian M.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Dunn, Ian F.; Golby, Alexandra J.; Johnson, Mark D.; Claus, Elizabeth B.; Chiocca, E. Antonio] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Neurosurg, Boston, MA 02215 USA.
[Ligon, Keith L.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Pathol, Boston, MA 02215 USA.
[Wen, Patrick Y.; Reardon, David A.; Lee, Eudocia Q.; Nayak, Lakshmi] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02215 USA.
[Tanguturi, Shyam K.] Harvard Radiat Oncol Program, Boston, MA USA.
[Claus, Elizabeth B.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
RP Alexander, BM (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 420 Brookline Ave, Boston, MA 02215 USA.
EM bmalexander@lroc.harvard.edu
NR 18
TC 14
Z9 15
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 384
EP 389
DI 10.1016/j.ijrobp.2015.01.017
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000029
PM 25841623
ER
PT J
AU Grogg, K
Alpert, NM
Zhu, XP
Min, CH
Testa, M
Winey, B
Normandin, MD
Shih, HA
Paganetti, H
Bortfeld, T
El Fakhri, G
AF Grogg, Kira
Alpert, Nathaniel M.
Zhu, Xuping
Min, Chul Hee
Testa, Mauro
Winey, Brian
Normandin, Marc D.
Shih, Helen A.
Paganetti, Harald
Bortfeld, Thomas
El Fakhri, Georges
TI Mapping O-15 Production Rate for Proton Therapy Verification
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; MONTE-CARLO SIMULATIONS; IN-VIVO
VERIFICATION; RANGE VERIFICATION; RADIATION-THERAPY; BEAM; PET;
UNCERTAINTIES; DISTRIBUTIONS; IRRADIATION
AB Purpose: This work was a proof-of-principle study for the evaluation of oxygen-15 (O-15) production as an imaging target through the use of positron emission tomography (PET), to improve verification of proton treatment plans and to study the effects of perfusion.
Methods and Materials: Dynamic PET measurements of irradiation-produced isotopes were made for a phantom and rabbit thigh muscles. The rabbit muscle was irradiated and imaged under both live and dead conditions. A differential equation was fitted to phantom and in vivo data, yielding estimates of O-15 production and clearance rates, which were compared to live versus dead rates for the rabbit and to Monte Carlo predictions.
Results: PET clearance rates agreed with decay constants of the dominant radionuclide species in 3 different phantom materials. In 2 oxygen-rich materials, the ratio of O-15 production rates agreed with the expected ratio. In the dead rabbit thighs, the dynamic PET concentration histories were accurately described using O-15 decay constant, whereas the live thigh activity decayed faster. Most importantly, the O-15 production rates agreed within 2% (P>.5) between conditions.
Conclusions: We developed a new method for quantitative measurement of O-15 production and clearance rates in the period immediately following proton therapy. Measurements in the phantom and rabbits were well described in terms of O-15 production and clearance rates, plus a correction for other isotopes. These proof-of-principle results support the feasibility of detailed verification of proton therapy treatment delivery. In addition, O-15 clearance rates may be useful in monitoring permeability changes due to therapy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Grogg, Kira; Alpert, Nathaniel M.; Zhu, Xuping; Normandin, Marc D.; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Radiol Sci Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Min, Chul Hee] Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Wonju, Kangwon, South Korea.
[Testa, Mauro; Winey, Brian; Shih, Helen A.; Paganetti, Harald; Bortfeld, Thomas] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Testa, Mauro; Winey, Brian; Shih, Helen A.; Paganetti, Harald; Bortfeld, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
RP El Fakhri, G (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM elfakhri@pet.mgh.harvard.edu
RI Normandin, Marc/C-6728-2015
OI Normandin, Marc/0000-0003-1645-523X
FU US National Institutes of Health [P01CA21239, R21CA153455, R21EB12823];
NIH training award [T32EB013180-03]
FX The project was funded by US National Institutes of Health grants
P01CA21239, R21CA153455, and R21EB12823. Dr Grogg was supported by NIH
training award T32EB013180-03.
NR 23
TC 6
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 453
EP 459
DI 10.1016/j.ijrobp.2015.01.023
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000038
PM 25817530
ER
PT J
AU van de Water, S
Kooy, HM
Heijmen, BJM
Hoogeman, MS
AF van de Water, Steven
Kooy, Hanne M.
Heijmen, Ben J. M.
Hoogeman, Mischa S.
TI Shortening Delivery Times of Intensity Modulated Proton Therapy by
Reducing Proton Energy Layers During Treatment Plan Optimization
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID TREATMENT UNCERTAINTIES; INTER-FRACTION; PROSTATE; MOTION; SENSITIVITY;
GENERATION; REDUCTION
AB Purpose: To shorten delivery times of intensity modulated proton therapy by reducing the number of energy layers in the treatment plan.
Methods and Materials: We have developed an energy layer reduction method, which was implemented into our in-house-developed multicriteria treatment planning system "Erasmus-iCycle." The method consisted of 2 components: (1) minimizing the logarithm of the total spot weight per energy layer; and (2) iteratively excluding low-weighted energy layers. The method was benchmarked by comparing a robust "time-efficient plan" (with energy layer reduction) with a robust "standard clinical plan" (without energy layer reduction) for 5 oropharyngeal cases and 5 prostate cases. Both plans of each patient had equal robust plan quality, because the worst-case dose parameters of the standard clinical plan were used as dose constraints for the time-efficient plan. Worst-case robust optimization was performed, accounting for setup errors of 3 mm and range errors of 3% + 1 mm. We evaluated the number of energy layers and the expected delivery time per fraction, assuming 30 seconds per beam direction, 10 ms per spot, and 400 Giga-protons per minute. The energy switching time was varied from 0.1 to 5 seconds.
Results: The number of energy layers was on average reduced by 45% (range, 30%-56%) for the oropharyngeal cases and by 28% (range, 25%-32%) for the prostate cases. When assuming 1, 2, or 5 seconds energy switching time, the average delivery time was shortened from 3.9 to 3.0 minutes (25%), 6.0 to 4.2 minutes (32%), or 12.3 to 7.7 minutes (38%) for the oropharyngeal cases, and from 3.4 to 2.9 minutes (16%), 5.2 to 4.2 minutes (20%), or 10.6 to 8.0 minutes (24%) for the prostate cases.
Conclusions: Delivery times of intensity modulated proton therapy can be reduced substantially without compromising robust plan quality. Shorter delivery times are likely to reduce treatment uncertainties and costs. (C) 2015 Elsevier Inc. All rights reserved.
C1 [van de Water, Steven; Heijmen, Ben J. M.; Hoogeman, Mischa S.] Erasmus MC Canc Inst, Dept Radiat Oncol, NL-3075 EA Rotterdam, Netherlands.
[Kooy, Hanne M.] Massachusetts Gen Hosp, Dept Radiat Oncol, FH Burr Proton Therapy Ctr, Boston, MA 02114 USA.
[Kooy, Hanne M.] Harvard Univ, Sch Med, Boston, MA USA.
RP van de Water, S (reprint author), Erasmus MC Canc Inst, Dept Radiat Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
EM s.vandewater@erasmusmc.nl
NR 24
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2015
VL 92
IS 2
BP 460
EP 468
DI 10.1016/j.ijrobp.2015.01.031
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CH4FO
UT WOS:000353989000039
PM 25823447
ER
PT J
AU Fried, R
Hirshfeld-Becker, D
Petty, C
Batchelder, H
Biederman, J
AF Fried, Ronna
Hirshfeld-Becker, Dina
Petty, Carter
Batchelder, Holly
Biederman, Joseph
TI How Informative Is the CANTAB to Assess Executive Functioning in
Children With ADHD? A Controlled Study
SO JOURNAL OF ATTENTION DISORDERS
LA English
DT Article
DE ADHD; CANTAB; executive functions
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY
DISORDER; WORKING-MEMORY; PERFORMANCE; ADULTS; NEUROPSYCHOLOGY;
DYSFUNCTION; BATTERY; IMPACT
AB Objective: The authors examined the utility of the computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) to evaluate executive functioning deficits in children with ADHD. Method: Participants were unmedicated children and adolescents with (n = 107) and without (n = 45) Diagnostic and Statistical Manual of Mental Disorders (4th ed.) ADHD. The authors administered the CANTAB Eclipse battery, which comprises specific tasks shown to be deficient in individuals with ADHD. Results: With the exception of the affective go/no-go total omissions, ADHD participants were significantly more impaired on all other subtests of the CANTAB in comparison with controls. Effect sizes for individual CANTAB tests were largely in the medium range with the largest effect sizes seen in spatial working memory total and between errors. Conclusion: These CANTAB results are highly congruent with those reported in studies using traditional neuropsychological testing batteries, supporting the utility of the CANTAB to assess neuropsychological deficits in children with ADHD in clinical and research settings.
C1 [Fried, Ronna] Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Neuropsychol, Boston, MA 02114 USA.
[Fried, Ronna] Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol & Adult ADHD, Neuropsychol, Boston, MA 02114 USA.
[Fried, Ronna] Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Paradigm Dev, Boston, MA 02114 USA.
[Fried, Ronna] Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol & Adult ADHD, Paradigm Dev, Boston, MA 02114 USA.
[Hirshfeld-Becker, Dina] Massachusetts Gen Hosp, Child Cognit Behav Therapy Program, Boston, MA 02114 USA.
[Hirshfeld-Becker, Dina] Massachusetts Gen Hosp, High Risk Studies & Anxiety Res Pediat Psychophar, Boston, MA 02114 USA.
[Petty, Carter] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA.
[Batchelder, Holly; Biederman, Joseph] Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Boston, MA 02114 USA.
[Batchelder, Holly; Biederman, Joseph] Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol & Adult ADHD, Boston, MA 02114 USA.
[Biederman, Joseph] Harvard Univ, Sch Med, Psychiat, Cambridge, MA 02138 USA.
RP Fried, R (reprint author), Massachusetts Gen Hosp, Warren 705,55 Fruit St, Boston, MA 02114 USA.
EM rfried@partners.org
FU Pediatric Psychopharmacology Council Fund
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported, in part, by the Pediatric Psychopharmacology Council
Fund.
NR 39
TC 6
Z9 7
U1 5
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0547
EI 1557-1246
J9 J ATTEN DISORD
JI J. Atten. Disord.
PD JUN
PY 2015
VL 19
IS 6
SI SI
BP 468
EP 475
DI 10.1177/1087054712457038
PG 8
WC Psychology, Developmental; Psychiatry
SC Psychology; Psychiatry
GA CH6EJ
UT WOS:000354128800002
PM 22923781
ER
PT J
AU Kredlow, MA
Capozzoli, MC
Hearon, BA
Calkins, AW
Otto, MW
AF Kredlow, M. Alexandra
Capozzoli, Michelle C.
Hearon, Bridget A.
Calkins, Amanda W.
Otto, Michael W.
TI The effects of physical activity on sleep: a meta-analytic review
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Review
DE Sleep; Physical activity; Exercise; Insomnia; Sleep quality
ID SLOW-WAVE SLEEP; MODERATE-INTENSITY EXERCISE; RANDOMIZED
CONTROLLED-TRIAL; HEART-RATE-VARIABILITY; NURSING-HOME RESIDENTS;
OLDER-ADULTS; AEROBIC EXERCISE; SUBSEQUENT SLEEP; PUBLICATION BIAS;
CHRONIC INSOMNIA
AB A significant body of research has investigated the effects of physical activity on sleep, yet this research has not been systematically aggregated in over a decade. As a result, the magnitude and moderators of these effects are unclear. This meta-analytical review examines the effects of acute and regular exercise on sleep, incorporating a range of outcome and moderator variables. PubMed and PsycINFO were used to identify 66 studies for inclusion in the analysis that were published through May 2013. Analyses reveal that acute exercise has small beneficial effects on total sleep time, sleep onset latency, sleep efficiency, stage 1 sleep, and slow wave sleep, a moderate beneficial effect on wake time after sleep onset, and a small effect on rapid eye movement sleep. Regular exercise has small beneficial effects on total sleep time and sleep efficiency, small-to-medium beneficial effects on sleep onset latency, and moderate beneficial effects on sleep quality. Effects were moderated by sex, age, baseline physical activity level of participants, as well as exercise type, time of day, duration, and adherence. Significant moderation was not found for exercise intensity, aerobic/anaerobic classification, or publication date. Results were discussed with regards to future avenues of research and clinical application to the treatment of insomnia.
C1 [Kredlow, M. Alexandra; Hearon, Bridget A.; Otto, Michael W.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.
[Capozzoli, Michelle C.] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA.
[Calkins, Amanda W.] Harvard Univ, Ctr Anxiety & Traumat Stress Disorders, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Kredlow, MA (reprint author), Boston Univ, Dept Psychol & Brain Sci, 648 Beacon St,5th Floor, Boston, MA 02215 USA.
EM kredlow@bu.edu
OI Baker, Amanda/0000-0002-0103-5411
NR 139
TC 31
Z9 31
U1 18
U2 74
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
EI 1573-3521
J9 J BEHAV MED
JI J. Behav. Med.
PD JUN
PY 2015
VL 38
IS 3
BP 427
EP 449
DI 10.1007/s10865-015-9617-6
PG 23
WC Psychology, Clinical
SC Psychology
GA CH5PN
UT WOS:000354087900004
PM 25596964
ER
PT J
AU Yuen, EK
Gros, DF
Price, M
Zeigler, S
Tuerk, PW
Foa, EB
Acierno, R
AF Yuen, Erica K.
Gros, Daniel F.
Price, Matthew
Zeigler, Stephanie
Tuerk, Peter W.
Foa, Edna B.
Acierno, Ron
TI Randomized Controlled Trial of Home-Based Telehealth Versus In-Person
Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary
Results
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE telehealth; telemental health; psychotherapy; posttraumatic stress
disorder; prolonged exposure; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY;
MENTAL-HEALTH PROBLEMS; IRAQ; AFGHANISTAN; SERVICE; VIDEOCONFERENCE;
TELEPSYCHIATRY; NONINFERIORITY; PSYCHOTHERAPY
AB ObjectivesTelehealth technology may reduce the effect of treatment barriers and improve participation in treatment for veterans with posttraumatic stress disorder (PTSD). The present study is an ongoing randomized controlled trial comparing the effectiveness of prolonged exposure (PE) delivered via in person or home-based video telehealth modalities.
MethodA total of 52 veterans with combat-related PTSD were randomized to receive 8-12 weeks of PE through either home-based telehealth or standard in-person office-based care.
ResultsParticipants evinced significant reductions in symptoms of PTSD, depression, and anxiety from pre- to posttreatment across both conditions. Analyses conducted within a noninferiority framework suggested nonsignificant treatment outcome differences in clinician-reported PTSD and self-reported anxiety between the conditions. Results were inconclusive for self-reported PTSD and depression symptoms. Patient satisfaction ratings did not significantly differ between the two groups.
ConclusionsResults suggest that PE can be delivered via home-based telehealth with outcomes and satisfaction ratings comparable to in-person practices for certain symptoms, however additional research is needed. This modality has the potential to address stigma- and geographic-related barriers to treatment, such as travel time and cost.
C1 [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA.
[Gros, Daniel F.; Zeigler, Stephanie; Tuerk, Peter W.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Gros, Daniel F.; Zeigler, Stephanie; Tuerk, Peter W.; Acierno, Ron] Med Univ S Carolina, Columbia, SC USA.
[Price, Matthew] Univ Vermont, Burlington, VT 05405 USA.
[Foa, Edna B.] Univ Penn, Philadelphia, PA 19104 USA.
RP Yuen, EK (reprint author), Univ Tampa, Dept Psychol, Box Q,401 W Kennedy Blvd, Tampa, FL 33606 USA.
EM eyuen@ut.edu
FU Veterans Affairs Health Services Research and Development [NCT01102764];
Veteran Affairs Clinical Sciences Research and Development [CX000845,
NCT01031979]
FX This work was supported by grants from Veterans Affairs Health Services
Research and Development awarded to R. Acierno (NCT01102764) and from
Veteran Affairs Clinical Sciences Research and Development awarded to D.
Gros (CX000845) and Dr. Tuerk (NCT01031979).
NR 42
TC 12
Z9 12
U1 2
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
EI 1097-4679
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD JUN
PY 2015
VL 71
IS 6
BP 500
EP 512
DI 10.1002/jclp.22168
PG 13
WC Psychology, Clinical
SC Psychology
GA CI0HG
UT WOS:000354417100002
PM 25809565
ER
PT J
AU Yoon, JH
Larson, P
Grandelis, A
La, C
Cui, E
Carter, CS
Minzenberg, MJ
AF Yoon, Jong H.
Larson, Paul
Grandelis, Anthony
La, Christian
Cui, Edward
Carter, Cameron S.
Minzenberg, Michael J.
TI Delay Period Activity of the Substantia Nigra during Proactive Control
of Response Selection as Determined by a Novel fMRI Localization Method
SO JOURNAL OF COGNITIVE NEUROSCIENCE
LA English
DT Article
ID VENTRAL TEGMENTAL AREA; BASAL GANGLIA; SUBTHALAMIC NUCLEUS; PREFRONTAL
CORTEX; PARKINSONS-DISEASE; DOPAMINERGIC MIDBRAIN; COGNITIVE CONTROL;
FUNCTIONAL MRI; WORKING-MEMORY; DECISION-MAKING
AB The ability to proactively control motor responses, particularly to overcome overlearned or automatic actions, is an essential prerequisite for adaptive, goal-oriented behavior. The substantia nigra (SN), an element of the BG, has figured prominently in current models of response selection. However, because of its small size and proximity to functionally distinct subcortical structures, it has been challenging to test the SN's involvement in response selection using conventional in vivo functional neuroimaging approaches. We developed a new fMRI localization method for directly distinguishing, on echoplanar images, the SN BOLD signal from that of neighboring structures, including the subthalamic nucleus (STN). Using this method, we tested the hypothesis that the SN supports the proactive control of response selection. We acquired high-resolution EPI volumes at 3 T from 16 healthy participants while they completed the Preparing to Overcome Prepotency task of proactive control. There was significantly elevated delay period signal selectively during high-compared with lowcontrol trials in the SN. The STN did not show delay period activity in either condition. SN delay period signal was significantly inversely associated with task performance RTs across participants. These results suggest that our method offers a novel means for measuring SN BOLD responses, provides unique evidence of SN involvement in cognitive control in humans, and suggests a novel mechanism for proactive response selection.
C1 [Yoon, Jong H.] Stanford Univ, Stanford, CA 94305 USA.
[Yoon, Jong H.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Larson, Paul; Minzenberg, Michael J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grandelis, Anthony; La, Christian; Carter, Cameron S.] Univ Calif Davis, Davis, CA 95616 USA.
[Cui, Edward] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Minzenberg, Michael J.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Yoon, JH (reprint author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave,Bldg 4,2nd Floor, Palo Alto, CA 94304 USA.
EM jhyoon1@stanford.edu
FU NARSAD Foundation; NIH/NIMH
FX This study has been funded by the NARSAD Foundation and NIH/NIMH.
NR 72
TC 0
Z9 0
U1 3
U2 5
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0898-929X
EI 1530-8898
J9 J COGNITIVE NEUROSCI
JI J. Cogn. Neurosci.
PD JUN
PY 2015
VL 27
IS 6
BP 1238
EP 1248
DI 10.1162/jocn_a_00775
PG 11
WC Neurosciences; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA CH5YI
UT WOS:000354111600014
PM 25514657
ER
PT J
AU Harel, NY
Martinez, SA
Knezevic, S
Asselin, PK
Spungen, AM
AF Harel, Noam Y.
Martinez, Stephanie A.
Knezevic, Steven
Asselin, Pierre K.
Spungen, Ann M.
TI Acute changes in soleus H-reflex facilitation and central motor
conduction after targeted physical exercises
SO JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY
LA English
DT Article
DE H-reflex facilitation; Transcranial magnetic stimulation; Corticospinal;
Reticulospinal; Balance exercise
ID SPINAL-CORD-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; DESCENDING
PATHWAYS; CLINICAL-TRIALS; MOTONEURONS; MODULATION; TRACT; RECOVERY;
EXCITABILITY; CONNECTIONS
AB We tested the acute effect of exercises targeted simultaneously at cortical and brainstem circuits on neural transmission through corticobulbar connections. Corticobulbar pathways represent a potential target for rehabilitation after spinal cord injury (SCI), which tends to spare brainstem circuits to a greater degree than cortical circuits. To explore this concept, able-bodied volunteers (n = 20) underwent one session each of three exercises targeted at different nervous system components: treadmill walking (spinal locomotor circuits), isolated balance exercise (brainstem and other pathways), and multimodal balance plus skilled hand exercise (hand motor cortex and corticospinal tract). We found that short-interval soleus H-reflex facilitation increased after one session of balance and multimodal exercise by 13.2 +/- 4.0% and 8.3 +/- 4.7%, and slightly decreased by 1.9 +/- 4.4% after treadmill exercise (p = 0.042 on ANOVA across exercise type). Increases in long-interval H-reflex facilitation were not significantly different between exercises. Both balance and multimodal exercise increased central motor conduction velocity by 4.3 +/- 2.6% and 4.5 +/- 2.8%, whereas velocity decreased by 4.3 +/- 2.7% after treadmill exercise (p = 0.045 on ANOVA across exercise type). In conclusion, electrophysiological transmission between the motor cortex and spinal motor neurons in able-bodied subjects increased more following one session of balance exercise than treadmill exercise. Published by Elsevier Ltd.
C1 [Harel, Noam Y.; Martinez, Stephanie A.; Knezevic, Steven; Asselin, Pierre K.; Spungen, Ann M.] RR&D Natl Ctr Excellence Med Consequences Spinal, James J Peters VA Med Ctr, Bronx, NY USA.
[Harel, Noam Y.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Harel, Noam Y.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
[Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
RP Harel, NY (reprint author), 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM noam.harel@mssm.edu
FU VA Rehabilitation Research Development [B0881-W, B9212-C]; Department of
Neurology at Icahn School of Medicine at Mount Sinai
FX This work was funded by VA Rehabilitation Research & Development Grants
B0881-W and B9212-C, as well as salary and equipment support from the
Department of Neurology at Icahn School of Medicine at Mount Sinai. We
thank Ajax Yang, MD, DPT, for insights into different exercises related
to this work. We thank William A. Bauman, MD, for review and improvement
of this manuscript.
NR 36
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1050-6411
EI 1873-5711
J9 J ELECTROMYOGR KINES
JI J. Electromyogr. Kinesiol.
PD JUN
PY 2015
VL 25
IS 3
BP 438
EP 443
DI 10.1016/j.jelekin.2015.02.009
PG 6
WC Neurosciences; Physiology; Rehabilitation; Sport Sciences
SC Neurosciences & Neurology; Physiology; Rehabilitation; Sport Sciences
GA CH4TQ
UT WOS:000354026200003
PM 25771437
ER
PT J
AU Bose, A
Truong, QA
Singh, JP
AF Bose, Abhishek
Truong, Quynh A.
Singh, Jagmeet P.
TI Biomarkers in electrophysiology: role in arrhythmias and
resynchronization therapy
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Review
DE Biomarkers; Arrhythmias; Cardiac resynchronization therapy
ID CHRONIC HEART-FAILURE; SUDDEN CARDIAC DEATH; C-REACTIVE PROTEIN; BRAIN
NATRIURETIC PEPTIDE; PAROXYSMAL ATRIAL-FIBRILLATION; LEFT-VENTRICULAR
DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE;
GROWTH-DIFFERENTIATION FACTOR-15; LONG-TERM RESPONSE
AB Circulating biomarkers related to inflammation, neurohormones, myocardial stress, and necrosis have been associated with commonly encountered arrhythmic disorders such as atrial fibrillation (AF) and more malignant processes including ventricular arrhythmias (VA) and sudden cardiac death (SCD). Both direct and indirect biomarkers implicated in the heart failure cascade have potential prognostic value in patients undergoing cardiac resynchronization therapy (CRT). This review will focus on the role of biomarkers in AF, history of SCD, and CRT with an emphasis to improve clinical risk assessment for arrhythmias and patient selection for device therapy. Notably, information obtained from biomarkers may supplement traditional diagnostic and imaging techniques, thus providing an additional benefit in the management of patients.
C1 [Bose, Abhishek; Singh, Jagmeet P.] Massachusetts Gen Hosp, Ctr Heart, Div Cardiol, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Truong, Quynh A.] New York Presbyterian Hosp, Dalio Inst Cardiovasc Imaging, New York, NY 10021 USA.
[Truong, Quynh A.] Weill Cornell Med Coll, New York, NY 10021 USA.
RP Singh, JP (reprint author), Massachusetts Gen Hosp, Ctr Heart, Div Cardiol, Cardiac Arrhythmia Serv, 55 Fruit St, Boston, MA 02114 USA.
EM jsingh@partners.org
FU NIH [K23HL098370, L30HL093896]; St. Jude Medical; Duke Clinical Research
Institute; American College of Radiology Imaging Network; Medtronic;
Boston Scientific; Sorin; Biotronik
FX Dr. Bose has no disclosures to report. Dr. Truong received support from
NIH grant K23HL098370 and L30HL093896 and research grant support from
St. Jude Medical, Duke Clinical Research Institute, and American College
of Radiology Imaging Network. I am serving consultant for Biotronik,
Boston Scientific, Medtronic, Sorin, St. Jude Medical, Respicardia, and
CardioInsight; have spoken at symposiums sponsored by Medtronic, Boston
Scientific, Sorin, and St. Jude Medical; and receive research grants for
clinical research from Biotronik, Boston Scientific, Medtronic, Sorin,
and St. Jude Medical.
NR 130
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
EI 1572-8595
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD JUN
PY 2015
VL 43
IS 1
BP 31
EP 44
DI 10.1007/s10840-015-9982-7
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CH5IF
UT WOS:000354068200005
PM 25715916
ER
PT J
AU Kron, J
Sauer, W
Mueller, G
Schuller, J
Bogun, F
Sarsam, S
Rosenfeld, L
Mitiku, TY
Cooper, JM
Mehta, D
Greenspon, AJ
Ortman, M
Delurgio, DB
Valadri, R
Narasimhan, C
Swapna, N
Singh, JP
Danik, S
Markowitz, SM
Almquist, AK
Krahn, AD
Wolfe, LG
Feinstein, S
Ellenbogen, KA
Crawford, T
AF Kron, Jordana
Sauer, William
Mueller, Gisela
Schuller, Joseph
Bogun, Frank
Sarsam, Sinan
Rosenfeld, Lynda
Mitiku, Teferi Y.
Cooper, Joshua M.
Mehta, Davendra
Greenspon, Arnold J.
Ortman, Matthew
Delurgio, David B.
Valadri, Ravinder
Narasimhan, Calambur
Swapna, Nalla
Singh, Jagmeet P.
Danik, Stephan
Markowitz, Steven M.
Almquist, Adrian K.
Krahn, Andrew D.
Wolfe, Luke G.
Feinstein, Shawn
Ellenbogen, Kenneth A.
Crawford, Thomas
TI Outcomes of patients with definite and suspected isolated cardiac
sarcoidosis treated with an implantable cardiac defibrillator
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE Cardiac sarcoidosis; Isolated cardiac sarcoidosis; Implantable cardiac
defibrillator; Ventricular tachycardia; Sudden cardiac death
ID MYOCARDIAL-INFARCTION; MAGNETIC-RESONANCE; HEART-DISEASE; DIAGNOSIS;
ARRHYTHMIAS
AB Cardiac sarcoidosis (CS) patients are at increased risk for sudden death. Isolated CS is rare and can be difficult to diagnose.
In this multicenter retrospective review, patients with CS and an implantable cardiac defibrillator (ICD) were identified.
Of 235 patients with CS and ICD, 13 (5.5 %) had isolated CS, including 7 (3.0 %) with definite isolated CS (biopsy or necropsy-proven) and 6 (2.6 %) with suspected isolated CS based on a constellation of clinical, ECG, and imaging findings. Among 13 patients with isolated CS, 10 (76.9 %) were male, mean age was 53.8 +/- 7.6 years, and mean left ventricular ejection fraction was 38.3 +/- 16.5. Diagnosis was made by cardiac magnetic resonance (CMR) (n = 2), biopsy (n = 3), CMR and biopsy (n = 2), CMR and positron emission tomography (PET) (n = 2), PET (n = 1), late enhanced cardiac CT (n = 1), pathology at heart transplant (n = 1), and autopsy (n = 1). Eight of 13 (61.5 %) patients with isolated CS had a secondary prevention indication (VT in 6 and VF in 2) vs. 80 of 222 (36.0 %) with sarcoidosis in other organs (p = 0.04). Over a mean of 4.2 years, 9 of 13 (69.2 %) patients with isolated CS received appropriate ICD therapy, including anti-tachycardia pacing (ATP) and/or shock, compared with 75 of 222 (33.8 %) patients with cardiac and extracardiac sarcoidosis (p = 0.0150). Six of 7 (85.7 %) patients with definite isolated CS received appropriate ICD intervention, compared with 78 of 228 patients (34.2 %) without definite isolated CS (p = 0.0192.)
In this retrospective study, patients with isolated CS had very high rates of appropriate ICD therapy. Prospective, long-term follow-up of consecutive patients with isolated CS is needed to determine the true natural history and rates of ventricular arrhythmias in this rare and difficult-to-diagnose disease.
C1 [Kron, Jordana; Feinstein, Shawn; Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Dept Cardiac Electrophysiol, Richmond, VA 23298 USA.
[Sauer, William; Schuller, Joseph] Univ Colorado, Dept Cardiol, Denver, CO 80202 USA.
[Mueller, Gisela] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA.
[Bogun, Frank; Sarsam, Sinan; Crawford, Thomas] Univ Michigan, Dept Cardiol, Ann Arbor, MI 48109 USA.
[Rosenfeld, Lynda] Yale Univ, Dept Cardiac Electrophysiol, New Haven, CT USA.
[Mitiku, Teferi Y.] Wayne State Univ, Detroit, MI USA.
[Cooper, Joshua M.] Temple Univ, Dept Cardiol, Philadelphia, PA 19122 USA.
[Mehta, Davendra] Mt Sinai Hosp, Dept Cardiol, New York, NY 10029 USA.
[Greenspon, Arnold J.] Thomas Jefferson Univ Hosp, Div Cardiol, Philadelphia, PA 19107 USA.
[Ortman, Matthew] Cooper Univ Hosp, Camden, NJ USA.
[Delurgio, David B.] Emory Univ, Dept Cardiol, Atlanta, GA 30322 USA.
[Valadri, Ravinder] Wright Ctr Grad Med Educ, Scranton, PA USA.
[Narasimhan, Calambur; Swapna, Nalla] CARE Hosp, Dept Cardiol, Hyderabad, Andhra Pradesh, India.
[Singh, Jagmeet P.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA.
[Danik, Stephan] St Lukes Roosevelt Hosp, New York, NY 10025 USA.
[Markowitz, Steven M.] Weill Cornell Med Ctr, Dept Cardiol, New York, NY USA.
[Almquist, Adrian K.] Minneapolis Heart Inst, Dept Cardiol, Minneapolis, MN USA.
[Krahn, Andrew D.] Univ British Columbia, Div Cardiol, Vancouver, BC V5Z 1M9, Canada.
[Wolfe, Luke G.] Virginia Commonwealth Univ, Dept Gen Surg, Richmond, VA 23298 USA.
RP Kron, J (reprint author), Virginia Commonwealth Univ, Dept Cardiac Electrophysiol, POB 980053, Richmond, VA 23298 USA.
EM jkron@mcvh-vcu.edu
FU Medtronic Inc.; St. Jude Medical; Boston Scientific Corp.; Boston
Scientific; Biotronik; CardioInsight Inc.; Thoratec Inc.; Biosense
Webster; Sanofi; Biosense Web; Cardiovascular Center at the University
of Michigan; Boston Scientific, Inc.
FX Dr. Sauer has reported that he received education grants for EP
fellowship and consulting fees from Medtronic Inc., St. Jude Medical,
and Boston Scientific Corp.; Dr. Rosenfeld has reported that she has
received fellowship support from Medtronic Inc., Boston Scientific, and
St. Jude Medical.; Dr. Singh has reported that he received research
grants from St. Jude Medical, Medtronic Inc., Boston Scientific Corp.,
and Biotronik; consultant fees from Boston Scientific Corp., Biotronik,
St. Jude Medical, Medtronic Inc., CardioInsight Inc., Thoratec Inc., and
Biosense Webster; honoraria from Medtronic Inc., Biotronik, Guidant
Corp., St. Jude Medical, and Sorin Group.; Dr. Ellenbogen has received
honoraria from Medtronic Inc., Boston Scientific, and Cameron Medical;
speaking fees from Medtronic Inc., Boston Scientific, St. Jude Medical,
Biotronik, and Sanofi; research grants from Medtronic Inc., Boston
Scientific, Biosense Web, and Sanofi; fellowship support from Medtronic
Inc., Boston Scientific, and Biosense Web.; Dr. Crawford has received
grant support from Cardiovascular Center at the University of Michigan
and Boston Scientific, Inc. for the development and maintenance of
cardiac sarcoidosis registry.
NR 20
TC 6
Z9 7
U1 1
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
EI 1572-8595
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD JUN
PY 2015
VL 43
IS 1
BP 55
EP 64
DI 10.1007/s10840-015-9978-3
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CH5IF
UT WOS:000354068200007
PM 25676929
ER
PT J
AU Parrish, J
Schachter, S
Dempsey, M
Collins, J
AF Parrish, John
Schachter, Steve
Dempsey, Mike
Collins, John
TI Facilitating Translational Research
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
C1 [Parrish, John] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Parrish, J (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
EM japarrish@partners.org
NR 0
TC 3
Z9 3
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2015
VL 135
IS 6
BP 1463
EP 1465
DI 10.1038/jid.2015.5
PG 3
WC Dermatology
SC Dermatology
GA CH9XF
UT WOS:000354389200002
PM 25964262
ER
PT J
AU Cohen, S
Schulz, MS
Liu, SR
Halassa, M
Waldinger, RJ
AF Cohen, Shiri
Schulz, Marc S.
Liu, Sabrina R.
Halassa, Muhannad
Waldinger, Robert J.
TI Empathic Accuracy and Aggression in Couples: Individual and Dyadic Links
SO JOURNAL OF MARRIAGE AND FAMILY
LA English
DT Article
DE couples; empathic accuracy; empathy; intimate partner aggression
ID INTIMATE PARTNER VIOLENCE; PSYCHOLOGICAL AGGRESSION; OVERATTRIBUTION
BIAS; PHYSICAL AGGRESSION; ATTRIBUTIONS; BEHAVIOR; SATISFACTION;
CONFLICT; MARRIAGE; MENS
AB The authors examined links between intimate partner aggression and empathic accuracyhow accurately partners can read one another's emotionsduring highly affective moments from couples' (N=109) video recall of laboratory-based discussions of upsetting events. Less empathic accuracy between partners was generally related to higher levels of aggression by both partners. More specific patterns emerged based on the type of aggression and emotion being expressed. Women's poorer ability to read their partners' vulnerable and positive emotions was linked to both men's and women's greater physical and psychological aggression. Moreover, women's inaccuracy in reading their partner's hostility was linked to women's greater psychological aggression toward the men. Men's inaccuracy in reading their partner's hostility was linked to women's (not men's) greater physical and psychological aggression. The results suggest important nuances in the links between empathic inaccuracy and aggression, and implications for prevention and treatment of partner aggression are discussed.
C1 [Cohen, Shiri; Liu, Sabrina R.; Halassa, Muhannad; Waldinger, Robert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Schulz, Marc S.] Bryn Mawr Coll, Dept Psychol, Bryn Mawr, PA 19010 USA.
RP Cohen, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 101 Merrimac St,Suite, Boston, MA 02114 USA.
EM scohen17@mgh.harvard.edu
FU National Institute of Mental Health [K08 MH 01555, T32 MH 016259-29]
FX This study was supported by grants from the National Institute of Mental
Health: K08 MH 01555, Robert J. Waldinger, Principal Investigator; and
Postdoctoral Fellowship T32 MH 016259-29, awarded to Shiri Cohen.
NR 52
TC 0
Z9 0
U1 2
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-2445
EI 1741-3737
J9 J MARRIAGE FAM
JI J. Marriage Fam.
PD JUN
PY 2015
VL 77
IS 3
BP 697
EP 711
DI 10.1111/jomf.12184
PG 15
WC Family Studies; Sociology
SC Family Studies; Sociology
GA CH3VB
UT WOS:000353957500007
PM 26339100
ER
PT J
AU Reich, J
Wall, C
Dunne, LE
AF Reich, Jordyn
Wall, Conrad
Dunne, Lucy E.
TI Design and Implementation of a Textile-Based Wearable Balance Belt
SO JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
LA English
DT Article; Proceedings Paper
CT Design of Medical Devices DMD Conference
CY APR 13-16, 2015
CL McNamara Alumni Ctr, Minneapolis, MN
HO McNamara Alumni Ctr
C1 [Reich, Jordyn] Univ Minnesota, Coll Design, Minneapolis, MN 55455 USA.
[Wall, Conrad] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Dunne, Lucy E.] Univ Minnesota, Dept Design Housing & Apparel, Minneapolis, MN 55455 USA.
NR 3
TC 0
Z9 0
U1 2
U2 7
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1932-6181
EI 1932-619X
J9 J MED DEVICES
JI J. Med. Devices
PD JUN
PY 2015
VL 9
IS 2
AR 020919
DI 10.1115/1.4030188
PG 2
WC Engineering, Biomedical
SC Engineering
GA CH4WY
UT WOS:000354035200020
ER
PT J
AU Shah, RR
Nerurkar, NL
Wang, CC
Galloway, JL
AF Shah, Rishita R.
Nerurkar, Nandan L.
Wang, Calvin C.
Galloway, Jenna L.
TI Tensile Properties of Craniofacial Tendons in the Mature and Aged
Zebrafish
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE tendon; zebrafish; aging; mechanical properties
ID DIGITAL FLEXOR TENDON; HUMAN PATELLAR TENDON; MECHANICAL-PROPERTIES;
ACHILLES-TENDON; CRIMP PATTERN; TAIL TENDONS; IN-VIVO; MODEL; COLLAGEN;
EXPRESSION
AB The zebrafish Danio rerio is a powerful model for the study of development, regenerative biology, and human disease. However, the analysis of load-bearing tissues such as tendons and ligaments has been limited in this system. This is largely due to technical limitations that preclude accurate measurement of their mechanical properties. Here, we present a custom tensile testing system that applies nano-Newton scale forces to zebrafish tendons as small as 1mm in length. Tendon properties were remarkably similar to mammalian tendons, including stress-strain nonlinearity and a linear modulus (515 +/- 152MPa) that aligned closely with mammalian data. Additionally, a simple exponential constitutive law used to describe tendon mechanics was successfully fit to zebrafish tendons; the associated material constants agreed with literature values for mammalian tendons. Finally, mature and aged zebrafish comparisons revealed a significant decline in mechanical function with age. Based on the exponential constitutive model, age-related changes were primarily caused by a reduction in nonlinearity (e.g., changes in collagen crimp or fiber recruitment). These findings demonstrate the utility of zebrafish as a model to study tendon biomechanics in health and disease. Moreover, these findings suggest that tendon mechanical behavior is highly conserved across vertebrates. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:867-873, 2015.
C1 [Shah, Rishita R.; Wang, Calvin C.; Galloway, Jenna L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed Surg,Ctr Regenerat Med, Boston, MA 02114 USA.
[Nerurkar, Nandan L.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02129 USA.
RP Nerurkar, NL (reprint author), Harvard Univ, Sch Med, Dept Genet, NRB 360,77 Ave Louis Pasteur, Boston, MA 02129 USA.
EM nlnerurkar@genetics.med.harvard.edu; jenna_galloway@hms.harvard.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) of the NIH [R00HD069533]; Harvard Stem Cell
Institute; NICHD [F32HD069074]
FX Grant sponsor: Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) of the NIH; Grant number: R00HD069533;
Grant sponsor: Harvard Stem Cell Institute; Grant sponsor: NICHD; Grant
number: F32HD069074.
NR 50
TC 2
Z9 2
U1 1
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
EI 1554-527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUN
PY 2015
VL 33
IS 6
BP 867
EP 873
DI 10.1002/jor.22847
PG 7
WC Orthopedics
SC Orthopedics
GA CH4SX
UT WOS:000354024300013
PM 25665155
ER
PT J
AU Leyva, B
Nguyen, AB
Allen, JD
Taplin, SH
Moser, RP
AF Leyva, Bryan
Nguyen, Anh B.
Allen, Jennifer D.
Taplin, Stephen H.
Moser, Richard P.
TI Is Religiosity Associated with Cancer Screening? Results from a National
Survey
SO JOURNAL OF RELIGION & HEALTH
LA English
DT Article
DE Religiosity; Health care use; Cancer screening; Social support;
Ethnicity
ID AFRICAN-AMERICAN WOMEN; SOCIAL SUPPORT; MENTAL-HEALTH; PARTICIPATORY
APPROACH; CHURCH ATTENDANCE; MODERATING ROLE; BLACK CHURCHES;
UNITED-STATES; OLDER-ADULTS; BREAST
AB This study examined the following: (1) relationships between religiosity-as measured by religious service attendance-and screening for breast, cervical, and colorectal cancers; (2) the potential mediating role of social support; and (3) the potential moderating effect of race/ethnicity. Statistical analyses showed that religiosity was associated with greater utilization of breast, cervical, and colorectal cancer screening. Social support fully mediated the relationship between religiosity and Pap screening, and partially mediated the relationship between religiosity and colorectal screening, but had no effect on the relationship between religiosity and mammography screening. Race/ethnicity moderated the relationship between religiosity and social support in the cervical cancer screening model, such that the positive association between religiosity and social support was stronger for non-Hispanic Blacks than it was for non-Hispanic Whites. These findings have implications for the role of social networks in health promotion and can inform cancer screening interventions in faith-based settings.
C1 [Leyva, Bryan; Taplin, Stephen H.] NCI, Div Canc Control & Populat Sci, Behav Res Program, Proc Care Res Branch, Rockville, MD 20850 USA.
[Nguyen, Anh B.; Moser, Richard P.] NCI, Div Canc Control & Populat Sci, Behav Res Program, Sci Res & Technol Branch, Rockville, MD 20850 USA.
[Allen, Jennifer D.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02115 USA.
[Allen, Jennifer D.] Harvard Univ, Sch Med, Boston, MA USA.
RP Leyva, B (reprint author), NCI, Div Canc Control & Populat Sci, Behav Res Program, Proc Care Res Branch, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
EM leyvavengoechb@mail.nih.gov; Anh.nguyen3@nih.gov;
jennifer_allen@dfci.harvard.edu; taplins@mail.nih.gov;
moserr@mail.nih.gov
RI Allen, Jennifer/M-2113-2015
FU Centers for Disease Control and Prevention [U48DP001946]
FX This study was supported in part by Cooperative Agreement Number
U48DP001946 from the Centers for Disease Control and Prevention. The
findings and conclusions in this journal article are those of the
author(s) and do not necessarily represent the official position of the
Centers for Disease Control and Prevention.
NR 72
TC 3
Z9 3
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-4197
EI 1573-6571
J9 J RELIG HEALTH
JI J. Relig. Health
PD JUN
PY 2015
VL 54
IS 3
BP 998
EP 1013
DI 10.1007/s10943-014-9843-1
PG 16
WC Public, Environmental & Occupational Health; Religion
SC Public, Environmental & Occupational Health; Religion
GA CH2UA
UT WOS:000353879000015
PM 24833158
ER
PT J
AU Olufajo, OA
Agaku, IT
AF Olufajo, Olubode Ademola
Agaku, Israel Terungwa
TI Assessment of Secondhand Smoke Exposure at School Among US Middle and
High School Students
SO JOURNAL OF SCHOOL NURSING
LA English
DT Article
DE National Youth Tobacco Survey; school; school nurses; secondhand smoke;
students; tobacco control; youth
ID UNITED-STATES; TOBACCO USE; RISK
AB To obtain nationally representative estimates of the prevalence of secondhand smoke (SHS) exposure at U.S. schools, we assessed the prevalence and correlates of SHS exposure at school among U.S. middle and high school students using data from the 2011 National Youth Tobacco Survey comprising of 18,866 students spread across all the U.S. states. Overall prevalence of SHS exposure at school was 25.7% (95% CI: [23.6%, 27.8%]). Multivariate logistic regression indicated that having 1 smoker friends (adjusted Odds Ratio [aOR] = 2.92; p < .001); being a smoker (aOR = 2.75; p < .001); and being aged 13-16 years, or 17 years (vs. 9-12 years) significantly increased the likelihood of SHS exposure. Understanding the health risks of SHS exposure alone did not seem to play a significant role in reducing exposure (aOR = .89; p = .342). These findings show there are significant levels of SHS exposure among students at U.S. middle and high schools, and sustained multipronged efforts are needed to reduce youth SHS exposure.
C1 [Olufajo, Olubode Ademola] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
[Olufajo, Olubode Ademola] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Agaku, Israel Terungwa] Harvard Univ, Sch Publ Hlth, Ctr Global Tobacco Control, Dept Social & Behav Sci, Boston, MA 02115 USA.
RP Olufajo, OA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
EM oao777@mail.harvard.edu
NR 30
TC 1
Z9 1
U1 6
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1059-8405
EI 1546-8364
J9 J SCH NURS
JI J. Sch. Nurs.
PD JUN
PY 2015
VL 31
IS 3
BP 212
EP 218
DI 10.1177/1059840514537075
PG 7
WC Nursing
SC Nursing
GA CH4EG
UT WOS:000353984700007
PM 24912960
ER
PT J
AU Shapiro, M
Rashid, NU
Whang, EE
Boosalis, VA
Huang, Q
Yoon, C
Saund, MS
Gold, JS
AF Shapiro, Mia
Rashid, Naim U.
Whang, Edward E.
Boosalis, Valia A.
Huang, Qin
Yoon, Charles
Saund, Mandeep S.
Gold, Jason S.
TI Trends and Predictors of Resection of the Primary Tumor for Patients
With Stage IV Colorectal Cancer
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE metastatic colorectal cancer; primary tumor resection; SEER
ID METASTATIC COLON-CANCER; LIVER METASTASES; INTESTINAL COMPLICATIONS;
SYNCHRONOUS METASTASES; ASYMPTOMATIC PATIENTS; SURGICAL-TREATMENT;
ELDERLY-PATIENTS; INSURANCE STATUS; SURVIVAL; SURGERY
AB Background and ObjectivesOver 130,000 patients are diagnosed with colorectal cancer annually, with approximately 20% presenting with unresectable metastatic disease. Recent consensus guidelines recommend against primary tumor resection for asymptomatic patients with unresectable metastases. Our goal was to examine the trends and predictors of surgical resection.
MethodsCases of colorectal cancer with synchronous metastases diagnosed between 1988-2010 were identified using the Surveillance, Epidemiology and End Results (SEER) Database. Associations between resection and clinicopathologic variables were sought using univariate and multivariate logistic regression.
ResultsOverall, 68% of patients with synchronous metastatic colorectal cancer underwent primary tumor resection. Resection rates were as high as 76% in the earliest time period (1988-1992) and steadily dropped to 60% in the most recent period (2008-2010). Socioeconomic factors associated with resection on univariate analysis included age, race, gender, marital status, insurance status, and geographic region. Clinicopathologic characteristics associated with resection included tumor location, grade, size, and CEA level. In the multivariate model, gender, geographic region, insurance status, tumor location, grade and CEA level were independent predictors of primary tumor resection.
ConclusionsSurgical resection of the primary site remains common practice for patients with synchronous metastatic colorectal cancer. Treatment disparities are associated with socioeconomic as well as clinicopathologic factors. J. Surg. Oncol. 2015 111:911-916. (c) 2014 Wiley Periodicals, Inc.
C1 [Shapiro, Mia; Whang, Edward E.; Yoon, Charles; Gold, Jason S.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Surg Serv, West Roxbury, MA USA.
[Shapiro, Mia; Whang, Edward E.; Huang, Qin; Yoon, Charles; Saund, Mandeep S.; Gold, Jason S.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, West Roxbury, MA USA.
[Rashid, Naim U.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Whang, Edward E.; Yoon, Charles; Gold, Jason S.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Boosalis, Valia A.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Med Serv, West Roxbury, MA USA.
[Boosalis, Valia A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Huang, Qin] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Pathol Serv, West Roxbury, MA USA.
[Saund, Mandeep S.] Harvard Vanguard Med Associates, Boston, MA USA.
[Saund, Mandeep S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Gold, JS (reprint author), VA Boston Healthcare Syst 112, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM jgold4@partners.org
RI Gold, Jason/O-5112-2014
OI Gold, Jason/0000-0002-2925-4755
FU VA Career Development Award
FX Grant sponsor: VA Career Development Award.
NR 32
TC 3
Z9 4
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUN 1
PY 2015
VL 111
IS 7
BP 911
EP 916
DI 10.1002/jso.23906
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA CH4IE
UT WOS:000353996400019
PM 25919984
ER
PT J
AU Spraggins, JM
Rizzo, DG
Moore, JL
Rose, KL
Hammer, ND
Skaar, EP
Caprioli, RM
AF Spraggins, Jeffrey M.
Rizzo, David G.
Moore, Jessica L.
Rose, Kristie L.
Hammer, Neal D.
Skaar, Eric P.
Caprioli, Richard M.
TI MALDI FTICR IMS of Intact Proteins: Using Mass Accuracy to Link Protein
Images with Proteomics Data
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
DE FTICR MS; Imaging MS; MALDI; Proteomics; Mass accuracy; Top-down;
Calprotectin; PTMs; Staphylococcus aureus; Nutritional immunity
ID NEUTROPHIL EXTRACELLULAR TRAPS; STAPHYLOCOCCUS-AUREUS;
ATMOSPHERIC-PRESSURE; TISSUE-SECTIONS; POSTTRANSLATIONAL MODIFICATIONS;
ELECTROSPRAY-IONIZATION; TRYPTIC PEPTIDES; SPECTROMETRY; LASER;
CALPROTECTIN
AB MALDI imaging mass spectrometry is a highly sensitive and selective tool used to visualize biomolecules in tissue. However, identification of detected proteins remains a difficult task. Indirect identification strategies have been limited by insufficient mass accuracy to confidently link ion images to proteomics data. Here, we demonstrate the capabilities of MALDI FTICR MS for imaging intact proteins. MALDI FTICR IMS provides an unprecedented combination of mass resolving power (similar to 75,000 at m/z 5000) and accuracy (< 5ppm) for proteins up to similar to 12kDa, enabling identification based on correlation with LC-MS/MS proteomics data. Analysis of rat brain tissue was performed as a proof-of-concept highlighting the capabilities of this approach by imaging and identifying a number of proteins including N-terminally acetylated thymosin beta(4) (m/z 4,963.502, 0.6ppm) and ATP synthase subunit epsilon (m/z 5,636.074, -2.3ppm). MALDI FTICR IMS was also used to differentiate a series of oxidation products of S100A8 (m/z 10,164.03, -2.1ppm), a subunit of the heterodimer calprotectin, in kidney tissue from mice infected with Staphylococcus aureus. S100A8 - M37O/C42O(3) (m/z 10228.00, -2.6ppm) was found to co-localize with bacterial microcolonies at the center of infectious foci. The ability of MALDI FTICR IMS to distinguish S100A8 modifications is critical to understanding calprotectin's roll in nutritional immunity.
C1 [Spraggins, Jeffrey M.; Rose, Kristie L.; Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37205 USA.
[Spraggins, Jeffrey M.; Rizzo, David G.; Moore, Jessica L.; Rose, Kristie L.; Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA.
[Rizzo, David G.; Moore, Jessica L.; Caprioli, Richard M.] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.
[Hammer, Neal D.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
[Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA.
[Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA.
[Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
RP Spraggins, JM (reprint author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37205 USA.
EM jeff.spraggins@vanderbilt.edu
FU NIH/NIGMS [5 P41 GM103391-04, 5R01GM058008]; National Institutes of
Health [1S10OD012359-01]; National Institute of Allergy and Infectious
Diseases [R01 AI101171-01A1, R21 AI107233]; Vanderbilt University;
Vanderbilt Chemical Biology Interface training program [T32 GM 065086];
Mitchum Warren Graduate Research Fellowship
FX The authors acknowledge support for this work by grants from the
NIH/NIGMS (5 P41 GM103391-04 and 5R01GM058008) and the National
Institutes of Health Shared Instrumentation Grant Program
(1S10OD012359-01) awarded to R.M.C. and the National Institute of
Allergy and Infectious Diseases (R01 AI101171-01A1 and R21 AI107233)
awarded to E.P.S.D.G.R. is supported by the Aegis Sciences Fellowship in
Chemistry, Vanderbilt University. J.L.M. is supported by Vanderbilt
Chemical Biology Interface training program (T32 GM 065086) and the
Mitchum Warren Graduate Research Fellowship. N.D.H. is a CF Foundation
Ann Weinberg Memorial Research Fellow. The authors also thank Dr. Junhai
Yang, Dr. Dhananjay Sakrikar, Salisha Hill M.S., and Amanda Hachey for
their technical support.
NR 63
TC 19
Z9 19
U1 14
U2 67
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1044-0305
EI 1879-1123
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD JUN
PY 2015
VL 26
IS 6
BP 974
EP 985
DI 10.1007/s13361-015-1147-5
PG 12
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA CH5OE
UT WOS:000354084400017
PM 25904064
ER
PT J
AU Tsai, HT
Keating, NL
Van den Eeden, SK
Haque, R
Cassidy-Bushrow, AE
Yood, MU
Smith, MR
Potosky, AL
AF Tsai, Huei-Ting
Keating, Nancy L.
Van den Eeden, Stephen K.
Haque, Reina
Cassidy-Bushrow, Andrea E.
Yood, Marianne Ulcickas
Smith, Matthew R.
Potosky, Arnold L.
TI Risk of Diabetes among Patients Receiving Primary Androgen Deprivation
Therapy for Clinically Localized Prostate Cancer
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostatic neoplasms; androgens; diabetes mellitus; risk
ID CARDIOVASCULAR-DISEASE; MEN; COMPLICATIONS; IMMEDIATE; TRIAL
AB Purpose: Androgen deprivation therapy may increase diabetes risk. As the benefits of primary androgen deprivation therapy for localized prostate cancer are controversial, and most prostate cancer survivors are of advanced age with comorbidities, it is important to determine if primary androgen deprivation therapy increases the risk of diabetes and to determine the susceptibility factors.
Materials and Methods: We conducted a retrospective cohort study of 12,191 men diagnosed with incident localized prostate cancer during 1995 to 2008, age 35 to 100 years, and without diabetes or receipt of prostatectomy or radiation 1 year after diagnosis. Patients were enrolled in 1 of 3 managed health plans and followed through 2010. Primary androgen deprivation therapy was defined as androgen deprivation therapy within 1 year after diagnosis. Incident diabetes was ascertained using inpatient and outpatient diagnosis codes, diabetes medications and hemoglobin A1c values. We estimated primary androgen deprivation therapy associated diabetes risk using Cox proportional hazard models in conventional and propensity score analyses.
Results: Diabetes developed in 1,203 (9.9%) patients during followup (median 4.8 years) with incidence rates of 2.5 and 1.6 events per 100 person-years in the primary androgen deprivation therapy and nonprimary androgen deprivation therapy groups, respectively. Primary androgen deprivation therapy was associated with a 1.61-fold increased diabetes risk (95% CI 1.38-1.88). The number needed to harm was 29. The association was stronger in men age 70 or younger than in older men (HR 2.25 vs 1.40, p value for interaction=0.008).
Conclusions: Primary androgen deprivation therapy may increase diabetes risk by 60% and should be used with caution when managing localized prostate cancer. Because of the consistent association between androgen deprivation therapy and greater diabetes risk across disease states, we recommend routine screening and lifestyle interventions to reduce the risk of diabetes in men receiving androgen deprivation therapy.
C1 [Tsai, Huei-Ting; Potosky, Arnold L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Yood, Marianne Ulcickas] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Smith, Matthew R.] Massachusetts Gen Hosp, Genitourinary Oncol Program, Boston, MA 02114 USA.
[Van den Eeden, Stephen K.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Haque, Reina] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Cassidy-Bushrow, Andrea E.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA.
RP Tsai, HT (reprint author), Georgetown Univ, Med Ctr, 3300 Whitehaven St NW,Suite 4100,Room 4137, Washington, DC 20007 USA.
EM ht92@georgetown.edu
FU National Cancer Institute [R01CA142934, RC1CA146238, P30CA051008]
FX Supported by R01CA142934, RC1CA146238 and P30CA051008 from the National
Cancer Institute. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Cancer Institute or the National Institutes of Health.
NR 27
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2015
VL 193
IS 6
BP 1956
EP 1962
DI 10.1016/j.juro.2014.12.027
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA CH7DV
UT WOS:000354196700024
PM 25524243
ER
PT J
AU Althaus, AB
Li, K
Pattison, E
Eisner, B
Pais, V
Steinberg, P
AF Althaus, Adam B.
Li, Kai
Pattison, Erik
Eisner, Brian
Pais, Vernon
Steinberg, Peter
TI Rate of Dislodgment of Ureteral Stents When Using an Extraction String
after Endoscopic Urological Surgery
SO JOURNAL OF UROLOGY
LA English
DT Article
DE ureter; ureteroscopy; stent; nephrolithiasis; postoperative
complications
ID URETEROSCOPY; COMPLICATIONS; MANAGEMENT; OUTCOMES; CALCULI
AB Purpose: Ureteral stents are manufactured with an extraction string tethered to the distal end, which facilitates removal after urological surgery. However, the string may allow for stent dislodgment. We report the stent dislodgment rate in a multi-institutional series.
Materials and Methods: We retrospectively reviewed the records of ureteroscopy cases at 3 academic endourology practices. Demographic and operative data were obtained as well as string use and stent dislodgment data. Categorical variables were assessed with the Fisher exact test and the Student t-test was used to assess continuous variables.
Results: Of the 512 cases a string was used in 98 (19.1%) comprising 41 females (41.8%) and 57 males ( 58.2%). The stent was dislodged in 10 women and 3 men. No dislodgment occurred when a string was not used. When stratified by gender, 5.3% of men and 24.4% of women with a string experienced stent dislodgment ( p = 0.013). Women were more than fourfold more likely to experience stent dislodgment than men ( RR 4.6, 95% CI 1.36-15.8, p = 0.01).
Conclusions: Almost 15% of patients in whom a stent is placed with a string sustain stent dislodgment and most of these patients will be women. We recommend considering the risks of dislodgment in each patient who undergoes ureteroscopy with stent placement and considering string removal if the surgeon believes that dislodgment could result in adverse events such as severe colic or obstruction.
C1 [Althaus, Adam B.] Brigham & Womens Hosp, Boston, MA 02215 USA.
[Althaus, Adam B.; Steinberg, Peter] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Li, Kai; Eisner, Brian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pattison, Erik; Pais, Vernon] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
RP Althaus, AB (reprint author), Brigham & Womens Hosp, Dept Urol, 45 Francis St, Boston, MA 02215 USA.
EM aalthaus@partners.org
FU Boston Scientific; Bard; PercSys; Radius Pharmaceuticals; Cook; Olympus
FX Financial interest and/or other relationship with Boston Scientific,
Bard, PercSys, Radius Pharmaceuticals, Cook and Olympus.
NR 11
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2015
VL 193
IS 6
BP 2011
EP 2014
DI 10.1016/j.juro.2014.12.087
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA CH7DV
UT WOS:000354196700044
PM 25541339
ER
PT J
AU Cheng, D
Zhang, LL
Yang, GB
Zhao, L
Peng, F
Tian, Y
Xiao, XQ
Chung, RT
Gong, GZ
AF Cheng, Du
Zhang, Leiliang
Yang, Guangbo
Zhao, Lei
Peng, Feng
Tian, Yi
Xiao, Xinqiang
Chung, Raymond T.
Gong, Guozhong
TI Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support
cell survival
SO LIVER INTERNATIONAL
LA English
DT Article
DE HCV; NF-B; NS5A; PTEN; ROS
ID NF-KAPPA-B; NONSTRUCTURAL 5A PROTEIN; HEPATOCELLULAR-CARCINOMA; PTEN
EXPRESSION; TENSIN HOMOLOG; DOWN-REGULATION; PHOSPHATASE; APOPTOSIS;
PATHWAY; P53
AB Background & AimsDecreased levels of phosphatase and tensin homologue (PTEN) are associated with hepatocellular carcinoma (HCC) pathogenesis and poor prognosis in hepatitis C virus (HCV)-infected HCC patients. The molecular processes governing the reduction in PTEN and outcome of PTEN dysfunction in hepatocytes are poorly understood.
MethodsThe levels of proteins and mRNA were assessed by real time PCR and immunoblot. PTEN promoter activity was measured by reporter assay. Signalling pathways were perturbed using siRNAs or pharmacological inhibitors.
ResultsHere, we report that HCV down-regulates PTEN expression at the transcriptional level by decreasing its promoter activity, mRNA transcription, and protein levels. We further identify NS5A protein as a key determinant of PTEN reduction among HCV proteins. NS5A-mediated down-regulation of PTEN occurs through a cooperation of reactive oxygen species (ROS)-dependent Nuclear Factor- kappa B (NF-B) and ROS-independent phosphoinositol-3-kinase (PI3K) pathways. Moreover, NS5A protects cells against apoptosis. In addition, we found that down-regulation of PTEN relieves its inhibitory effect on PI3K-Akt pathway and triggers cumulative activation of Akt. This PTEN-PI3K/Akt feedback network mediates the suppression of cell apoptosis caused by NS5A.
ConclusionsThese data demonstrate that HCV NS5A down-regulates PTEN expression through a cooperation of ROS-dependent and -independent pathways that subsequently drives a PTEN-PI3K/Akt feedback loop to support cell survival. Our findings provide new insights suggesting that NS5A contributes to HCV-related hepatocarcinogenesis.
C1 [Cheng, Du] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Peoples R China.
[Cheng, Du; Zhang, Leiliang; Zhao, Lei; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Liver Ctr,Gastrointestinal Div,Dept Med, Boston, MA USA.
[Cheng, Du; Peng, Feng; Tian, Yi; Xiao, Xinqiang; Gong, Guozhong] Cent S Univ, Xiangya Hosp 2, Dept Infect Dis, Liver Dis Ctr, Changsha, Hunan, Peoples R China.
[Zhang, Leiliang; Yang, Guangbo] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China.
[Zhang, Leiliang; Yang, Guangbo] Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Gong, GZ (reprint author), Second Xiangya Hosp, Dept Infect Dis, Liver Dis Ctr, Changsha 410011, Hunan, Peoples R China.
EM guozhonggong@yahoo.com
FU Chinese Scholarship Council; National Science and Technology Major
Project of China [2013ZX10004-601, 2008ZX10002-013]; National Natural
Science Foundation of China [30471531, 81370542, 81400624]
FX This study was supported by Chinese Scholarship Council, National
Science and Technology Major Project of China (2013ZX10004-601 and
2008ZX10002-013) and National Natural Science Foundation of China
(30471531, 81370542 and 81400624).
NR 34
TC 9
Z9 9
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD JUN
PY 2015
VL 35
IS 6
BP 1682
EP 1691
DI 10.1111/liv.12733
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CH9NA
UT WOS:000354361200006
PM 25388655
ER
PT J
AU Singer, SJ
Jiang, W
Huang, LC
Gibbons, L
Kiang, MV
Edmondson, L
Gawande, AA
Berry, WR
AF Singer, Sara J.
Jiang, Wei
Huang, Lyen C.
Gibbons, Lorri
Kiang, Mathew V.
Edmondson, Lizabeth
Gawande, Atul A.
Berry, William R.
TI Surgical Team Member Assessment of the Safety of Surgery Practice in 38
South Carolina Hospitals
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE survey; surgery; checklist; implementation; health delivery innovation
ID OPERATING-ROOM; HEALTH-CARE; CHECKLIST; IMPLEMENTATION; CLIMATE;
COMMUNICATION; TECHNOLOGY; MORTALITY; CULTURE; NURSES
AB We assessed surgical team member perceptions of multiple dimensions of safe surgical practice in 38 South Carolina hospitals participating in a statewide initiative to implement surgical safety checklists. Primary data were collected using a novel 35-item survey. We calculated the percentage of 1,852 respondents with strongly positive, positive, and neutral/negative responses about the safety of surgical practice, compared results by hospital and professional discipline, and examined how readiness, teamwork, and adherence related to staff perception of care quality. Overall, 78% of responses were positive about surgical safety at respondent's hospitals, but in each survey dimension, from 16% to 40% of responses were neutral/negative, suggesting significant opportunity to improve surgical safety. Respondents not reporting they would feel safe being treated in their operating rooms varied from 0% to 57% among hospitals. Surgeons responded more positively than nonsurgeons. Readiness, teamwork, and practice adherence related directly to staff perceptions of patient safety (p < .001).
C1 [Singer, Sara J.; Kiang, Mathew V.; Gawande, Atul A.; Berry, William R.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Singer, Sara J.; Gawande, Atul A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Singer, Sara J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Edmondson, Lizabeth; Gawande, Atul A.; Berry, William R.] Ariadne Labs, Boston, MA USA.
[Jiang, Wei; Gawande, Atul A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Singer, Sara J.; Huang, Lyen C.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Gibbons, Lorri] South Carolina Hosp Assoc, Columbia, SC USA.
RP Singer, SJ (reprint author), Harvard Univ, Dept Hlth Policy & Management, TH Chan Sch Publ Hlth, 677 Huntington Ave,Kresge Bldg 3,Room 317, Boston, MA 02115 USA.
EM ssinger@hsph.harvard.edu
RI JIANG, WEI /F-3930-2015
FU AHRQ [R18:HS019631]; Branta Foundation
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported by a grant from AHRQ (R18:HS019631). The Safe Surgery 2015
initiative is supported by a grant from the Branta Foundation.
NR 50
TC 2
Z9 2
U1 5
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
EI 1552-6801
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD JUN
PY 2015
VL 72
IS 3
BP 298
EP 323
DI 10.1177/1077558715577479
PG 26
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CH6AO
UT WOS:000354117900004
PM 25828528
ER
PT J
AU Iglesias, JE
Van Leemput, K
Bhatt, P
Casillas, C
Dutt, S
Schuff, N
Truran-Sacrey, D
Boxer, A
Fischl, B
AF Eugenio Iglesias, Juan
Van Leemput, Koen
Bhatt, Priyanka
Casillas, Christen
Dutt, Shubir
Schuff, Norbert
Truran-Sacrey, Diana
Boxer, Adam
Fischl, Bruce
CA Alzheimer's Dis Neuroimaging Initi
TI Bayesian segmentation of brainstem structures in MRI
SO NEUROIMAGE
LA English
DT Article
DE Brainstem; Bayesian segmentation; Probabilistic atlas
ID PROGRESSIVE SUPRANUCLEAR PALSY; PARKINSONS-DISEASE; MODEL; REGISTRATION;
VALIDATION; CEREBELLUM; ALGORITHM; REGION; IMAGES; AGE
AB In this paper we present a method to segment four brainstem structures (midbrain, pons, medulla oblongata and superior cerebellar peduncle) from 3D brain MRI scans. The segmentation method relies on a probabilistic atlas of the brainstem and its neighboring brain structures. To build the atlas, we combined a dataset of 39 scans with already existing manual delineations of the whole brainstem and a dataset of 10 scans in which the brainstem structures were manually labeled with a protocol that was specifically designed for this study. The resulting atlas can be used in a Bayesian framework to segment the brainstem structures in novel scans. Thanks to the generative nature of the scheme, the segmentation method is robust to changes in MRI contrast or acquisition hardware. Using cross validation, we show that the algorithm can segment the structures in previously unseen T1 and FLAIR scans with great accuracy (mean error under 1mm) and robustness (no failures in 383 scans including 168 AD cases). We also indirectly evaluate the algorithm with a experiment in which we study the atrophy of the brainstem in aging. The results show that, when used simultaneously, the volumes of the midbrain, pons and medulla are significantly more predictive of age than the volume of the entire brainstem, estimated as their sum. The results also demonstrate that the method can detect atrophy patterns in the brainstem structures that have been previously described in the literature. Finally, we demonstrate that the proposed algorithm is able to detect differential effects of AD on the brainstem structures. The method will be implemented as part of the popular neuroimaging package FreeSurfer. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Eugenio Iglesias, Juan] Basque Ctr Cognit Brain & Language BCBL, San Sebastian, Spain.
[Van Leemput, Koen; Fischl, Bruce] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Van Leemput, Koen; Fischl, Bruce] Harvard Univ, Sch Med, Boston, MA USA.
[Bhatt, Priyanka; Casillas, Christen; Dutt, Shubir; Boxer, Adam] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA.
[Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Van Leemput, Koen] Tech Univ Denmark, Dept Appl Math & Comp Sci, Lyngby, Denmark.
[Van Leemput, Koen] Aalto Univ, Dept Informat & Comp Sci, Espoo, Finland.
[Van Leemput, Koen] Aalto Univ, Dept Biomed Engn & Computat Sci, Espoo, Finland.
[Schuff, Norbert; Truran-Sacrey, Diana] Univ Calif San Francisco, Dept Radiol, Ctr Imaging Neurodegenerat Dieases, San Francisco, CA USA.
RP Iglesias, JE (reprint author), Basque Ctr Cognit Brain & Language BCBL, San Sebastian, Spain.
EM e.iglesias@bcbl.eu
RI Iglesias, Juan Eugenio/K-1184-2014; Van Leemput, Koen/A-9197-2009
OI Iglesias, Juan Eugenio/0000-0001-7569-173X; Van Leemput,
Koen/0000-0001-6466-5309
FU National Center for Research Resources [U24 RR021382, P41 RR14075, 1 K
L2RR025757-01]; National Institute for Biomedical Imaging and
Bioengineering [P41 EB015896, R01 EB006758, R01 EB013565, 1 K 25
EB013649-01]; National Institute on Aging [AG022381, 5R01 AG008122-22,
R01 AG016495-11, R01 AG038791]; National Center for Alternative Medicine
[RC1 AT005728-01]; National Institute for Neurological Disorders and
Stroke [R01 NS052585-01, 1R21 NS 072652-01, 1R01 NS070963, R01 NS083534,
U54NS092089]; Tau Consortium; Shared Instrumentation Grant [1S10RR0
23401, 1S10RR0 19307, 1S10RR0 23043]; Autism & Dyslexia Project; Ellison
Medical Foundation; NIH Blueprint for Neuroscience Research [5U01
MH093765]; multi-institutional Human Connectome Project; TEKES
(ComBrain); Harvard Catalyst; Gipuzkoako Foru Aldundia; Harvard and
affiliations; Alzheimer's Disease Neuroimaging Initiative (ADNI);
National Institutes of Health [U01 AG024904]; DOD ADNI
[W81XWH-122-0012]; National Institute on Aging; National Institute of
Biomedical Imaging and Bioengineering; ADNI clinical sites in Canada
FX Support for this research was provided in part by the National Center
for Research Resources (U24 RR021382, P41 RR14075, 1 K L2RR025757-01),
the National Institute for Biomedical Imaging and Bioengineering (P41
EB015896, R01 EB006758, R01 EB013565, 1 K 25 EB013649-01), the National
Institute on Aging (AG022381, 5R01 AG008122-22, R01 AG016495-11, R01
AG038791), the National Center for Alternative Medicine (RC1
AT005728-01), the National Institute for Neurological Disorders and
Stroke (R01 NS052585-01, 1R21 NS 072652-01, 1R01 NS070963, R01 NS083534,
U54NS092089), the Tau Consortium, and was made possible by the resources
provided by Shared Instrumentation Grants 1S10RR0 23401, 1S10RR0 19307,
and 1S10RR0 23043. Additional support was provided by The Autism &
Dyslexia Project funded by the Ellison Medical Foundation, and by the
NIH Blueprint for Neuroscience Research (5U01 MH093765), part of the
multi-institutional Human Connectome Project. This research was also
funded by TEKES (ComBrain), Harvard Catalyst, and financial
contributions from Harvard and affiliations. JEI was supported by the
Gipuzkoako Foru Aldundia (Fellows Gipuzkoa Program).; The collection and
sharing of the MRI data used in the robustness experiment was funded by
the Alzheimer's Disease Neuroimaging Initiative (ADNI), National
Institutes of Health (Grant U01 AG024904) and DOD ADNI (Department of
Defense award number W81XWH-122-0012). ADNI is funded by the National
Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following:
Alzheimers Association; Alzheimers Drug Discovery Foundation;
BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La
Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare;
Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research
& Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and
Takeda Pharmaceutical Company. The Canadian Institutes of Health
Research is providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation for the
National Institutes of Health (www.fnih.org). The grantee organization
is the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern California.
NR 37
TC 8
Z9 8
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2015
VL 113
BP 184
EP 195
DI 10.1016/j.neuroimage.2015.02.065
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CH9YN
UT WOS:000354392700018
PM 25776214
ER
PT J
AU Baskaran, C
Volkening, LK
Diaz, M
Laffel, LM
AF Baskaran, Charumathi
Volkening, Lisa K.
Diaz, Monica
Laffel, Lori M.
TI A decade of temporal trends in overweight/obesity in youth with type 1
diabetes after the Diabetes Control and Complications Trial
SO PEDIATRIC DIABETES
LA English
DT Article
DE obesity; overweight; prevalence; T1D; youth
ID BODY-MASS INDEX; INSULIN REGIMENS; BLOOD-GLUCOSE; WEIGHT-GAIN; CHILDREN;
PREVALENCE; ADOLESCENTS; MELLITUS; OBESITY; TRIAL/EPIDEMIOLOGY
AB BackgroundYouth with type 1 diabetes (T1D) are at risk for weight gain due to the epidemic of childhood overweight/obesity and common use of intensive insulin therapy; the latter resulted in weight gain in the Diabetes Control and Complications Trial.
ObjectiveTo assess overweight/obesity prevalence and intensive insulin therapy use in youth with T1D over a decade and identify factors associated with weight status and glycemic control.
MethodsWe obtained cross-sectional data from four unique cohorts (1999, 2002, 2006, and 2009). Youth (N = 507, 49% male) were 8-16 yr old with T1D duration 6 months, A1c 6.0-12.0% (42-108 mmol/mol), and daily insulin dose 0.5 U/kg.
ResultsAcross cohorts, age, body mass index (BMI) percentile, and A1c ranged from 12.0 2.2 to 12.8 +/- 2.3 yr, 70 +/- 22 to 72 +/- 21, and 8.3 +/- 1.0 (67 +/- 11) to 8.5 +/- 1.1% (69 +/- 12 mmol/mol), respectively. Intensive insulin therapy use increased from 52 to 97% (p < 0.001) between 1999 and 2009. However, prevalence of overweight/obesity remained similar, 27% (1999), 36% (2002), 33% (2006), and 31% (2009) (p = 0.54), as did z-BMI. In multivariate analysis, higher A1c was related to higher insulin dose (p < 0.01), less frequent blood glucose monitoring (p < 0.001), and non-white race (p < 0.001); A1c was not related to z-BMI, intensive insulin therapy, or cohort. z-BMI was related to insulin dose (p < 0.005) but not intensive insulin therapy or cohort.
ConclusionsDespite near-universal implementation of intensive insulin therapy, overweight/obesity prevalence in youth with T1D remained stable over a decade, similar to the general pediatric population. However, A1c remained suboptimal, underscoring the need to optimize T1D treatment to reduce future complication risk.
C1 [Baskaran, Charumathi; Volkening, Lisa K.; Diaz, Monica; Laffel, Lori M.] Joslin Diabet Ctr, Genet & Epidemiol Sect, Boston, MA 02215 USA.
[Diaz, Monica] SUNY Downstate Coll Med, Brooklyn, NY USA.
RP Laffel, LM (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM lori.laffel@joslin.harvard.edu
FU NIH [T32DK007260, R01DK046887, P30DK036836]; Charles H. Hood Foundation;
Eleanor Chesterman Beatson Fund; Katherine Adler Astrove Youth Education
Fund; Maria Griffin Drury Pediatric Fund
FX Charumathi Baskaran and Lori Laffel had full access to all of the data
in the study and took responsibility for the integrity of the data and
the accuracy of the data analysis. This study was supported by funding
from: NIH grants T32DK007260, R01DK046887, P30DK036836; the Charles H.
Hood Foundation; the Eleanor Chesterman Beatson Fund; the Katherine
Adler Astrove Youth Education Fund; and the Maria Griffin Drury
Pediatric Fund.
NR 28
TC 5
Z9 6
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1399-543X
EI 1399-5448
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD JUN
PY 2015
VL 16
IS 4
BP 263
EP 270
DI 10.1111/pedi.12166
PG 8
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA CH6CL
UT WOS:000354123300004
PM 25039317
ER
PT J
AU Yang, XQ
Iyer, AK
Singh, A
Milane, L
Choy, E
Hornicek, FJ
Amiji, MM
Duan, ZF
AF Yang, Xiaoqian
Iyer, Arun K.
Singh, Amit
Milane, Lara
Choy, Edwin
Hornicek, Francis J.
Amiji, Mansoor M.
Duan, Zhenfeng
TI Cluster of Differentiation 44 Targeted Hyaluronic Acid Based
Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in
Ovarian Cancer
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE CD44 targeting; HA-PEI/HA-PEG nanoparticle; multidrug resistance;
ovarian cancer; siRNA delivery
ID SMALL INTERFERING RNA; MESOPOROUS SILICA NANOPARTICLES;
MULTIDRUG-RESISTANCE; PACLITAXEL-RESISTANCE; GENE DELIVERY; IN-VIVO;
INTRACELLULAR DELIVERY; CELLS; MECHANISMS; EXPRESSION
AB Approaches for the synthesis of biomaterials to facilitate the delivery of "biologics" is a major area of research in cancer therapy. Here we designed and characterized a hyaluronic acid (HA) based self-assembling nanoparticles that can target CD44 receptors overexpressed on multidrug resistance (MDR) ovarian cancer. The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model.
HA-PEI/HA-PEG nanoparticles were synthesized and characterized, then the cellular uptake and knockdown efficiency of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles was further determined. A human xenograft MDR ovarian cancer model was established to evaluate the effects of the combination of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles and paclitaxel on MDR tumor growth.
Our results demonstrated that HA-PEI/HA-PEG nanoparticles successfully targeted CD44 and delivered MDR1 siRNA into OVCAR8TR (established paclitaxel resistant) tumors. Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. HA-PEI/HA-PEG/MDR1 siRNA nanoparticle therapy followed by paclitaxel treatment inhibited tumor growth in MDR ovarian cancer mouse models.
These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
C1 [Yang, Xiaoqian; Choy, Edwin; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Yang, Xiaoqian; Choy, Edwin; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Yang, Xiaoqian] Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynaecol, Zhengzhou 450052, Henan Province, Peoples R China.
[Iyer, Arun K.; Singh, Amit; Milane, Lara; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02114 USA.
[Iyer, Arun K.] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, 100 Blossom St,Jackson 1115, Boston, MA 02114 USA.
EM zduan@mgh.harvard.edu
OI Iyer, Arun/0000-0002-4428-0222
FU China Scholarship Council; NIH/NCI, Cancer Nanotechnology Platform
Partnership (CNPP) [U01-CA151452]
FX We thank Dr. Meghna Talekar for measurement of the particle size and
surface charge. Dr. Yang is supported by Scholarship from China
Scholarship Council. This study is supported by the NIH/NCI, Cancer
Nanotechnology Platform Partnership (CNPP) grants U01-CA151452.
NR 50
TC 13
Z9 13
U1 14
U2 72
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2015
VL 32
IS 6
BP 2097
EP 2109
DI 10.1007/s11095-014-1602-1
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CH5TQ
UT WOS:000354098600020
PM 25515492
ER
PT J
AU Zvolensky, MJ
Farris, SG
Kotov, R
Schechter, CB
Bromet, E
Gonzalez, A
Vujanovic, A
Pietrzak, RH
Crane, M
Kaplan, J
Moline, J
Southwick, SM
Feder, A
Udasin, I
Reissman, DB
Luft, BJ
AF Zvolensky, Michael J.
Farris, Samantha G.
Kotov, Roman
Schechter, Clyde B.
Bromet, Evelyn
Gonzalez, Adam
Vujanovic, Anka
Pietrzak, Robert H.
Crane, Michael
Kaplan, Julia
Moline, Jacqueline
Southwick, Steven M.
Feder, Adriana
Udasin, Iris
Reissman, Dori B.
Luft, Benjamin J.
TI World Trade Center disaster and sensitization to subsequent life stress:
A longitudinal study of disaster responders
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Stress exposure; Disaster; Trauma; Responder; Posttraumatic stress;
Functioning
ID CENTER HEALTH REGISTRY; PTSD CHECKLIST PCL; POSTTRAUMATIC-STRESS;
RECOVERY WORKERS; RISK-FACTORS; PSYCHOMETRIC PROPERTIES; CENTER RESCUE;
SYMPTOMS; DISORDER; EXPOSURE
AB Purpose. : The current study examined the role of World Trade Center (WTC) disaster exposure (hours spent working on the site, dust cloud exposure, and losing friend/loved one) in exacerbating the effects of post-disaster life stress on posttraumatic stress disorder (PTSD) symptoms and overall functioning among WTC responders.
Method. : Participants were 18,896 responders (8466 police officers and 10,430 non-traditional responders) participating in the WTC Health Program who completed an initial examination between July, 2002 and April, 2010 and were reassessed an average of two years later.
Results.: Among police responders, there was a significant interaction, such that the effect of post-disaster life stress on later PTSD symptoms and overall functioning was stronger among police responders who had greater WTC disaster exposure (beta's=.029 and .054, respectively, for PTSD symptoms and overall functioning). This moderating effect was absent in non-traditional responders. Across both groups, post-disaster life stress also consistently was related to the dependent variables in a more robust manner than WTC exposure.
Discussion.: The present findings suggest that WTC exposure may compound post-disaster life stress, thereby resulting in a more chronic course of PTSD symptoms and reduced functioning among police responders. (C) 2015 Elsevier Inc All rights reserved.
C1 [Zvolensky, Michael J.; Farris, Samantha G.] Univ Houston, Dept Psychol, Houston, TX 77204 USA.
[Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA.
[Kotov, Roman; Bromet, Evelyn; Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA.
[Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA.
[Vujanovic, Anka] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Pietrzak, Robert H.; Southwick, Steven M.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
[Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Crane, Michael; Kaplan, Julia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA.
[Moline, Jacqueline] North Shore LIJ Hlth Syst, Dept Populat Hlth, Great Neck, NY USA.
[Feder, Adriana] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Udasin, Iris] Rutgers Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA.
[Reissman, Dori B.] NIOSH, World Trade Ctr, Hlth Program, Washington, DC USA.
[Reissman, Dori B.] US PHS, Washington, DC USA.
[Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.
RP Zvolensky, MJ (reprint author), Univ Houston, 126 Heyne Bldg,Suite 104, Houston, TX 77204 USA.
EM mjzvolen@central.uh.edu
NR 42
TC 5
Z9 5
U1 4
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD JUN
PY 2015
VL 75
BP 70
EP 74
DI 10.1016/j.ypmed.2015.03.017
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA CH6MC
UT WOS:000354149700011
PM 25840022
ER
PT J
AU Schutzer, ME
Orio, PF
Biagioli, MC
Asher, DA
Lomas, H
Moghanaki, D
AF Schutzer, M. E.
Orio, P. F.
Biagioli, M. C.
Asher, D. A.
Lomas, H.
Moghanaki, D.
TI A review of rectal toxicity following permanent low dose-rate prostate
brachytherapy and the potential value of biodegradable rectal spacers
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Review
ID EXTERNAL-BEAM RADIOTHERAPY; PHASE-II TRIAL; INTENSITY-MODULATED
RADIOTHERAPY; POLYETHYLENE-GLYCOL HYDROGEL; CHRONIC RADIATION PROCTITIS;
ARGON PLASMA COAGULATION; STEREOTACTIC BODY RADIOTHERAPY;
HYPERBARIC-OXYGEN TREATMENT; VOLUME HISTOGRAM ANALYSIS; LONG-TERM
AB Permanent radioactive seed implantation provides highly effective treatment for prostate cancer that typically includes multidisciplinary collaboration between urologists and radiation oncologists. Low dose-rate (LDR) prostate brachytherapy offers excellent tumor control rates and has equivalent rates of rectal toxicity when compared with external beam radiotherapy. Owing to its proximity to the anterior rectal wall, a small portion of the rectum is often exposed to high doses of ionizing radiation from this procedure. Although rare, some patients develop transfusion-dependent rectal bleeding, ulcers or fistulas. These complications occasionally require permanent colostomy and thus can significantly impact a patient's quality of life. Aside from proper technique, a promising strategy has emerged that can help avoid these complications. By injecting biodegradable materials behind Denonviller's fascia, brachytherpists can increase the distance between the rectum and the radioactive sources to significantly decrease the rectal dose. This review summarizes the progress in this area and its applicability for use in combination with permanent LDR brachytherapy.
C1 [Schutzer, M. E.; Lomas, H.; Moghanaki, D.] Virginia Commonwealth Univ, Med Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA.
[Orio, P. F.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Orio, P. F.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Biagioli, M. C.] Florida Hosp, Inst Canc, Dept Radiat Oncol, Orlando, FL USA.
[Asher, D. A.] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23298 USA.
[Moghanaki, D.] Hunter Holmes McGuire Vet Affairs Med Ctr, Dept Radiat Oncol Serv, Richmond, VA USA.
RP Schutzer, ME (reprint author), Virginia Commonwealth Univ, Med Ctr, Dept Radiat Oncol, 401 Coll St,POB 980058, Richmond, VA 23298 USA.
EM matthew.schutzer@gmail.com
NR 103
TC 2
Z9 2
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
EI 1476-5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2015
VL 18
IS 2
BP 96
EP 103
DI 10.1038/pcan.2015.4
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA CH9NU
UT WOS:000354363300002
PM 25687401
ER
PT J
AU Macleod, LC
Chery, LJ
Hu, EYC
Zeliadt, SB
Holt, SK
Lin, DW
Porter, MP
Gore, JL
Wright, JL
AF Macleod, L. C.
Chery, L. J.
Hu, E. Y. C.
Zeliadt, S. B.
Holt, S. K.
Lin, D. W.
Porter, M. P.
Gore, J. L.
Wright, J. L.
TI Metabolic syndrome, dyslipidemia and prostate cancer recurrence after
primary surgery or radiation in a veterans cohort
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
ID TREATMENT PANEL-III; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY;
MULTIETHNIC COHORT; ANDROGEN RECEPTOR; NATURAL-HISTORY; UNITED-STATES;
RISK; ASSOCIATION; CHOLESTEROL
AB BACKGROUND: Metabolic syndrome (MetS) has been hypothesized to be associated with cancer, including prostate cancer (PCa), but the relationship is not well characterized. We analyze the relationship between MetS features and localized PCa recurrence after treatment.
METHODS: Men having primary treatment for localized PCa were included from a multi-site regional veteran network. Recurrence was defined as nadir PSA +2 ng ml(-1) (radiation) or PSA >= 0.2 ng ml(-1) (prostatectomy). MetS was based on consensus professional society guidelines from the American Heart Association and International Diabetes Federation (three of: hypertension > 130/85mmHg, fasting blood glucose >= 100 mg dl(-1), waist circumference > 102 cm, high-density lipoprotein < 40 mg dl(-1), triglycerides >= 150 mg dl(-1)). Closely related abnormality in low-density lipoprotein (LDL; > 130 mg dl(-1)) was also examined. Analysis of PCa recurrence risk included multivariable Cox proportional hazards regression with propensity adjustment.
RESULTS: Of the 1706 eligible men, 279 experienced recurrence over a median follow-up period of 41 months (range 1-120 months). Adjustment variables associated with PCa recurrence included: index PSA, Gleason, and tumor stage. Independent variables of interest associated with PCa recurrence were hyperglycemia and elevated LDL. Elevated LDL was associated with PCa recurrence (multivariable hazard ratio (HR) 1.34, 95% confidence interval (CI) 1.03, 1.74; propensity adjusted HR 1.33, 95% CI 1.03, 1.72). There was also an association between impaired fasting glucose and PCa recurrence in (multivariable HR 1.54, 95% CI 1.10, 2.15; propensity adjusted HR 1.41, 95% CI 1.01, 1.95). MetS was not associated with PCa recurrence (multivariable: HR 0.96, 95% CI 0.61, 1.50; propensity adjusted HR 1.04, 95% CI 0.67, 1.62).
CONCLUSIONS: PCa recurrence is not associated with MetS but is associated with elevated LDL and impaired fasting glucose. If confirmed, these data may help provide modifiable targets in preventing recurrence of PCa.
C1 [Macleod, L. C.; Chery, L. J.; Holt, S. K.; Lin, D. W.; Porter, M. P.; Gore, J. L.; Wright, J. L.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
[Hu, E. Y. C.; Zeliadt, S. B.; Lin, D. W.; Porter, M. P.; Wright, J. L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Lin, D. W.; Gore, J. L.; Wright, J. L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
RP Macleod, LC (reprint author), Univ Washington, Med Ctr, Dept Urol, 1959 NE Pacific St, Seattle, WA 98195 USA.
EM liamcm@uw.edu
OI macleod, liam/0000-0003-1163-6621
FU NIH from the National Cancer Institute [P50CA097186]; Fred Hutchinson
Cancer Research Center; VA Puget Sound Health Care system
FX This work was supported by an NIH Grant: P50CA097186 from the National
Cancer Institute, with additional support and resources from the Fred
Hutchinson Cancer Research Center and VA Puget Sound Health Care system.
NR 51
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
EI 1476-5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2015
VL 18
IS 2
BP 190
EP 195
DI 10.1038/pcan.2015.12
PG 6
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA CH9NU
UT WOS:000354363300015
PM 25823651
ER
PT J
AU Bromberger, JT
Schott, L
Kravitz, HM
Joffe, H
AF Bromberger, J. T.
Schott, L.
Kravitz, H. M.
Joffe, H.
TI Risk factors for major depression during midlife among a community
sample of women with and without prior major depression: are they the
same or different?
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Incident major depression; major depression; midlife; recurrent major
depression; women
ID R PSYCHIATRIC-DISORDERS; STRUCTURED CLINICAL INTERVIEW; NATIONAL
EPIDEMIOLOGIC SURVEY; MENTAL-HEALTH SURVEY; MENOPAUSAL TRANSITION;
GENERAL-POPULATION; ANXIETY DISORDERS; PHYSICAL-ACTIVITY; SOCIAL
SUPPORT; 1ST INCIDENCE
AB Background. Women's vulnerability for a first lifetime-onset of major depressive disorder (MDD) during midlife is substantial. It is unclear whether risk factors differ for first lifetime-onset and recurrent MDD. Identifying these risk factors can provide more focused depression screening and earlier intervention. This study aims to evaluate whether lifetime psychiatric and health histories, personality traits, menopausal status and factors that vary over time, e.g. symptoms, are independent risk factors for first-onset or recurrent MDD across 13 annual follow-ups.
Method. Four hundred and forty-three women, aged 42-52 years, enrolled in the Study of Women's Health Across the Nation in Pittsburgh and participated in the Mental Health Study. Psychiatric interviews obtained information on lifetime psychiatric disorders at baseline and on occurrences of MDD episodes annually. Psychosocial and health-related data were collected annually. Cox multivariable analyses were conducted separately for women with and without a MDD history at baseline.
Results. Women without lifetime MDD at baseline had a lower risk of developing MDD during midlife than those with a prior MDD history (28% v. 59%) and their risk profiles differed. Health conditions prior to baseline and during follow-ups perception of functioning (ps<0.05) and vasomotor symptoms (VMS) (p = 0.08) were risk factors for first lifetimeonset MDD. Being peri-and post-menopausal, psychological symptoms and a prior anxiety disorder were predominant risk factors for MDD recurrence.
Conclusions. The menopausal transition warrants attention as a period of vulnerability to MDD recurrence, while health factors and VMS should be considered important risk factors for first lifetime-onset of MDD during midlife.
C1 [Bromberger, J. T.; Schott, L.] Univ Pittsburgh Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Bromberger, J. T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Kravitz, H. M.] Rush Univ Med Ctr, Dept Psychiat, Chicago, IL USA.
[Kravitz, H. M.] Rush Univ Med Ctr, Dept Prevent Med, Chicago, IL USA.
[Joffe, H.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Joffe, H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Bromberger, JT (reprint author), Univ Pittsburgh, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM brombergerjt@umpc.edu
FU National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA); National Institute of Nursing Research (NINR);
NIH Office of Research on Women's Health (ORWH) [U01NR004061,
U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546,
U01AG012553, U01AG012554, U01AG012495]; National Institute of Mental
Health [R01MH59689]
FX The Study of Women's Health Across the Nation (SWAN) has grant support
from the National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA), the National Institute of Nursing Research
(NINR) and the NIH Office of Research on Women's Health (ORWH) (Grants
U01NR004061; U01AG012505, U01AG012535, U01AG012531, U01AG012539,
U01AG012546, U01AG012553, U01AG012554, U01AG012495). The SWAN Mental
Health Study has grant support from the National Institute of Mental
Health (R01MH59689). The content of this manuscript is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIA, NINR, ORWH or the NIH. Clinical Centers:
University of Michigan, Ann Arbor - Sioban Harlow, PI 2011-present,
MaryFran Sowers, PI 1994-2011; Massachusetts General Hospital, Boston,
MA - Joel Finkelstein, PI 1999-present; Robert Neer, PI 1994-1999; Rush
University, Rush University Medical Center, Chicago, IL - Howard
Kravitz, PI 2009-present; Lynda Powell, PI 1994-2009; University of
California, Davis/Kaiser - Ellen Gold, PI; University of California, Los
Angeles - Gail Greendale, PI; Albert Einstein College of Medicine,
Bronx, NY - Carol Derby, PI 2011-present, Rachel Wildman, PI 2010-2011;
Nanette Santoro, PI 2004-2010; University of Medicine and Dentistry -
New Jersey Medical School, Newark Gerson Weiss, PI 1994-2004; and the
University of Pittsburgh, Pittsburgh, PA - Karen Matthews, PI. NIH
Program Office: National Institute on Aging, Bethesda, MD - Winifred
Rossi 2012-present; Sherry Sherman 1994-2012; Marcia Ory 1994-2001;
National Institute of Nursing Research, Bethesda, MD - Program Officers.
Central Laboratory: University of Michigan, Ann Arbor - Daniel McConnell
(Central Ligand Assay Satellite Services). Coordinating Center:
University of Pittsburgh, Pittsburgh, PA - Maria Mori Brooks, PI
2012-present; Kim Sutton-Tyrrell, PI 2001-2012; New England Research
Institutes, Watertown, MA - Sonja McKinlay, PI 1995-2001. Steering
Committee: Susan Johnson, Current Chair. Chris Gallagher, Former Chair.
We thank the study staff at each site and all the women who participated
in SWAN.
NR 44
TC 5
Z9 5
U1 3
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JUN
PY 2015
VL 45
IS 8
BP 1653
EP 1664
DI 10.1017/S0033291714002773
PG 12
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CH4WW
UT WOS:000354035000008
PM 25417760
ER
PT J
AU Kaplan, KA
McGlinchey, EL
Soehner, A
Gershon, A
Talbot, LS
Eidelman, P
Gruber, J
Harvey, AG
AF Kaplan, K. A.
McGlinchey, E. L.
Soehner, A.
Gershon, A.
Talbot, L. S.
Eidelman, P.
Gruber, J.
Harvey, A. G.
TI Hypersomnia subtypes, sleep and relapse in bipolar disorder
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Bipolar disorder; diagnosis; hypersomnia; relapse; sleep
ID STRUCTURED CLINICAL INTERVIEW; TEST-RETEST RELIABILITY; OF-FIT INDEXES;
MOOD DISORDERS; QUALITY INDEX; BRIGHT LIGHT; OLDER-ADULTS; DEPRESSIVE
SYMPTOMATOLOGY; PSYCHOMETRIC EVALUATION; STATE MISPERCEPTION
AB Background. Though poorly defined, hypersomnia is associated with negative health outcomes and new-onset and recurrence of psychiatric illness. Lack of definition impedes generalizability across studies. The present research clarifies hypersomnia diagnoses in bipolar disorder by exploring possible subgroups and their relationship to prospective sleep data and relapse into mood episodes.
Method. A community sample of 159 adults (aged 18-70 years) with bipolar spectrum diagnoses, euthymic at study entry, was included. Self-report inventories and clinician-administered interviews determined features of hypersomnia. Participants completed sleep diaries and wore wrist actigraphs at home to obtain prospective sleep data. Approximately 7 months later, psychiatric status was reassessed. Factor analysis and latent profile analysis explored empirical groupings within hypersomnia diagnoses.
Results. Factor analyses confirmed two separate subtypes of hypersomnia ('long sleep' and 'excessive sleepiness') that were uncorrelated. Latent profile analyses suggested a four-class solution, with 'long sleep' and 'excessive sleepiness' again representing two separate classes. Prospective sleep data suggested that the sleep of 'long sleepers' is characterized by a long time in bed, not long sleep duration. Longitudinal assessment suggested that 'excessive sleepiness' at baseline predicted mania/hypomania relapse.
Conclusions. This study is the largest of hypersomnia to include objective sleep measurement, and refines our understanding of classification, characterization and associated morbidity. Hypersomnia appears to be comprised of two separate subgroups: long sleep and excessive sleepiness. Long sleep is characterized primarily by long bedrest duration. Excessive sleepiness is not associated with longer sleep or bedrest, but predicts relapse to mania/hypomania. Understanding these entities has important research and treatment implications.
C1 [Kaplan, K. A.; Gershon, A.] Stanford Univ Sch Med, Dept Psychiat, Stanford, CA USA.
[McGlinchey, E. L.] Columbia Univ Med Ctr, New York State Psychiat Inst, Div Child & Adolescent Psychiat, New York, NY USA.
[Soehner, A.] Univ Pittsburgh Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Talbot, L. S.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Eidelman, P.] Cognit Behav Therapy & Sci Ctr, Oakland, CA USA.
[Gruber, J.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA.
[Harvey, A. G.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA.
RP Harvey, AG (reprint author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA.
EM aharvey@berkeley.edu
FU National Institute of Mental Health [R34 MH080958]; National Science
Foundation Graduate Research Fellowship
FX This project was supported by a National Institute of Mental Health
grant (no. R34 MH080958) awarded to A.G.H. and a National Science
Foundation Graduate Research Fellowship grant awarded to K.A.K.
NR 104
TC 3
Z9 3
U1 2
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JUN
PY 2015
VL 45
IS 8
BP 1751
EP 1763
DI 10.1017/S0033291714002918
PG 13
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA CH4WW
UT WOS:000354035000017
PM 25515854
ER
PT J
AU Smucny, J
Olincy, A
Eichman, LS
Tregellas, JR
AF Smucny, Jason
Olincy, Ann
Eichman, Lindsay S.
Tregellas, Jason R.
TI Neuronal effects of nicotine during auditory selective attention
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Attention; Auditory; fMRI; Nicotine; Parietal cortex
ID ANTERIOR CINGULATE CORTEX; SHORT-TERM-MEMORY; TRANSDERMAL NICOTINE;
DEFICIT/HYPERACTIVITY DISORDER; ACETYLCHOLINE-RECEPTORS; VISUOSPATIAL
ATTENTION; VISUAL-ATTENTION; PARIETAL CORTEX; BRAIN; DISTRACTION
AB Although the attention-enhancing effects of nicotine have been behaviorally and neurophysiologically well-documented, its localized functional effects during selective attention are poorly understood.
In this study, we examined the neuronal effects of nicotine during auditory selective attention in healthy human nonsmokers. We hypothesized to observe significant effects of nicotine in attention-associated brain areas, driven by nicotine-induced increases in activity as a function of increasing task demands.
A single-blind, prospective, randomized crossover design was used to examine neuronal response associated with a go/no-go task after 7 mg nicotine or placebo patch administration in 20 individuals who underwent functional magnetic resonance imaging at 3T. The task design included two levels of difficulty (ordered vs. random stimuli) and two levels of auditory distraction (silence vs. noise).
Significant treatment x difficulty x distraction interaction effects on neuronal response were observed in the hippocampus, ventral parietal cortex, and anterior cingulate. In contrast to our hypothesis, U and inverted U-shaped dependencies were observed between the effects of nicotine on response and task demands, depending on the brain area.
These results suggest that nicotine may differentially affect neuronal response depending on task conditions. These results have important theoretical implications for understanding how cholinergic tone may influence the neurobiology of selective attention.
C1 [Smucny, Jason; Olincy, Ann; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA.
[Smucny, Jason; Olincy, Ann; Eichman, Lindsay S.; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO USA.
[Smucny, Jason; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA.
RP Smucny, J (reprint author), Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA.
EM jason.smucny@ucdenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Smucny, Jason/0000-0001-5656-7987
FU NIMH Conte Center [MH-086383]; VA Biomedical Laboratory and Clinical
Science Research and Development Service; Brain and Behavior Foundation;
Blowitz-Ridgeway Foundation
FX The authors thank Debra Singel for assistance with data acquisition.
This work was supported by NIMH Conte Center Grant MH-086383, the VA
Biomedical Laboratory and Clinical Science Research and Development
Service, the Brain and Behavior Foundation, and the Blowitz-Ridgeway
Foundation.
NR 51
TC 4
Z9 4
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUN
PY 2015
VL 232
IS 11
BP 2017
EP 2028
DI 10.1007/s00213-014-3832-7
PG 12
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA CH7VV
UT WOS:000354245600015
PM 25491929
ER
PT J
AU Pachas, GN
Gilman, J
Orr, SP
Hoeppner, B
Carlini, SV
Grasser, EB
Loebl, T
Nino, J
Pitman, RK
Evins, AE
AF Pachas, Gladys N.
Gilman, Jodi
Orr, Scott P.
Hoeppner, Bettina
Carlini, Sara V.
Grasser, Elisabeth B.
Loebl, Tsafrir
Nino, Johanna
Pitman, Roger K.
Evins, A. Eden
TI Single dose propranolol does not affect physiologic or emotional
reactivity to smoking cues (vol 232, pg 1619, 2015)
SO PSYCHOPHARMACOLOGY
LA English
DT Correction
C1 [Pachas, Gladys N.; Gilman, Jodi; Orr, Scott P.; Hoeppner, Bettina; Carlini, Sara V.; Grasser, Elisabeth B.; Loebl, Tsafrir; Nino, Johanna; Pitman, Roger K.; Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Pachas, Gladys N.; Gilman, Jodi; Orr, Scott P.; Hoeppner, Bettina; Pitman, Roger K.; Evins, A. Eden] Harvard Univ, Sch Med, Boston, MA USA.
[Pachas, Gladys N.; Gilman, Jodi; Hoeppner, Bettina; Evins, A. Eden] Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02114 USA.
RP Evins, AE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM a_eden_evins@hms.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUN
PY 2015
VL 232
IS 11
BP 2029
EP 2029
DI 10.1007/s00213-015-3930-1
PG 1
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA CH7VV
UT WOS:000354245600016
PM 25877745
ER
PT J
AU Stain, SC
Schwarz, E
Shadduck, PP
Shah, PC
Ross, SB
Hori, Y
Sylla, P
AF Stain, Steven C.
Schwarz, Erin
Shadduck, Phillip P.
Shah, Paresh C.
Ross, Sharona B.
Hori, Yumi
Sylla, Patricia
TI A comprehensive process for disclosing and managing conflicts of
interest on perceived bias at the SAGES annual meeting
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
Society-of-American-Gastrointestinal-and-Endoscopic-Surgeons (SAGES) /
17th World Congress of Endoscopic Surgery
CY APR 02-05, 2014
CL Salt Lake City, UT
SP Soc Amer Gastrointestinal & Endoscop Surg
DE Conflict of interest; Disclosure; Bias
ID PROFESSIONAL MEDICAL ASSOCIATIONS; INDUSTRY; SURGERY
AB The relationship between the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and its industry partners has been longstanding, productive technologically, and beneficial to patient care and education. In order to both maintain this important relationship to honor its responsibility to society for increasing transparency, SAGES established a Conflict of Interest Task Force (CITF) and charged it with identifying and managing potential conflicts of interest (COI) and limiting bias at the SAGES Annual Scientific Meetings. The CITF developed and implemented a comprehensive process for reporting, evaluating, and managing COI in accordance with (and exceeding) Accreditation Council for Continuing Medical Education guidelines.
From 2011 to 2013, all presenters, moderators, and session chairs received proactive and progressively increasing levels of education regarding the CITF rationale and processes and were required to disclose all relationships with commercial interests. Disclosures were reviewed and discussed by multiple layers of reviewers, including moderators, chairs, and CITF committee members with tiered, prescribed actions in a standardized, uniform fashion. Meeting attendees were surveyed anonymously after the annual meeting regarding perceived bias. The CITF database was then analyzed and compared to the reports of perceived bias to determine whether the implementation of this comprehensive process had been effective.
In 2011, 68 of 484 presenters (14 %) disclosed relationships with commercial interests. In 2012, 173 of 523 presenters (33.5 %) disclosed relationships, with 49 having prior review (9.4 %), and eight required alteration. In 2013, 190 of 454 presenters disclosed relationships (41.9 %), with 93 presentations receiving prior review (20.4 %), and 20 presentations were altered. From 2008 to 2010, the perceived bias among attendees surveyed was 4.7, 6.2, and 4.4 %; and in 2011-2013, was 2.2, 1.2, and 1.5 %.
It is possible to have a surgical meeting that includes participation of speakers that have industry relationships, and minimize perceived bias.
C1 [Stain, Steven C.] Albany Med Coll, Dept Surg, Albany, NY 12208 USA.
[Schwarz, Erin; Hori, Yumi] BSC Management, Los Angeles, CA USA.
[Shadduck, Phillip P.] Duke Reg Hosp, Durham, NC USA.
[Shah, Paresh C.] NYU, Langone Med Ctr, New York, NY USA.
[Ross, Sharona B.] Florida Hosp Tampa, Tampa, FL USA.
[Sylla, Patricia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Stain, SC (reprint author), Albany Med Coll, Dept Surg, 50 New Scotland Ave,MC 194, Albany, NY 12208 USA.
EM stains@mail.amc.edu
OI shah, paresh/0000-0002-1353-2474
NR 14
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
EI 1432-2218
J9 SURG ENDOSC
JI Surg. Endosc.
PD JUN
PY 2015
VL 29
IS 6
BP 1334
EP 1340
DI 10.1007/s00464-014-3571-1
PG 7
WC Surgery
SC Surgery
GA CH6EX
UT WOS:000354130200011
PM 24859615
ER
PT J
AU Rossini, PM
Burke, D
Chen, R
Cohen, LG
Daskalakis, Z
Di Iorio, R
Di Lazzaro, V
Ferreri, F
Fitzgerald, PB
George, MS
Hallett, M
Lefaucheur, JP
Langguth, B
Matsumoto, H
Miniussi, C
Nitsche, MA
Pascual-Leone, A
Paulus, W
Rossi, S
Rothwell, JC
Siebner, HR
Ugawa, Y
Walsh, V
Ziemann, U
AF Rossini, P. M.
Burke, D.
Chen, R.
Cohen, L. G.
Daskalakis, Z.
Di Iorio, R.
Di Lazzaro, V.
Ferreri, F.
Fitzgerald, P. B.
George, M. S.
Hallett, M.
Lefaucheur, J. P.
Langguth, B.
Matsumoto, H.
Miniussi, C.
Nitsche, M. A.
Pascual-Leone, A.
Paulus, W.
Rossi, S.
Rothwell, J. C.
Siebner, H. R.
Ugawa, Y.
Walsh, V.
Ziemann, U.
TI Non-invasive electrical and magnetic stimulation of the brain, spinal
cord, roots and peripheral nerves: Basic principles and procedures for
routine clinical and research application. An updated report from an
IFCN Committee
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Review
DE Non-invasive stimulation; Transcranial magnetic stimulation; Human
cortex; Clinical neurophysiology; TMS measures; Excitability threshold
ID HUMAN MOTOR CORTEX; THETA-BURST-STIMULATION; PAIRED ASSOCIATIVE
STIMULATION; INTRACTABLE DEAFFERENTATION PAIN; DORSOLATERAL PREFRONTAL
CORTEX; AMYOTROPHIC-LATERAL-SCLEROSIS; LATENCY AFFERENT INHIBITION;
FORAMEN MAGNUM LEVEL; INTERVAL INTRACORTICAL INHIBITION; PROGRESSIVE
MYOCLONUS EPILEPSY
AB These guidelines provide an up-date of previous IFCN report on ``Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application'' (Rossini et al., 1994). A new Committee, composed of international experts, some of whom were in the panel of the 1994 ''Report'', was selected to produce a current state-of-the-art review of non-invasive stimulation both for clinical application and research in neuroscience.
Since 1994, the international scientific community has seen a rapid increase in non-invasive brain stimulation in studying cognition, brain-behavior relationship and pathophysiology of various neurologic and psychiatric disorders. New paradigms of stimulation and new techniques have been developed. Furthermore, a large number of studies and clinical trials have demonstrated potential therapeutic applications of non-invasive brain stimulation, especially for TMS. Recent guidelines can be found in the literature covering specific aspects of non-invasive brain stimulation, such as safety (Rossi et al., 2009), methodology (Groppa et al., 2012) and therapeutic applications (Lefaucheur et al., 2014).
This up-dated review covers theoretical, physiological and practical aspects of non-invasive stimulation of brain, spinal cord, nerve roots and peripheral nerves in the light of more updated knowledge, and include some recent extensions and developments. (C) 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd.
C1 [Rossini, P. M.; Di Iorio, R.] Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthoped, Policlin A Gemelli, Inst Neurol, I-00168 Rome, Italy.
[Burke, D.] Univ Sydney, Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW 2006, Australia.
[Chen, R.] Univ Toronto, Toronto Western Res Inst, Div Neurol, Toronto, ON, Canada.
[Cohen, L. G.] NINDS, Human Cort Physiol & Neurorehabil Sect, NIH, Bethesda, MD 20892 USA.
[Daskalakis, Z.] Univ Toronto, Temerty Ctr Therapeut Brain Intervent, Ctr Addict & Mental Hlth, Toronto, ON, Canada.
[Di Lazzaro, V.; Ferreri, F.] Univ Campus Biomed, Dept Neurol, Rome, Italy.
[Ferreri, F.] Univ Eastern Finland, Dept Clin Neurophysiol, Kuopio, Finland.
[Fitzgerald, P. B.] Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia.
[Fitzgerald, P. B.] The Alfred, Melbourne, Vic, Australia.
[George, M. S.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Hallett, M.] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bethesda, MD 20892 USA.
[Lefaucheur, J. P.] Henri Mondor Hosp, AP HP, Dept Physiol, F-94010 Creteil, France.
[Lefaucheur, J. P.] Paris Est Creteil Univ, Fac Med, Nerve Excitabil & Therapeut Team, EA 4391, F-94010 Creteil, France.
[Langguth, B.] Univ Regensburg, Dept Psychiat & Psychotherapy, D-93053 Regensburg, Germany.
[Matsumoto, H.] Japanese Red Cross Med Ctr, Dept Neurol, Tokyo, Japan.
[Miniussi, C.] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy.
[Miniussi, C.] IRCCS, Ctr San Giovanni Dio Fatebenefratelli, Brescia, Italy.
[Nitsche, M. A.] Univ Gottingen, Univ Med Ctr Groningen, Dept Clin Neurophysiol, D-37073 Gottingen, Germany.
[Pascual-Leone, A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA USA.
[Paulus, W.] Univ Gottingen, Dept Clin Neurophysiol, D-37073 Gottingen, Germany.
[Rossi, S.] Univ Siena, Brain Invest & Neuromodulat Lab, Unit Neurol & Clin Neurophysiol, Dept Neurosci, I-53100 Siena, Italy.
[Rothwell, J. C.] UCL, Inst Neurol, London, England.
[Siebner, H. R.] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark.
[Siebner, H. R.] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, Ctr Funct & Diagnost Imaging & Res, DK-2650 Hvidovre, Denmark.
[Ugawa, Y.] Fukushima Med Univ, Dept Neurol, Sch Med, Fukushima, Japan.
[Walsh, V.] UCL, Inst Cognit Neurosci, London, England.
[Ziemann, U.] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany.
[Ziemann, U.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany.
RP Di Iorio, R (reprint author), Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthoped, Policlin A Gemelli, Inst Neurol, Lgo A Gemelli 8, I-00168 Rome, Italy.
EM r.diiorio@live.it
RI Siebner, Hartwig/G-4052-2016; Miniussi, Carlo/E-7602-2010; Chen,
Robert/B-3899-2009; Paulus, Walter/A-3544-2009;
OI Miniussi, Carlo/0000-0002-5436-4745; Chen, Robert/0000-0002-8371-8629;
Paulus, Walter/0000-0001-5549-8377; Ferreri,
Florinda/0000-0002-7938-905X; Rothwell, John/0000-0003-1367-6467; Di
Lazzaro, Vincenzo/0000-0002-9113-5925; rossi, simone/0000-0001-6697-9459
NR 493
TC 140
Z9 141
U1 27
U2 100
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUN
PY 2015
VL 126
IS 6
BP 1071
EP 1107
DI 10.1016/j.clinph.2015.02.001
PG 37
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CH1ME
UT WOS:000353785000006
PM 25797650
ER
PT J
AU Volz, MS
Suarez-Contreras, V
Portilla, ALS
Illigens, B
Bermpohl, F
Fregni, F
AF Volz, Magdalena Sarah
Suarez-Contreras, Vanessa
Santos Portilla, Andrea L.
Illigens, Ben
Bermpohl, Felix
Fregni, Felipe
TI Movement observation-induced modulation of pain perception and motor
cortex excitability
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE Motor cortex; M1; Movement observation; Pain; Corticospinal excitability
ID TRANSCRANIAL MAGNETIC STIMULATION; SPINAL-CORD-INJURY; CORTICOSPINAL
EXCITABILITY; CORTICAL EXCITABILITY; HAND MOVEMENTS; INTRACORTICAL
INHIBITION; EVOKED-POTENTIALS; NEUROPATHIC PAIN; VISUAL ILLUSION; RELAY
NUCLEUS
AB Objective: The observation of movements increases primary motor cortex (M1) excitability. This exploratory study examined the effects of movement observation on pressure pain threshold (PPT) and transcranial magnetic stimulation (TMS)-indexed corticospinal excitability bilaterally.
Methods: Thirty healthy right-handed subjects were randomized to a left hand-movement observation task or a control task. Statistical analyses were performed using ANOVA models and t-tests. Results were not corrected for multiple comparisons. Quantitative sensory assessments were measured in both hands, while M1 excitability has only been tested for the right (non-dominant) M1 corresponding to the observed left hand movements.
Results: Analysis of pain and cortical silent period (CSP) outcomes demonstrated a significant interaction between task (hand-movement group) versus control group and time (pre-/postintervention). PPT increased in the left hand (moving hand in the task) and declined significantly in the contralateral hand (still hand) in the movement-observation-task-group, whereas PTT in the control group remained unchanged. CSP was significantly shorter in the movement-observation group indicating decreased intracortical inhibition (results uncorrected for multiple comparisons).
Conclusions: The observation of hand-movements led to a side-specific reduction in pain perception and a decrease in intracortical inhibition.
Significance: These exploratory findings support the notion that M1 is a robust modulator of pain-related neural networks. This effect might be mediated through modulation of the GABAergic system and appears to differ from what is observed in chronic pain. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Santos Portilla, Andrea L.; Fregni, Felipe] Harvard Univ, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Sch Med,Spaulding Neuromodulat Ctr, Charlestown, MA 02129 USA.
[Volz, Magdalena Sarah; Suarez-Contreras, Vanessa; Santos Portilla, Andrea L.; Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
[Volz, Magdalena Sarah; Bermpohl, Felix] Charite Univ Med Berlin, Berlin, Germany.
[Illigens, Ben; Fregni, Felipe] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Charlestown, MA 02129 USA.
[Fregni, Felipe] Univ Sao Paulo, Inst Psychol, NEC, Sao Paulo, Brazil.
RP Fregni, F (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat, 79-96 13th St, Charlestown, MA 02129 USA.
EM fregni.felipe@mgh.harvard.edu
FU Deutsche Schmerzgesellschaft e.V. (German Society for the Study of
Pain); FAPESP [2012/06519-5]
FX Volz MS received the scholarship "Promotionsstipendium" from the
"Deutsche Schmerzgesellschaft e.V." (German Society for the Study of
Pain). We are also grateful to support of FAPESP (grant number
2012/06519-5).
NR 70
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUN
PY 2015
VL 126
IS 6
BP 1204
EP 1211
DI 10.1016/j.clinph.2014.09.022
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CH1ME
UT WOS:000353785000018
PM 25308309
ER
PT J
AU Bryant, AE
Bayer, CR
Aldape, MJ
Stevens, DL
AF Bryant, Amy E.
Bayer, Clifford R.
Aldape, Michael J.
Stevens, Dennis L.
TI The roles of injury and nonsteroidal anti-inflammatory drugs in the
development and outcomes of severe group A streptococcal soft tissue
infections
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE group A streptococcus; myonecrosis; necrotizing fasciitis; NSAIDs;
trauma
ID SKELETAL-MUSCLE REGENERATION; NECROTIZING FASCIITIS; FIBRO/ADIPOGENIC
PROGENITORS; BACTERIAL-INFECTIONS; VIMENTIN EXPRESSION; GENE-EXPRESSION;
SATELLITE CELLS; RISK; VARICELLA; CHILDREN
AB Purpose of review
This review summarizes clinical and basic science evidence linking trauma and nonsteroidal anti-inflammatory drug (NSAID) use to initiation and progression of severe group A streptococcal (GAS) soft tissue infection.
Recent findings
New evidence includes recent clinical series and controlled studies that lend support to an NSAID/GAS association, basic science studies that demonstrate unique roles for nonpenetrating injury and NSAID administration in initiation of cryptogenic GAS infection and experimental studies showing that nonselective NSAIDs accelerate disease progression and limit antibiotic efficacy in established GAS soft tissue infections. Potential mechanisms for these processes are discussed.
Summary
NSAIDs are important anti-inflammatory and analgesic drugs; however, new experimental data suggest that nonselective NSAIDs do more than simply mask the signs and symptoms of developing GAS infection. A more thorough understanding of the triadic interplay of injury-triggered immune signaling, GAS soft tissue infection and NSAIDs is of significant clinical importance and could shift the current paradigm of pain management to avert the consequences of such devastating infections.
C1 [Bryant, Amy E.; Bayer, Clifford R.; Aldape, Michael J.; Stevens, Dennis L.] US Dept Vet Affairs, Off Res & Dev, Boise, ID USA.
[Bryant, Amy E.; Stevens, Dennis L.] Univ Washington, Sch Med, Seattle, WA USA.
RP Bryant, AE (reprint author), Res & Dev Serv, US Dept Vet Affairs, Med Ctr, Infect Dis Sect, Bldg 117,500 West Ft St, Boise, ID 83702 USA.
EM amy.bryant@va.gov
FU United States Department of Veterans Affairs, Biomedical Laboratory
Research and Development Program [I01BX007080]; National Institute of
General Medical Sciences of the National Institutes of Health
[P20GM103408]
FX This work was supported in part by a Merit Review Award (#I01BX007080,
A.E.B.) from the United States Department of Veterans Affairs,
Biomedical Laboratory Research and Development Program and by an
Institutional Development Award (IDeA) from the National Institute of
General Medical Sciences of the National Institutes of Health under
Grant #P20GM103408.
NR 51
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0951-7375
EI 1473-6527
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD JUN
PY 2015
VL 28
IS 3
BP 231
EP 239
DI 10.1097/QCO.0000000000000160
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA CH0DI
UT WOS:000353688800006
PM 25918957
ER
PT J
AU Turan, S
Bastepe, M
AF Turan, Serap
Bastepe, Murat
TI GNAS Spectrum of Disorders
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE GNAS; Pseudohypoparathyroidism; Gs alpha; Alpha-subunit of the
stimulatory G protein
ID PSEUDOHYPOPARATHYROIDISM-TYPE-IB; XL-ALPHA-S; MCCUNE-ALBRIGHT-SYNDROME;
PROGRESSIVE OSSEOUS HETEROPLASIA; STIMULATORY G-PROTEIN;
PARATHYROID-HORMONE RESISTANCE; BECKWITH-WIEDEMANN-SYNDROME; IMPRINTING
CONTROL ELEMENT; IN-VITRO FERTILIZATION; HUMAN ENDOCRINE TUMORS
AB The GNAS complex locus encodes the alpha-subunit of the stimulatory G protein (Gs alpha), a ubiquitous signaling protein mediating the actions of many hormones, neurotransmitters, and paracrine/autocrine factors via generation of the second messenger cAMP. GNAS gives rise to other gene products, most of which exhibit exclusively monoallelic expression. In contrast, Gs alpha is expressed biallelically in most tissues; however, paternal Gs alpha expression is silenced in a small number of tissues through as-yet-poorly understood mechanisms that involve differential methylation within GNAS. Gs alpha-coding GNAS mutations that lead to diminished Gs alpha expression and/or function result in Albright's hereditary osteodystrophy (AHO) with or without hormone resistance, i.e., pseudohypoparathyroidism type-Ia/Ic and pseudo-pseudohypoparathyroidism, respectively. Microdeletions that alter GNAS methylation and, thereby, diminish Gs alpha expression in tissues in which the paternal Gs alpha allele is normally silenced also cause hormone resistance, which occurs typically in the absence of AHO, a disorder termed pseudohypoparathyroidism type-Ib. Mutations of GNAS that cause constitutive Gs alpha signaling are found in patients with McCune-Albright syndrome, fibrous dysplasia of bone, and different endocrine and non-endocrine tumors. Clinical features of these diseases depend significantly on the parental allelic origin of the GNAS mutation, reflecting the tissue-specific paternal Gs alpha silencing. In this article, we review the pathogenesis and the phenotypes of these human diseases.
C1 [Turan, Serap] Marmara Univ, Sch Med Hosp, Pediat Endocrinol, Istanbul, Turkey.
[Bastepe, Murat] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Bastepe, Murat] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Bastepe, M (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, 55 Fruit St Thier 10, Boston, MA 02114 USA.
EM serap.turan@marmara.edu.tr; bastepe@helix.mgh.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases [RO1
DK073911]; March of Dimes Foundation; Milton Fund
FX The studies conducted in the laboratory of M.B. are funded in part by
research grants from the National Institute of Diabetes and Digestive
and Kidney Diseases (RO1 DK073911), the March of Dimes Foundation, and
the Milton Fund.
NR 131
TC 11
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
EI 1544-2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD JUN
PY 2015
VL 13
IS 3
BP 146
EP 158
DI 10.1007/s11914-015-0268-x
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CH2CS
UT WOS:000353833000003
PM 25851935
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Ignorance isn't bliss: why patients become angry
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE anger; cognitive deficits; decision analysis; medical practice; outcome
research; threshold analysis
ID ANGER
AB Patients with cognitive limitations may struggle understanding complex arguments and feel overwhelmed by the need to choose among medical options that they poorly understand. Such struggle may result in frustration and anger directed at the physician. The aim of the present study is to explain the characteristics underlying such situations. A decision tree is modeled to capture the choice that every patient has to make after receiving medical advice. Patient choices are phrased in terms of a threshold probability for accepting or rejecting advice by physicians. To a patient with poor understanding of medical exigencies all differences between present or absent disease state, prognosis, and risks of intervention may seem largely arbitrary and meaningless. With little or no guidance to make an informed decision, taking any medical action is deemed wasted and harmful, whereas inaction leaves the underlying medical problem unsolved. Both choices appear equally ineffective with respect to the patient's symptoms and therefore unappealing. As shown by applying threshold analysis to a patient in a state of ignorance, no threshold probability for following medical advice exists. Patients with cognitive limitations will become frustrated and angry by a seemingly dismal situation without good alternatives to choose from. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 12
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD JUN
PY 2015
VL 27
IS 6
BP 619
EP 622
DI 10.1097/MEG.0000000000000323
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CH0DE
UT WOS:000353688400001
PM 25769095
ER
PT J
AU Charaziak, KK
Siegel, JH
AF Charaziak, Karolina K.
Siegel, Jonathan H.
TI Tuning of SFOAEs Evoked by Low-Frequency Tones Is Not Compatible with
Localized Emission Generation
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE acoustic trauma; two-tone suppression; compound action potential;
suppression tuning curve; chinchilla
ID PRODUCT OTOACOUSTIC EMISSIONS; PERMANENT THRESHOLD SHIFT; AUDITORY-NERVE
FIBERS; ACOUSTIC TRAUMA; GUINEA-PIG; COCHLEAR FUNCTION; INTERFERENCE
TONES; CHINCHILLA COCHLEA; LATENCY COMPONENTS; 2-TONE SUPPRESSION
AB Stimulus-frequency otoacoustic emissions (SFOAEs) appear to be well suited for assessing frequency selectivity because, at least on theoretical grounds, they originate over a restricted region of the cochlea near the characteristic place of the evoking tone. In support of this view, we previously found good agreement between SFOAE suppression tuning curves (SF-STCs) and a control measure of frequency selectivity (compound action potential suppression tuning curves (CAP-STC)) for frequencies above 3 kHz in chinchillas. For lower frequencies, however, SF-STCs and were over five times broader than the CAP-STCs and demonstrated more high-pass rather than narrow band-pass filter characteristics. Here, we test the hypothesis that the broad tuning of low-frequency SF-STCs is because emissions originate over a broad region of the cochlea extending basal to the characteristic place of the evoking tone. We removed contributions of the hypothesized basally located SFOAE sources by either pre-suppressing them with a high-frequency interference tone (IT; 4.2, 6.2, or 9.2 kHz at 75 dB sound pressure level (SPL)) or by inducing acoustic trauma at high frequencies (exposures to 8, 5, and lastly 3-kHz tones at 110-115 dB SPL). The 1-kHz SF-STCs and CAP-STCs were measured for baseline, IT present and following the acoustic trauma conditions in anesthetized chinchillas. The IT and acoustic trauma affected SF-STCs in an almost indistinguishable way. The SF-STCs changed progressively from a broad high-pass to narrow band-pass shape as the frequency of the IT was lowered and for subsequent exposures to lower-frequency tones. Both results were in agreement with the "basal sources" hypothesis. In contrast, CAP-STCs were not changed by either manipulation, indicating that neither the IT nor acoustic trauma affected the 1-kHz characteristic place. Thus, unlike CAPs, SFOAEs cannot be considered as a place-specific measure of cochlear function at low frequencies, at least in chinchillas.
C1 [Charaziak, Karolina K.; Siegel, Jonathan H.] Northwestern Univ, Roxelyn & Richard Pepper Dept Commun Sci & Disord, Evanston, IL USA.
[Charaziak, Karolina K.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
RP Charaziak, KK (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
EM KarolinaCharaziak2013@u.northwestern.edu
FU NIH [DC-00419]; Northwestern University School of Communication Ignition
grant; Northwestern University
FX This study was supported by the NIH Grant DC-00419 (M. Ruggero),
Northwestern University School of Communication Ignition grant, and
Northwestern University. We thank Dr. Sumitrajit Dhar and Dr. Steven
Zecker for statistical consultations.
NR 81
TC 7
Z9 7
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
EI 1438-7573
J9 JARO-J ASSOC RES OTO
JI JARO
PD JUN
PY 2015
VL 16
IS 3
BP 317
EP 329
DI 10.1007/s10162-015-0513-0
PG 13
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA CH2EV
UT WOS:000353839400001
PM 25813430
ER
PT J
AU Yu, ZY
Li, ZY
Liu, N
Jizhang, YN
McCarthy, TJ
Tedford, CE
Lo, EH
Wang, XY
AF Yu, Zhanyang
Li, Zhaoyu
Liu, Ning
Jizhang, Yunneng
McCarthy, Thomas J.
Tedford, Clark E.
Lo, Eng H.
Wang, Xiaoying
TI Near infrared radiation protects against oxygen-glucose
deprivation-induced neurotoxicity by down-regulating neuronal nitric
oxide synthase (nNOS) activity in vitro
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE Near infrared radiation; Oxygen-glucose deprivation; Primary cortical
neurons; Nitric oxide; Neuronal nitric oxide synthase (nNOS)
ID TERM NEUROLOGICAL DEFICITS; ENERGY LASER IRRADIATION; CORTICAL-NEURONS;
PROMOTES REGENERATION; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE;
CYTOCHROME-OXIDASE; OXIDATIVE STRESS; ISCHEMIC-STROKE; THERAPY
AB Near infrared radiation (NIR) has been shown to be neuroprotective against neurological diseases including stroke and brain trauma, but the underlying mechanisms remain poorly understood. In the current study we aimed to investigate the hypothesis that NIR may protect neurons by attenuating oxygen-glucose deprivation (OGD)-induced nitric oxide (NO) production and modulating cell survival/death signaling. Primary mouse cortical neurons were subjected to 4 h OGD and NIR was applied at 2 h reoxygenation. OGD significantly increased NO level in primary neurons compared to normal control, which was significantly ameliorated by NIR at 5 and 30 min post-NIR. Neither OGD nor NIR significantly changed neuronal nitric oxide synthase (nNOS) mRNA or total protein levels compared to control groups. However, OGD significantly increased nNOS activity compared to normal control, and this effect was significantly diminished by NIR. Moreover, NIR significantly ameliorated the neuronal death induced by S-Nitroso-N-acetyl-DL-penicillamine (SNAP), a NO donor. Finally, NIR significantly rescued OGD-induced suppression of p-Akt and Bcl-2 expression, and attenuated OGD-induced upregulation of Bax, BAD and caspase-3 activation. These results suggest NIR may protect against OGD at least partially through reducing NO production by down-regulating nNOS activity, and modulating cell survival/death signaling.
C1 [Yu, Zhanyang; Li, Zhaoyu; Jizhang, Yunneng; Lo, Eng H.; Wang, Xiaoying] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.
[Yu, Zhanyang; Li, Zhaoyu; Jizhang, Yunneng; Lo, Eng H.; Wang, Xiaoying] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.
[Yu, Zhanyang; Li, Zhaoyu; Jizhang, Yunneng; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Liu, Ning] Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, State Educ Minist China, Changsha 410081, Hunan, Peoples R China.
[McCarthy, Thomas J.] Sequent Med Inc, Aliso Viejo, CA 92656 USA.
[Tedford, Clark E.] Solentix Biosci Inc, Poulsbo, WA 98370 USA.
RP Yu, ZY (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St,Room 2401, Charlestown, MA 02129 USA.
EM Yu.Zhanyang@mgh.harvard.edu; wangxi@helix.mgh.harvard.edu
NR 35
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
EI 1573-7365
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD JUN
PY 2015
VL 30
IS 3
BP 829
EP 837
DI 10.1007/s11011-015-9663-3
PG 9
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA CH1YZ
UT WOS:000353821000025
PM 25796222
ER
PT J
AU Tsapaki, V
Rehani, MM
AF Tsapaki, Virginia
Rehani, Madan M.
TI Female medical physicists: The results of a survey carried out by the
International Organization for Medical Physics
SO PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
LA English
DT Article
DE Medical physicist; Female medical physicists; Gender balance; Gender
distribution
ID GENDER-DIFFERENCES; SCIENCE; WOMEN
AB Introduction: The gender composition of the existing medical physicist (MP) workforce around the world is basically unknown. The International Organization for Medical Physics (IOMP) performed a survey in order to investigate the number of MPs in countries around the world and the percentage of women MPs compared to total number of MPs.
Materials and methods: A simple online questionnaire prepared as a Google Forms survey asking the country, the total number of MPs, the number of female MPs and finally the gender of the person providing the data was sent in mid-March 2013 to six regional member organizations of IOMP, as well as contact points in many member countries.
Results: Sixty-six countries responded to the survey by mid-July 2013. Fifty two percent of those who filled the form were females, the rest males. The total number of MPs was 17,024, of which 28% were female (4807). The median values of percentages of females were 21% in the USA, 47% in Europe, 35% in Asia, 33% in Africa and 24% in Latin America.
Conclusion: This is the first international survey that investigates the number and percentage of female MPs around the world. There are European countries that are far away from the target set by European Commission (40%) whereas in countries in the Middle East and Asia, female MPs actually outnumber males. This study is the first step in a more in-depth study that needs to be taken in near future. (C) 2015 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
C1 [Tsapaki, Virginia] Konstantopoulio Gen Hosp, Med Phys Unit, Nea Ionia 14233, Greece.
[Rehani, Madan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, Madan M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Tsapaki, V (reprint author), Konstantopoulio Gen Hosp, Med Phys Unit, Agias Olgas 3-5, Nea Ionia 14233, Greece.
EM virginia@otenet.gr; sg.iomp@gmail.com
NR 18
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1120-1797
EI 1724-191X
J9 PHYS MEDICA
JI Phys. Medica
PD JUN
PY 2015
VL 31
IS 4
BP 368
EP 373
DI 10.1016/j.ejmp.2015.02.009
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CH2FU
UT WOS:000353841900005
PM 25790723
ER
PT J
AU Pasinetti, GM
Wang, J
Ho, L
Zhao, W
Dubner, L
AF Pasinetti, Giulio Maria
Wang, Jun
Ho, Lap
Zhao, Wei
Dubner, Lauren
TI Roles of resveratrol and other grape-derived polyphenols in Alzheimer's
disease prevention and treatment
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
DE Resveratrol; Alzheimer's disease; Polyphenol; SIRT1
ID MILD COGNITIVE IMPAIRMENT; ACTIVATED PROTEIN-KINASE;
HUNTINGTONS-DISEASE; MOUSE MODEL; NEURODEGENERATIVE DISORDERS; AMYLOID
NEUROPATHOLOGY; CALORIE RESTRICTION; SIRT1 ACTIVATION; OLDER-ADULTS;
LIFE-SPAN
AB Alzheimer's disease (AD) is a devastating disorder that strikes 1 in 10 Americans over the age of 65, and almost half of all Americans over 85 years old. The odds of an individual developing AD double every five years after the age of 65. While it has become increasingly common to meet heart attack or cancer survivors, there are no AD survivors. There is mounting evidence that dietary polyphenols, including resveratrol, may beneficially influence AD. Based on this consideration, several studies reported in the last few years were designed to validate sensitive and reliable translational tools to mechanistically characterize brain bioavailable polyphenols as disease-modifying agents to help prevent the onset of AD dementia and other neurodegenerative disorders. Several research groups worldwide with expertise in AD, plant biology, nutritional sciences, and botanical sciences have reported very high quality studies that ultimately provided the necessary information showing that polyphenols and their metabolites, which Come from several dietary sources, including grapes, cocoa etc., are capable of preventing AD. The ultimate goal of these studies was to provide novel strategies to prevent the disease even before the onset of clinical symptoms. The studies discussed in this review article provide support that the information gathered in the last few years of research will have a major impact on AD prevention by providing vital knowledge on the protective roles of polyphenols, including resveratrol. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Pasinetti, Giulio Maria; Wang, Jun; Ho, Lap; Zhao, Wei; Dubner, Lauren] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurol, New York, NY 10029 USA.
[Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Psychiat, New York, NY 10029 USA.
[Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA.
[Pasinetti, Giulio Maria; Wang, Jun; Ho, Lap; Zhao, Wei] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
FU NIH-NCCAM, program of the Icahn School of Mount Sinai Center of
Excellence for Research in Complementary and Alternative Medicine for
Alzheimer's Disease [P01AT004511-01]
FX Funding was provided by the NIH-NCCAM grant P01AT004511-01 as part of a
program of the Icahn School of Mount Sinai Center of Excellence for
Research in Complementary and Alternative Medicine for Alzheimer's
Disease (to Pasinetti).
NR 83
TC 24
Z9 27
U1 9
U2 61
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUN
PY 2015
VL 1852
IS 6
SI SI
BP 1202
EP 1208
DI 10.1016/j.bbadis.2014.10.006
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CG2FX
UT WOS:000353091400011
PM 25315300
ER
PT J
AU Charest, JM
Okamoto, T
Kitano, K
Yasuda, A
Gilpin, SE
Mathisen, DJ
Ott, HC
AF Charest, Jonathan M.
Okamoto, Tatsuya
Kitano, Kentaro
Yasuda, Atsushi
Gilpin, Sarah E.
Mathisen, Douglas J.
Ott, Harald C.
TI Design and validation of a clinical-scale bioreactor for long-term
isolated lung culture
SO BIOMATERIALS
LA English
DT Article
DE Isolated lung culture; Lung preservation; Lung transplantation; Organ
repair; Ex-vivo perfusion
ID EX-VIVO; PRESSURE VENTILATION; PORCINE LUNGS; PERFUSION;
TRANSPLANTATION; INJURY; DONOR; GLUCOSE; MATRIX
AB The primary treatment for end-stage lung disease is lung transplantation. However, donor organ shortage remains a major barrier for many patients. In recent years, techniques for maintaining lungs ex vivo for evaluation and short-term (<12 h) resuscitation have come into more widespread use in an attempt to expand the donor pool. In parallel, progress in whole organ engineering has provided the potential perspective of patient derived grafts grown on demand. As both of these strategies advance to more complex interventions for lung repair and regeneration, the need for a long-term organ culture system becomes apparent. Herein we describe a novel clinical scale bioreactor capable of maintaining functional porcine and human lungs for at least 72 h in isolated lung culture (ILC). The fully automated, computer controlled, sterile, closed circuit system enables physiologic pulsatile perfusion and negative pressure ventilation, while gas exchange function, and metabolism can be evaluated. Creation of this stable, biomimetic long-term culture environment will enable advanced interventions in both donor lungs and engineered grafts of human scale. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Charest, Jonathan M.; Okamoto, Tatsuya; Kitano, Kentaro; Yasuda, Atsushi; Gilpin, Sarah E.; Mathisen, Douglas J.; Ott, Harald C.] Massachusetts Gen Hosp, Thorac Surg, Boston, MA 02114 USA.
[Gilpin, Sarah E.; Ott, Harald C.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Ott, Harald C.] Harvard Stem Cell Inst, Boston, MA USA.
RP Ott, HC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, 185 Cambridge St,CPZN 4812, Boston, MA 02114 USA.
FU United Therapeutics Corporation; National Institutes of Health
[DP2-OD008749-01]
FX This study was supported by the United Therapeutics Corporation, and the
National Institutes of Health Director's New Innovator Award
(DP2-OD008749-01).
NR 26
TC 8
Z9 8
U1 1
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2015
VL 52
BP 79
EP 87
DI 10.1016/j.biomaterials.2015.02.016
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CG2FT
UT WOS:000353091000007
PM 25818415
ER
PT J
AU Ren, X
Tapias, LF
Jank, BJ
Mathisen, DJ
Lanuti, M
Ott, HC
AF Ren, Xi
Tapias, Luis F.
Jank, Bernhard J.
Mathisen, Douglas J.
Lanuti, Michael
Ott, Harald C.
TI Ex vivo non-invasive assessment of cell viability and proliferation in
bio-engineered whole organ constructs
SO BIOMATERIALS
LA English
DT Article
DE Decellularization; Tissue engineering; Organ regeneration; Resazurin;
Perfusion; Viability
ID ENDOTHELIAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; ORTHOTOPIC
TRANSPLANTATION; COLORIMETRIC ASSAY; MATRIX SCAFFOLDS; IN-VITRO; GROWTH;
DECELLULARIZATION; REGENERATION; MONITOR
AB Decellularized organ scaffolds allow whole organ regeneration and study of cell behavior in three-dimensional culture conditions. Cell viability within the bin-engineered organ constructs is an essential parameter reflecting the performance of participating cells during long-term ex vivo culture, and is a prerequisite for further functional performance. Resazurin-based redox metabolic assays have been used to monitor cell viability in both two- and three-dimensional cell cultures. Here we developed a method for monitoring cell viability and proliferation in bin-engineered organ constructs using a resazurin perfusion assay. This method allows non-invasive, repetitive and rapid estimation of viable cell numbers during long-term ex vivo culture. As a proof-of-principle, we assessed the performance of two different endothelial sources and the impact of different perfusion programs on endothelial viability after reendothelialization of decellularized lung scaffolds. The resazurin-based perfusion assay revealed changes in endothelial viability and proliferation during long-term ex vivo culture, which was consistent with histological assessment at different time points. Finally, we showed that this method could be used for assessment of proliferation and cytotoxicity after pharmacological treatment on a three-dimensional non-small cell lung cancer culture model. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ren, Xi; Jank, Bernhard J.; Ott, Harald C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Ren, Xi; Tapias, Luis F.; Jank, Bernhard J.; Mathisen, Douglas J.; Lanuti, Michael; Ott, Harald C.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Tapias, Luis F.; Mathisen, Douglas J.; Lanuti, Michael; Ott, Harald C.] Massachusetts Gen Hosp, Div Thorac Surg, Dept Surg, Boston, MA 02114 USA.
[Ott, Harald C.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Ott, HC (reprint author), Harvard Univ, Sch Med, Harvard Stem Cell Inst, Div Thorac Surg,Dept Surg,Massachusetts Gen Hosp, 185 Cambridge St,CPZN 4800, Boston, MA 02114 USA.
EM hott@mgh.harvard.edu
OI Ren, Xi/0000-0003-3187-1311; Jank, Bernhard/0000-0003-1420-5034
FU United Therapeutics Corporation; National Institutes of Health (NIH)
[DP2-OD008749-01]
FX This work was supported by the United Therapeutics Corporation and the
National Institutes of Health (NIH) Director's New Innovator Award
(DP2-OD008749-01). The authors thank St. Louis Cord Blood Bank &
Cellular Therapy Laboratory at SSM Cardinal Glennon Children's Medical
Center, St. Louis, MO for providing the human umbilical cord blood
samples.
NR 44
TC 10
Z9 10
U1 2
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2015
VL 52
BP 103
EP 112
DI 10.1016/j.biomaterials.2015.01.061
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CG2FT
UT WOS:000353091000009
PM 25818417
ER
PT J
AU Reagan, MR
Liaw, L
Rosen, CJ
Ghobrial, IM
AF Reagan, Michaela R.
Liaw, Lucy
Rosen, Clifford J.
Ghobrial, Irene M.
TI Dynamic interplay between bone and multiple myeloma: Emerging roles of
the osteoblast
SO BONE
LA English
DT Review
DE Multiple myeloma; Osteoblasts; Bone
ID MESENCHYMAL STEM-CELLS; OSTEOGENIC DIFFERENTIATION; MARROW NICHE;
IN-VIVO; UNDETERMINED SIGNIFICANCE; SERUM CONCENTRATIONS; OSTEOLYTIC
LESIONS; KEY REGULATOR; BREAST-CANCER; MOUSE MODEL
AB Multiple myeloma is a B-cell malignancy characterized by the unrelenting proliferation of plasma cells. Multiple myeloma causes osteolytic lesions and fractures that do not heal due to decreased osteoblastic and increased osteoclastic activity. However, the exact relationship between osteoblasts and myeloma cells remains elusive. Understanding the interactions between these dynamic bone-forming cells and myeloma cells is crucial to understanding how osteolytic lesions form and persist and how tumors grow within the bone marrow. This review provides a comprehensive overview of basic and translational research focused on the role of osteoblasts in multiple myeloma progression and their relationship to osteolytic lesions. Importantly, current challenges for in vitro studies exploring direct osteoblastic effects on myeloma cells, and gaps in understanding the role of the osteoblast in myeloma progression are delineated. Finally, successes and challenges in myeloma treatment with osteoanabolic therapy (i.e., any treatment that induces increased osteoblastic number or activity) are enumerated. Our goal is to illuminate novel mechanisms by which osteoblasts may contribute to multiple myeloma disease progression and osteolysis to better direct research efforts. Ultimately, we hope this may provide a roadmap for new approaches to the pathogenesis and treatment of multiple myeloma with a particular focus on the osteoblast (C) 2015 Elsevier Inc. All rights reserved.
C1 [Reagan, Michaela R.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Reagan, Michaela R.; Liaw, Lucy; Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA.
[Liaw, Lucy; Rosen, Clifford J.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
RP Rosen, CJ (reprint author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.
EM rosenc@mmc.org; Irene_Ghobrial@dfci.harvard.edu
RI Reagan, Michaela/E-3549-2017;
OI Reagan, Michaela/0000-0003-2884-6481
FU NIH [R01CA154648]; NIH/NIGMS [P30GM106391]; Office of the Assistant
Secretary of Defense for Health Affairs [W81XWH-13-1-0390]
FX This work was supported by the NIH R01CA154648 and by a Pilot Project
Grant from NIH/NIGMS P30GM106391 at the Maine Medical Center Research
Institute. This work was also supported by the Office of the Assistant
Secretary of Defense for Health Affairs, through the Peer Reviewed
Cancer Research Program, Visionary Postdoctoral Fellowship Award, under
Award FY14 DoD Congressionally Directed Medical Research Program No.
W81XWH-13-1-0390. Opinions, interpretations, conclusions and
recommendations are those of the author and are not necessarily endorsed
blithe DoD.
NR 121
TC 10
Z9 11
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD JUN
PY 2015
VL 75
BP 161
EP 169
DI 10.1016/j.bone.2015.02.021
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG1ZQ
UT WOS:000353075100022
PM 25725265
ER
PT J
AU Brownlow, JA
Harb, GC
Ross, RJ
AF Brownlow, Janeese A.
Harb, Gerlinde C.
Ross, Richard J.
TI Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A
Review of the Literature
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Psychotherapy; Pharmacotherapy; Sleep disturbance; Insomnia; Nightmares;
Post-traumatic stress disorder
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; COMBAT
VETERANS; PSYCHIATRIC-DISORDERS; CHRONIC NIGHTMARES; IMAGERY REHEARSAL;
DOUBLE-BLIND; ADJUNCTIVE RISPERIDONE; PROLONGED EXPOSURE; TRAUMA
NIGHTMARES
AB Sleep disturbances are among the most commonly endorsed symptoms of post-traumatic stress disorder (PTSD). Treatment modalities that are effective for the waking symptoms of PTSD may have limited efficacy for post-traumatic sleep problems. The aim of this review is to summarize the evidence for empirically supported and/or utilized psychotherapeutic and pharmacological treatments for post-traumatic nightmares and insomnia. While there are few controlled studies of the applicability of general sleep-focused interventions to the management of the sleep disturbances in PTSD, evidence is growing to support several psychotherapeutic and pharmacological treatments. Future investigations should include trials that combine treatments focused on sleep with treatments effective in managing the waking symptoms of PTSD.
C1 [Brownlow, Janeese A.; Ross, Richard J.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Brownlow, Janeese A.; Harb, Gerlinde C.; Ross, Richard J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Brownlow, Janeese A.] Univ Penn, Behav Sleep Med Program, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
RP Brownlow, JA (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM brownlow@mail.med.upenn.edu
FU National Research Service Award (NRSA) Fellowship from the National
Heart, Lung, and Blood Institute [HL07713]
FX This material is the result of work supported by a National Research
Service Award (NRSA) Fellowship to a T32 to Dr. Allan Pack from the
National Heart, Lung, and Blood Institute (grant number HL07713). The
opinions expressed in this article do not represent those of the
Department of Veterans Affairs or the U.S. Government.
NR 120
TC 6
Z9 7
U1 9
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
EI 1535-1645
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD JUN
PY 2015
VL 17
IS 6
AR 41
DI 10.1007/s11920-015-0587-8
PG 10
WC Psychiatry
SC Psychiatry
GA CG2YD
UT WOS:000353141000004
PM 25894359
ER
PT J
AU Marin, MF
Lonak, SF
Milad, MR
AF Marin, Marie-France
Lonak, Sylwia Fowler
Milad, Mohammed R.
TI Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive
Enhancers
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Anxiety disorders; Fear-based disorders; Extinction learning;
D-Cycloserine; Beta-blockers; Endocannabinoids; Estrogen; Methylene
blue; HDAC inhibitors
ID POSTTRAUMATIC-STRESS-DISORDER; HISTONE DEACETYLASE INHIBITOR;
FACILITATES FEAR EXTINCTION; DRIVEN TRAUMATIC IMAGERY; D-CYCLOSERINE;
CONDITIONED FEAR; METHYLENE-BLUE; ANXIETY DISORDERS; EXPOSURE THERAPY;
IMPAIRS EXTINCTION
AB Exposure-based therapy has proven to be useful to treat various anxiety disorders as well as post-traumatic stress disorder (PTSD). Despite its efficacy, a fair proportion of patients remain symptomatic after treatment. Different lines of research have put considerable efforts to investigate ways to enhance the efficacy of exposure-based therapy, which could ultimately lead to better clinical outcomes for patients. Given that this type of therapy relies on extinction learning principles, neuroscience research has tested different adjuncts that could be used as cognitive enhancers through their impact on extinction learning and its consolidation. The current review will summarize some of the latest compounds that have received attention and show some promise to be used in clinical settings to improve the efficacy of exposure-based therapy.
C1 [Marin, Marie-France; Lonak, Sylwia Fowler; Milad, Mohammed R.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Marin, Marie-France; Milad, Mohammed R.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02129 USA.
RP Milad, MR (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 149 13th St, Charlestown, MA 02129 USA.
EM milad@nmr.mgh.harvard.edu
FU National Institute of Mental Health [R01MH097880, R01MH097964];
Department of Defense [W81XWH-11-2-0079]; Banting Post-doctoral
Fellowship, Canadian Institutes of Health Research
FX This project was supported by grants from the National Institute of
Mental Health to (R01MH097880 & R01MH097964) and from the Department of
Defense (W81XWH-11-2-0079) to MRM. MFM holds a Banting Post-doctoral
Fellowship, Canadian Institutes of Health Research.
NR 73
TC 4
Z9 4
U1 1
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
EI 1535-1645
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD JUN
PY 2015
VL 17
IS 6
AR 39
DI 10.1007/s11920-015-0582-0
PG 8
WC Psychiatry
SC Psychiatry
GA CG2YD
UT WOS:000353141000002
PM 25894356
ER
PT J
AU Scourtas, A
Pitman, MB
Chebib, I
AF Scourtas, Aristana
Pitman, Martha Bishop
Chebib, Ivan
TI Nodular Fasciitis Clinically Presenting as a Sarcoma
SO DIAGNOSTIC CYTOPATHOLOGY
LA English
DT Article
C1 Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Chebib, I (reprint author), Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, 55 Fruit St,WRN2, Boston, MA 02114 USA.
EM ichebib@partners.org
NR 3
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-1039
EI 1097-0339
J9 DIAGN CYTOPATHOL
JI Diagn. Cytopathol.
PD JUN
PY 2015
VL 43
IS 6
BP 488
EP 489
DI 10.1002/dc.23214
PG 2
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA CG6FX
UT WOS:000353393900009
PM 25363486
ER
PT J
AU Nelson, DS
van Halteren, A
Quispel, WT
van den Bos, C
Bovee, JVMG
Patel, B
Badalian-Very, G
van Hummelen, P
Ducar, M
Lin, L
MacConaill, LE
Egeler, RM
Rollins, BJ
AF Nelson, David S.
van Halteren, Astrid
Quispel, Willemijn T.
van den Bos, Cor
Bovee, Judith V. M. G.
Patel, Bhumi
Badalian-Very, Gayane
van Hummelen, Paul
Ducar, Matthew
Lin, Ling
MacConaill, Laura E.
Egeler, R. Maarten
Rollins, Barrett J.
TI MAP2K1 and MAP3K1 Mutations in Langerhans Cell Histiocytosis
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID PROTEIN-KINASE; MEK KINASE; BRAF; ACTIVATION; IDENTIFICATION;
PATHOGENESIS; INHIBITION; EXPRESSION; RESISTANCE; DISEASE
AB Langerhans cell histiocytosis (LCH) is now understood to be a neoplastic disease in which over 50% of cases have somatic activating mutations of BRAF. However, the extracellular signal-related (ERK) pathway is activated in all cases including those with wild type BRAF alleles. Here, we applied a targeted massively parallel sequencing panel to 30 LCH samples to test for the presence of additional genetic alterations that might cause ERK pathway activation. In 20 BRAF wild type samples, we found 3 somatic mutations in MAP2K1 (MEK1) including C121S and C121S/G128D in the kinase domain, and 56_61QKQKVG>R, an in-frame deletion in the N-terminal regulatory domain. All three variant proteins constitutively phosphorylated ERK in in vitro kinase assays. The C121S/G128D and 56_61QKQKVG>R variants were resistant to the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib in vitro. Within the entire sample set, we found 3 specimens with mutations in MAP3K1 (MEKK1), including two truncation mutants, T779fs and T1481fs; T1481fs encoded an unstable and nonfunctional protein when expressed in vitro. T779fs was present in a specimen carrying BRAF V600E. The third variant was a single nucleotide substitution, E1286V, which was fully functional and is likely a germline polymorphism. These results indicate that LCH cells can harbor additional genetic alterations in the RAS-RAF-MEK pathway which, in the case of MAP2K1, may be responsible for ERK activation in a wild type BRAF setting. The resistance of some of these variants to trametinib may also have clinical implications for the combined use of RAF and MEK inhibitors in LCH. (c) 2015 Wiley Periodicals, Inc.
C1 [Nelson, David S.; Patel, Bhumi; Badalian-Very, Gayane; Rollins, Barrett J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[van Halteren, Astrid; Quispel, Willemijn T.] Leiden Univ, Med Ctr, Immunol Lab, Willem Alexander Childrens Hosp, Leiden, Netherlands.
[van den Bos, Cor] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands.
[Bovee, Judith V. M. G.] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands.
[Badalian-Very, Gayane; Rollins, Barrett J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Badalian-Very, Gayane; MacConaill, Laura E.; Rollins, Barrett J.] Harvard Univ, Sch Med, Boston, MA USA.
[van Hummelen, Paul; Ducar, Matthew; Lin, Ling; MacConaill, Laura E.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[MacConaill, Laura E.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Egeler, R. Maarten] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada.
RP Rollins, BJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM barrett_rollins@dfci.harvard.edu
OI Bovee, Judith/0000-0003-1155-0481
FU Histiocytosis Association; Team Ippolittle/Deloitte of the Boston
Marathon Jimmy Fund Walk; Stichting Kaarsjes voor Juultje; Say Yes to
Education foundation
FX Supported by: Histiocytosis Association, Team Ippolittle/Deloitte of the
Boston Marathon Jimmy Fund Walk, Stichting 1000 Kaarsjes voor Juultje,
the Say Yes to Education foundation, and Mr. George Weiss.
NR 27
TC 28
Z9 29
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD JUN
PY 2015
VL 54
IS 6
BP 361
EP 368
DI 10.1002/gcc.22247
PG 8
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA CG4DB
UT WOS:000353231400003
PM 25899310
ER
PT J
AU Cunningham, R
Murray, A
Byrne, JS
Hammond, L
Barry, M
Mehigan, D
Sheehan, S
AF Cunningham, R.
Murray, A.
Byrne, J. S.
Hammond, L.
Barry, M.
Mehigan, D.
Sheehan, S.
TI Venous thromboembolism prophylaxis guideline compliance: a pilot study
of augmented medication charts
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE Deep venous thrombosis; Venous thromboembolism; Low molecular weight
heparin; Preventable hospital deaths
ID FATAL PULMONARY-EMBOLISM; PREVENTION; NECROPSY; RISK
AB Venous thromboembolism (VTE) is a common complication of hospital admission. The incidence of hospital-acquired deep vein thrombosis is approximately 10-40 % amongst medical and general surgical patients without prophylaxis. Pulmonary embolism accounts for 5-10 % of deaths in hospitalised patients, making hospital-acquired VTE the most common preventable cause of in-hospital death. Studies suggest that prophylactic measures are widely under- and inappropriately used.
We hypothesised that the introduction of a medication chart with a dedicated VTE prophylaxis section would improve compliance with local guidelines.
Trial medication charts were piloted over a 4-week period in one surgical and two medical wards. Data on compliance with hospital guidelines were collected before and after introduction using a detailed chart review. The difference in prescribing compliance was assessed with the Chi-squared test.
70 patients were assessed before and 38 after the introduction of the new charts. Initially, only 58.6 % (n = 41) of patients' prescriptions were in compliance with local guidelines. In 28.6 % (n = 20) of patients, VTE prophylaxis was needed and not prescribed. 7.1 % (n = 5) of patients were prescribed an inappropriately low dose of low molecular weight heparin (LMWH) prophylaxis. 2.9 % (n = 2) of patients were prescribed inappropriately high dose of LMWH prophylaxis. After introduction of the new medication chart, compliance with guidelines rose to 71 % (n = 27, p = 0.09).
Compliance with VTE guidelines is inadequate. Medication charts with specific sections on VTE assessment and prophylaxis may increase compliance with guidelines.
C1 [Cunningham, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Murray, A.] St James Hosp, Dublin 8, Ireland.
[Byrne, J. S.] Beaumont Hosp, Dublin 9, Ireland.
[Hammond, L.; Barry, M.; Mehigan, D.; Sheehan, S.] St Vincents Univ Hosp, Dublin 4, Ireland.
RP Cunningham, R (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM robbiecunningham@hotmail.com
NR 16
TC 2
Z9 3
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD JUN
PY 2015
VL 184
IS 2
BP 469
EP 474
DI 10.1007/s11845-014-1148-6
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CG3EL
UT WOS:000353160800035
PM 25023126
ER
PT J
AU Lee, J
Geyer, B
Naraghi, L
Kaafarani, HMA
Eikermann, M
Yeh, DD
Bajwa, EK
Cobb, JP
Raja, AS
AF Lee, Jarone
Geyer, Brian
Naraghi, Leily
Kaafarani, Haytham M. A.
Eikermann, Matthias
Yeh, D. Dante
Bajwa, Ednan K.
Cobb, J. Perren
Raja, Ali S.
TI Advanced imaging use in intensive care units has decreased, resulting in
lower charges without negative effects on patient outcomes
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Radiology use; Intensive care units; Resource use; Computed tomography
ID CRITICALLY-ILL PATIENTS; CT PULMONARY ANGIOGRAPHY; INTRAHOSPITAL
TRANSPORT; COMPUTED-TOMOGRAPHY; EMERGENCY-DEPARTMENT;
RADIATION-EXPOSURE; ULTRASOUND; IMPACT; RADIOGRAPHY; RADIOLOGY
AB Purpose: There has been both greater recognition and scrutiny of the increased use of advanced imaging. Our aim was to determine whether there has been a change over time in the use of computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) modalities in the intensive care units (ICUs).
Materials and Methods: A retrospective review of 75657 admissions to 20 ICUs was conducted. Results were analyzed with multivariate linear, negative binomial, and Poisson regressions. Primary outcomes were rates of use of CT, MRI, and US per 1000 ICU admissions every 6 months. Secondary outcomes were changes in radiology use associated with impacts on mortality, hospital length of stay (LOS), ICU LOS, and hospital charges.
Results: The rate of imaging use decreased by 13.5% between 2007 and 2011 (incidence rate ratio [IRR], 0.982; P < .001). Most of this decrease was by CTs (21.0%; IRR, 0.973; P < .001). Use of MRI decreased by 6.0% (IRR, 0.991; P = .04), whereas US increased by 18.9% (IRR, 1.012; P < .001). The charges associated with imaging decreased by $ 74 per ICU admission, which would save an estimated $ 1.2 million in charges during 2011. Decreased imaging was not associated with changes in mortality, hospital, and ICU LOS.
Conclusion: Advanced imaging use decreased for 5 years in the ICUs, resulting in decreased charges without negative effects on patient outcomes. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Lee, Jarone] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Lee, Jarone] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Lee, Jarone; Naraghi, Leily; Kaafarani, Haytham M. A.; Eikermann, Matthias; Yeh, D. Dante; Bajwa, Ednan K.; Cobb, J. Perren] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Geyer, Brian; Raja, Ali S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Geyer, Brian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Naraghi, Leily; Kaafarani, Haytham M. A.; Yeh, D. Dante] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[Eikermann, Matthias; Cobb, J. Perren] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bajwa, Ednan K.] Massachusetts Gen Hosp, Dept Pulm & Crit Care Med, Boston, MA 02114 USA.
RP Lee, J (reprint author), Massachusetts Gen Hosp, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM Lee.jarone@mgh.harvard.edu; bgeyer@partners.org; leily.n@aol.com;
Hkaafarani@partners.org; MEikermann@partners.org; DYeh2@partners.org;
ebajwa@partners.org; jpcobb@partners.org; asraja@partners.org
OI Lee, Jarone/0000-0002-4532-8523
NR 38
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD JUN
PY 2015
VL 30
IS 3
BP 460
EP 464
DI 10.1016/j.jcrc.2014.12.012
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA CG6HN
UT WOS:000353400100005
PM 25596998
ER
PT J
AU Tainter, CR
Wong, NL
Bittner, EA
AF Tainter, Christopher R.
Wong, Nelson L.
Bittner, Edward A.
TI Innovative strategies in critical care education
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Technology; Education; Medical education; Critical care; Intensive Care;
Innovation
ID CONTINUING MEDICAL-EDUCATION; SIMULATION-BASED EDUCATION;
EMERGENCY-MEDICINE; SOCIAL MEDIA; GENERATIONAL INFLUENCES; JOURNAL CLUB;
12 TIPS; ACCESS; PART; EXPERIENCE
AB The cadre of information pertinent to critical care medicine continues to expand at a tremendous pace, and we must adapt our strategies of medical education to keep up with the expansion. Differences in learners' characteristics can contribute to a mismatch with historical teaching strategies. Simulation is increasingly popular, but still far from universal. Emerging technology has the potential to improve our knowledge translation, but there is currently sparse literature describing these resources or their benefits and limitations. Directed strategies of assessment and feedback are often suboptimal. Even strategies of accreditation are evolving. This review attempts to summarize salient concepts, suggest resources, and highlight novel strategies to enhance practice and education in the challenging critical care environment. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Tainter, Christopher R.] Univ Calif San Diego, San Diego, CA 92109 USA.
[Wong, Nelson L.; Bittner, Edward A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Tainter, CR (reprint author), Univ Calif San Diego, 200 West Arbor Dr, San Diego, CA 92109 USA.
EM kittainter@gmail.com; nelsonlwong@gmail.com; ebittner@partners.org
OI Tainter, Christopher/0000-0002-9639-2795
NR 60
TC 4
Z9 4
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD JUN
PY 2015
VL 30
IS 3
BP 550
EP 556
DI 10.1016/j.jcrc.2015.02.001
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA CG6HN
UT WOS:000353400100022
PM 25702843
ER
PT J
AU Damgaard, C
Holmstrup, P
Van Dyke, TE
Nielsen, CH
AF Damgaard, C.
Holmstrup, P.
Van Dyke, T. E.
Nielsen, C. H.
TI The complement system and its role in the pathogenesis of periodontitis:
current concepts
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Review
DE biofilm; complement; humans; inflammation; periodontitis
ID GINGIVAL CREVICULAR FLUID; JOINT EFP/AAP WORKSHOP; INFLAMED HUMAN
GINGIVA; ORAL EPITHELIAL-CELLS; PORPHYROMONAS-GINGIVALIS;
TREPONEMA-DENTICOLA; TANNERELLA-FORSYTHIA; FACTOR-H; JUVENILE
PERIODONTITIS; MEMBRANE ATTACK
AB Periodontitis is a highly prevalent inflammatory disease in tooth supporting tissues, induced by bacteria growing in a biofilm on tooth surfaces. Components of the complement system are present in the periodontal tissue and the system is activated in periodontitis. Continuous complement activation and modulation by bacteria within the biofilm in periodontal pockets, however, may enhance local tissue destruction, providing the biofilm with both essential nutrients and space to grow. A more profound understanding of the mechanisms involved in complement-derived tissue degradation may facilitate the development of new treatment concepts for periodontitis. Further studies on the role of complement in periodontitis pathogenesis may also contribute to the understanding of why some individuals fail to resolve periodontitis. Here, we review evidence that links complement to the pathogenesis of periodontitis with an emphasis on interaction of complement with bacteria from periodontitis-associated biofilm.
C1 [Damgaard, C.; Holmstrup, P.; Nielsen, C. H.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Odontol, Sect Periodontol Microbiol & Community Dent, DK-2200 Copenhagen, Denmark.
[Damgaard, C.; Nielsen, C. H.] Copenhagen Univ Hosp, Dept Infect Dis & Rheumatol, Inst Inflammat Res, Rigshosp, Copenhagen, Denmark.
[Damgaard, C.; Van Dyke, T. E.] Forsyth Inst, Dept Appl Oral Sci, Ctr Periodontol, Cambridge, MA USA.
RP Damgaard, C (reprint author), Univ Copenhagen, Fac Hlth & Med Sci, Dept Odontol, Sect Periodontol Microbiol & Community Dent, Norre Alle 20, DK-2200 Copenhagen, Denmark.
EM chrd@sund.ku.dk
OI Damgaard, Christian/0000-0003-2394-746X
FU Research Account, Danish Dental Association
FX This study was supported by a grant from the Research Account, Danish
Dental Association.
NR 136
TC 4
Z9 4
U1 0
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3484
EI 1600-0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2015
VL 50
IS 3
BP 283
EP 293
DI 10.1111/jre.12209
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CG7VE
UT WOS:000353513000001
PM 25040158
ER
PT J
AU Mize, TW
Sundararaj, KP
Leite, RS
Huang, Y
AF Mize, T. W.
Sundararaj, K. P.
Leite, R. S.
Huang, Y.
TI Increased and correlated expression of connective tissue growth factor
and transforming growth factor beta 1 in surgically removed periodontal
tissues with chronic periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE connective tissue growth factor; gene expression; growth factors;
periodontitis; transforming growth factor beta 1
ID INDUCED GINGIVAL OVERGROWTH; CREVICULAR FLUID; TGF-BETA; FIBROBLASTS;
DISEASE; CELLS; CYCLOSPORINE; INFLAMMATION; MACROPHAGE; CYTOKINES
AB Background and ObjectiveBoth gingival tissue destruction and regeneration are associated with chronic periodontitis, although the former overwhelms the latter. Studies have shown that transforming growth factor beta 1 (TGF-1), a growth factor largely involved in tissue regeneration and remodeling, is upregulated in chronic periodontitis. However, the gingival expression of connective tissue growth factor (CTGF or CCN2), a TGF-1-upregulated gene, in patients with periodontitis remains undetermined. Although both CTGF/CCN2 and TGF-b1 increase the production of extracellular matrix, they have many different biological functions. Therefore, it is important to delineate the impact of periodontitis on gingival CTGF/CCN2 expression.
Material and MethodsPeriodontal tissue specimens were collected from seven individuals without periodontitis (group 1) and from 14 with periodontitis (group 2). The expression of CTGF and TGF1mRNAs were quantified using real-time PCR.
ResultsAnalysis using the nonparametric Mann-Whitney U-test showed that the levels of expression of both CTGF/CCN2 and TGF1 mRNAs were significantly increased in individuals with periodontitis compared with individuals without periodontitis. Furthermore, analysis using a nonparametric correlation (Spearman r) test showed a positive correlation between TGF1 and CTGF/CCN2mRNAs.
ConclusionThe gingival expression levels of CTGF/CCN2 and TGF1mRNAs in individuals with periodontitis are upregulated and correlated.
C1 [Mize, T. W.; Leite, R. S.] Med Univ S Carolina, Div Periodont, James B Edwards Coll Dent Med, Charleston, SC 29425 USA.
[Sundararaj, K. P.; Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Coll Med, Charleston, SC 29425 USA.
[Leite, R. S.] James B Edwards Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC USA.
[Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29425 USA.
EM huangyan@musc.edu
FU NIH [DE016353]; Biomedical Laboratory Research and Development Program
of the Department of Veterans Affairs
FX This work was supported by NIH grant DE016353 and Merit Review Grant
from the Biomedical Laboratory Research and Development Program of the
Department of Veterans Affairs (to Y.H.).
NR 27
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3484
EI 1600-0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2015
VL 50
IS 3
BP 315
EP 319
DI 10.1111/jre.12208
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CG7VE
UT WOS:000353513000003
PM 25040058
ER
PT J
AU White, PJ
Mitchell, PL
Schwab, M
Trottier, J
Kang, JX
Barbier, O
Marette, A
AF White, Phillip J.
Mitchell, Patricia L.
Schwab, Michael
Trottier, Jocelyn
Kang, Jing X.
Barbier, Olivier
Marette, Andre
TI Transgenic omega-3 PUFA enrichment alters morphology and gene expression
profile in adipose tissue of obese mice: Potential role for protectins
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Omega-3 PUFA; Adipose; Obesity; Microarray; Protectins
ID POLYUNSATURATED FATTY-ACIDS; ACTIVATED-RECEPTOR-GAMMA; MESSENGER-RNA
EXPRESSION; DIET-INDUCED OBESITY; INSULIN SENSITIVITY; DOCOSAHEXAENOIC
ACID; TYROSINE-PHOSPHATASE; FISH-OIL; TRIENE PROSTAGLANDINS;
EICOSAPENTAENOIC ACID
AB Objective. Dietary administration of omega-3 polyunsaturated fatty acids (PUFA) is often associated with altered adipose tissue (AT) morphology and/or function in obese mice. Yet, it is unclear whether this is an indirect consequence of reduced weight gain or results from direct actions of omega-3 PUFA. Here we studied the AT of high fat (HF)-fed fat-1 transgenic mice that convert endogenous omega-6 to omega-3 PUFA while maintaining equivalent fat accretion as their wild-type (WT) counterparts.
Materials and methods. Adipocyte size profiling, Affymetrix microarray pathway analysis, qPCR and protectin identification and analysis were performed in epididymal AT from hemizygous fat-1(+/-) mice and their wild type littermates that had been fed a HF diet for 8 weeks from 6 Weeks of age.
Results. Despite equivalent fat pad mass, we found that epididymal AT from HF-fed transgenic animals possesses fewer large and very large but more mid-size adipocytes compared to WT mice. In order to better understand the underlying mechanisms contributing to the observed alteration in adipocyte size we performed an Affymetrix microarray. Pathway analysis of these data highlighted adipogenesis, cholesterol biosynthesis, insulin signaling, prostaglandin synthesis/regulation and small ligand GPCRs as points where differentially expressed genes were significantly overrepresented. Observed changes were confirmed for four candidate genes: Cnr1, Cnr2, Faah and Pparg by qPCR. Finally we demonstrated that protectin DX is present in AT and that protectin DX and protectin D1 promote comparable PPAR gamma transcriptional activity.
Conclusions. These data provide unprecedented evidence that omega-3 PUFA coordinately regulate AT gene expression programs in a manner that is independent of restriction of weight gain or fat accrual and highlight an important influence of omega-3 PUFA on adipogenesis. Furthermore we provide primary evidence suggesting that protectins likely contribute to these effects via their influence on PPAR gamma. (C) 2015 Published by Elsevier Inc.
C1 [White, Phillip J.; Mitchell, Patricia L.; Schwab, Michael; Marette, Andre] Univ Laval, Quebec Heart & Lung Inst, Dept Med, Ste Foy, PQ, Canada.
[White, Phillip J.; Mitchell, Patricia L.; Schwab, Michael; Marette, Andre] Laval Univ Hosp, Res Ctr, Metab Vasc & Renal Hlth Axis, Ste Foy, PQ, Canada.
[Trottier, Jocelyn; Barbier, Olivier] Univ Laval, CHU Quebec Res Ctr, Mol Pharmacol Lab, Quebec City, PQ, Canada.
[Trottier, Jocelyn; Barbier, Olivier] Univ Laval, Fac Pharm, Quebec City, PQ, Canada.
[Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA.
[Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA.
RP Marette, A (reprint author), Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Pavillon Marguerite dYouville,Bur Y4340, Ste Foy, PQ G1V 4G5, Canada.
EM Andre.Marette@crchul.ulaval.ca
OI White, Phillip/0000-0002-0957-425X
FU Canadian Diabetes Association; CFI; CIHR; Fonds de la Recherche en Sante
du Quebec; Training Program in Obesity at Laval University
FX This work was supported by grants from the Canadian Diabetes Association
to AM, and grants from CFI and CIHR to OB. AM is the holder of a
CIHR/Pfizer research Chair in the pathogenesis of insulin resistance and
cardiovascular diseases. OB is supported by a new investigator grant
from the CIHR. PJW is the recipient of a PhD studentship from the Fonds
de la Recherche en Sante du Quebec. PLM is the recipient of a
Post-doctoral fellowship from the Training Program in Obesity at Laval
University.
NR 60
TC 14
Z9 16
U1 3
U2 16
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD JUN
PY 2015
VL 64
IS 6
BP 666
EP 676
DI 10.1016/j.metabol.2015.01.017
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CG7ZW
UT WOS:000353527400003
PM 25726444
ER
PT J
AU Ribeiro, KB
Degar, B
Antoneli, CBG
Rollins, B
Rodriguez-Galindo, C
AF Ribeiro, Karina Braga
Degar, Barbara
Gianotti Antoneli, Celia Beatriz
Rollins, Barrett
Rodriguez-Galindo, Carlos
TI Ethnicity, Race, and Socioeconomic Status Influence Incidence of
Langerhans Cell Histiocytosis
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE children; epidemiology; health disparities; langerhans cell
histiocytosis
ID SURVIVAL RATES; UNITED-STATES; CHILDHOOD; CHILDREN; LEUKEMIA;
EPIDEMIOLOGY; INFECTION
AB BackgroundLangerhans cell histiocytosis (LCH) is a rare disease, and its etiology is not well understood. Population-based studies may contribute to etiologic research by defining incidence patterns. This study was designed to evaluate the descriptive epidemiology of disseminated LCH in the United States, using data from population-based cancer registries.
ProcedureWe analyzed the incidence and survival of disseminated LCH in children and adolescents (0-19 years) from 18 SEER registries during 2000-2009. Age-standardized incidence rates (ASIR) per million and rate ratios (RR) were calculated by gender, race, ethnicity, age, and socioeconomic variables (crowding, rural/urban, education, and poverty) using the SEER*Stat software 8.0.1. Relative survival (RS) estimates were calculated using Ederer II method.
ResultsOne hundred forty-five cases of disseminated LCH were recorded; ASIR was 0.70/million per year. Lower ASIR was observed for blacks (vs. whites) (RR=0.41, 95% CI 0.18-0.81), while higher ASIR was noted for Hispanics (vs. non-Hispanics) (RR=1.63, 95% CI 1.15-2.29). Risk of LCH was higher in crowded counties (RR=1.84, 95% CI 1.31-2.58) and also in areas with low educational level (RR=1.49, 95% CI 1.02-2.22). Five-year relative survival was 90.0% (95% CI 83.0-94.2). Important differences in survival were noted according to gender (male: RS=96.0 vs. female: RS=83.4%, P=0.029) and age (<1 year: RS=78.5, 1-4 years: RS=95.6%, 5-19 years: RS=100%, P=0.004).
ConclusionsThis population-based study shows significant variations in the incidence of disseminated LCH by race and ethnic group, as well as the influence of socioeconomic factors. These data may provide clues to causation and point toward the need for analytical epidemiologic studies. Pediatr Blood Cancer 2015;62:982-987. (c) 2015 Wiley Periodicals, Inc.
C1 [Ribeiro, Karina Braga] Fac Ciencias Med Santa Casa de Sao Paulo, Dept Social Med, Sao Paulo, Brazil.
[Degar, Barbara; Rodriguez-Galindo, Carlos] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02215 USA.
[Gianotti Antoneli, Celia Beatriz] Univ Santo Amaro UNISA, Sao Paulo, Brazil.
[Rollins, Barrett] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Degar, Barbara; Rollins, Barrett; Rodriguez-Galindo, Carlos] Harvard Univ, Sch Med, Boston, MA USA.
RP Rodriguez-Galindo, C (reprint author), Dana Farber Boston Childrens Canc & Blood Disorde, 450 Brookline Ave D3-133, Boston, MA 02215 USA.
EM carlos_rodriguez-galindo@dfci.harvard.edu
RI Antoneli, Celia/P-5133-2015
OI Antoneli, Celia/0000-0003-1106-9751
NR 32
TC 6
Z9 6
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2015
VL 62
IS 6
BP 982
EP 987
DI 10.1002/pbc.25404
PG 6
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA CG4DC
UT WOS:000353231500011
PM 25586293
ER
PT J
AU Huang, A
Chang, C
Thomas, B
MacMahon, P
Palmer, W
AF Huang, Ambrose J.
Chang, Connie Y.
Thomas, Bijoy J.
MacMahon, Peter J.
Palmer, William E.
TI Using cone-beam CT as a low-dose 3D imaging technique for the
extremities: initial experience in 50 subjects
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Computed tomography; Cone-beam computed tomography; Radiation dose;
Fracture; Hardware; Artifact
ID COMPUTED-TOMOGRAPHY; FLAT-PANEL; RADIATION; CBCT; NOISE; RADIOGRAPHY;
RELIABILITY; REDUCTION; ARTIFACTS; SYSTEM
AB To prospectively evaluate a dedicated extremity cone-beam CT (CBCT) scanner in cases with and without orthopedic hardware by (1) comparing its imaging duration and image quality to those of radiography and multidetector CT (MDCT) and (2) comparing its radiation dose to that of MDCT.
Written informed consent was obtained for all subjects for this IRB-approved, HIPAA-compliant study. Fifty subjects with (1) fracture of small bones, (2) suspected intraarticular fracture, (3) fracture at the site of complex anatomy, or (4) a surgical site difficult to assess with radiography alone were recruited and scanned on an extremity CBCT scanner prior to FDA approval. Same-day radiographs were performed in all subjects. Some subjects also underwent MDCT within 1 month of CBCT. Imaging duration and image quality were compared between CBCT and radiographs. Imaging duration, effective radiation dose, and image quality were compared between CBCT and MDCT.
Fifty-one CBCT scans were performed in 50 subjects. Average imaging duration was shorter for CBCT than radiographs (4.5 min vs. 6.6 min, P = 0.001, n = 51) and MDCT (7.6 min vs. 10.9 min, P = 0.01, n = 7). Average estimated effective radiation dose was less for CBCT than MDCT (0.04 mSv vs. 0.13 mSv, P = 0.02, n = 7). CBCT images yielded more diagnostic information than radiographs in 23/51 cases and more diagnostic information than MDCT in 1/7 cases, although radiographs were superior for detecting hardware complications.
CBCT performs high-resolution imaging of the extremities using less imaging time than radiographs and MDCT and lower radiation dose than MDCT.
C1 [Huang, Ambrose J.; Chang, Connie Y.; Palmer, William E.] Massachusetts Gen Hosp, Div Musculoskeletal Imaging & Intervent, Dept Radiol, Boston, MA 02114 USA.
[Thomas, Bijoy J.] Univ Coll Med Sci, Dept Radiol, Bhairahawa, Nepal.
[MacMahon, Peter J.] Mater Misericordiae Univ Hosp, Dept Radiol, Dublin 7, Ireland.
RP Huang, A (reprint author), Massachusetts Gen Hosp, Div Musculoskeletal Imaging & Intervent, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM ajhuang@mgh.harvard.edu
NR 51
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
EI 1432-2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD JUN
PY 2015
VL 44
IS 6
BP 797
EP 809
DI 10.1007/s00256-015-2105-9
PG 13
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA CG4ED
UT WOS:000353235100004
PM 25652734
ER
PT J
AU Sampath, SC
Sampath, SC
Rosenthal, DI
AF Sampath, Srihari C.
Sampath, Srinath C.
Rosenthal, Daniel I.
TI Serially recurrent osteoid osteoma
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Osteoid osteoma; Radiofrequency; Ablation; Recurrence; Pediatric
ID PERCUTANEOUS RADIOFREQUENCY ABLATION; OPERATIVE TREATMENT; BONE; BENIGN;
CT; OSTEOBLASTOMA; COAGULATION; DIAGNOSIS; TUMOR; NIDUS
AB Osteoid osteoma is a relatively common, benign, painful tumor of bone. It is widely believed to run a course culminating in spontaneous regression. The tumor can usually be eliminated by excision or ablation, although it may recur locally. Although management has classically been surgical, thermocoagulation via percutaneously delivered radiofrequency energy has demonstrated excellent results, typically resulting in durable response following a single treatment. Here, we present an unusual case of serially recurrent pathologically proven pediatric osteoid osteoma, treated by radiofrequency ablation five times over the course of 11 years. Limitations of RF ablation of osteoid osteoma and possible factors predisposing to incomplete treatment or recurrence are discussed.
C1 [Sampath, Srihari C.; Sampath, Srinath C.; Rosenthal, Daniel I.] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02113 USA.
[Sampath, Srihari C.; Sampath, Srinath C.] Novartis Res Fdn, Genom Inst, Dept Genet Musculoskeletal Biol & Bioimaging, San Diego, CA USA.
RP Rosenthal, DI (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02113 USA.
EM dirosenthal@partners.org
NR 42
TC 2
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
EI 1432-2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD JUN
PY 2015
VL 44
IS 6
BP 875
EP 881
DI 10.1007/s00256-014-2061-9
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA CG4ED
UT WOS:000353235100014
PM 25503857
ER
PT J
AU Lytle, MC
De Luca, SM
Blosnich, JR
Brownson, C
AF Lytle, Megan C.
De Luca, Susan M.
Blosnich, John R.
Brownson, Chris
TI Associations of racial/ethnic identities and religious affiliation with
suicidal ideation among lesbian, gay, bisexual, and questioning
individuals
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Suicidal ideation; LGBT; Race/ethnicity; Religious affiliation
ID UNITED-STATES 1991-1992; COLLEGE-STUDENTS; MENTAL-HEALTH; YOUNG-ADULTS;
INTERSECTING IDENTITIES; SEXUAL ORIENTATION; AFRICAN-AMERICAN; USE
DISORDERS; RISK-FACTORS; SELF-HARM
AB Background: Our aim was to examine the associations of racial/ethnic identity and religious affiliation with suicidal ideation among lesbian, gay, bisexual, and questioning (LGBQ) and heterosexual college students. An additional aim was to determine the prevalence of passive suicidal ideation (i.e., death ideation) and active suicidal ideation among culturally diverse LGBQ individuals.
Methods: Data from the National Research Consortium probability-based sample of college students from 70 postsecondary institutions (n=24,626) were used to examine active and passive suicidal ideation in the past 12-months and lifetime active suicidal ideation among students by sexual orientation, racial/ethnic identity, and religious affiliation.
Results: Across most racial/ethnic groups and religious affiliations. LGBQ students were more likely to report active suicidal ideation than non-LGBQ individuals. Among LGBQ students, Latino individuals had lower odds of reporting both past 12-month passive and active suicidal ideation than their non-Hispanic white LGBQ counterparts. Compared to Christian LGBQ students, Agnostic/Atheist LGBQ individuals had greater odds of reporting past 12-month passive suicidal ideation, and Jewish LGBQ students were less likely to endorse past 12-month passive and active suicidal ideation.
Limitations: Cross-sectional design and self-reported data.
Conclusions: Results corroborate previous research showing elevated prevalence of suicidal ideation among LGBQ individuals in comparison to their heterosexual counterparts. These findings are among the first to document prevalence differences within the LGBQ population based on intersectional identities (race/ethnicity and religious affiliation). Providers should recognize that LGBQ individuals might need support in negotiating the complex relationship between multiple identities, especially due to their elevated prevalence of suicidal ideation. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lytle, Megan C.] Univ Rochester, Dept Psychiat, Med Ctr, Rochester, NY 14642 USA.
[De Luca, Susan M.] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA.
[Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Brownson, Chris] Univ Texas Austin, Counseling & Mental Hlth Ctr, Austin, TX 78712 USA.
RP Lytle, MC (reprint author), Univ Rochester, Dept Psychiat, Med Ctr, 300 Crittcndcn Blvd, Rochester, NY 14642 USA.
EM megan_lytle@unnc.rochester.edu
FU National Institute of Mental Health [5T32MH020061]; University of
Rochester CTSA from the National Center for Advancing Translational
Sciences of the National Institutes of Health [KL2TR000095]
FX The project described in this publication was supported partially by
postdoctoral fellowships to Megan C. Lytle and John Blosnich in an
Institutional National Research Service Award from the National
Institute of Mental Health (5T32MH020061). Dr. Lytle has also received
support front the University of Rochester CTSA Award number KL2TR000095
from the National Center for Advancing Translational Sciences of the
National Institutes of Health. The opinions expressed in this work are
those of the authors and do not necessarily represent those of the
finders, institutions, the Department of Veterans Affairs, or the U.S.
Government.
NR 50
TC 1
Z9 1
U1 4
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD JUN 1
PY 2015
VL 178
BP 39
EP 45
DI 10.1016/j.jad.2014.07.039
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CF7DO
UT WOS:000352716600007
PM 25795534
ER
PT J
AU Arnold, JG
Salcedo, S
Ketter, TA
Calabrese, JR
Rabideau, DJ
Nierenberg, AA
Bazan, M
Leon, AC
Friedman, ES
Iosifescu, D
Sylvia, LG
Ostacher, M
Thase, M
Reilly-Harrington, NA
Bowden, CL
AF Arnold, Jodi Gonzalez
Salcedo, Stephanie
Ketter, Terrence A.
Calabrese, Joseph R.
Rabideau, Dustin J.
Nierenberg, Andrew A.
Bazan, Melissa
Leon, Andrew C.
Friedman, Edward S.
Iosifescu, Dan
Sylvia, Louisa G.
Ostacher, Michael
Thase, Michael
Reilly-Harrington, Noreen A.
Bowden, Charles L.
TI An exploratory study of responses to low-dose lithium in African
Americans and Hispanics
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Hispanics; African Americans; Health disparities;
Lithium; Treatment outcome
ID BIPOLAR-I-DISORDER; MENTAL-HEALTH; DOUBLE-BLIND; LOW-INCOME; STEP-BD;
DEPRESSION; OUTCOMES; TRIAL; SCALE; QUESTIONNAIRE
AB Objectives: Few prospective studies examine the impact of ethnicity or race on outcomes with lithium for bipolar disorder. This exploratory study examines differences in lithium response and treatment outcomes in Hispanics, African Americans, and non-Hispanic whites with bipolar disorder in the Lithium Treatment Moderate Dose Use Study (LiTMUS).
Methods: LiTMUS was a six-site randomized controlled trial of low-dose lithium added to optimized treatment (OPT; personalized, evidence-based pharmacotherapy) vs. OPT alone in outpatients with bipolar disorder. 01 283 participants, 47 African Americans, 39 Hispanics, and 175 non-Hispanic whites were examined. We predicted minority groups would have more negative medication attitudes and higher attrition rates, but better clinical outcomes.
Results: African Americans in the lithium group improved more on depression and life functioning compared to whites over the 6 month study. African Americans in the OPT only group had marginal improvement on depression symptoms. For Hispanics, satisfaction with life did not significantly improve in the OPT only group, in contrast to whites and African Americans who improved over time on all measures. Attitudes toward medications did not differ across ethnic/racial groups.
Conclusions: African Americans show some greater improvements with lithium than non-Hispanic whites, and Hispanics showed more consistent improvements in the lithium group. The impact of low-dose lithium should be studied in a larger sample as there may be particular benefit for African Americans and Hispanics. Given that the control group (regardless of ethnicity/race) had significant improvements, optimized treatment may be beneficial for any ethnic group. (C) 2015 Elsevier B.V. All rights reserved
C1 [Arnold, Jodi Gonzalez; Bazan, Melissa; Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Salcedo, Stephanie; Rabideau, Dustin J.; Nierenberg, Andrew A.; Leon, Andrew C.; Sylvia, Louisa G.; Reilly-Harrington, Noreen A.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA.
[Salcedo, Stephanie; Rabideau, Dustin J.; Nierenberg, Andrew A.; Leon, Andrew C.; Sylvia, Louisa G.; Reilly-Harrington, Noreen A.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA.
[Ketter, Terrence A.; Ostacher, Michael] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Calabrese, Joseph R.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Friedman, Edward S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Iosifescu, Dan] Mt Sinai Sch Med, New York, NY USA.
[Thase, Michael] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
RP Arnold, JG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
EM arnoldjg@uth.scsa.edu
OI Ostacher, Michael/0000-0003-0353-7535
FU U.S. federal grant [NO1MH80001]
FX NO1MH80001.; This U.S. federal grant provided the funds to conduct the
study.
NR 27
TC 1
Z9 1
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD JUN 1
PY 2015
VL 178
BP 224
EP 228
DI 10.1016/j.jad.2015.02.035
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CF7DO
UT WOS:000352716600030
ER
PT J
AU Frederick, N
Bober, S
Recklitis, C
Blackmon, J
AF Frederick, Natasha
Bober, Sharon
Recklitis, Christopher
Blackmon, Jaime
TI SEXUAL DYSFUNCTION IN YOUNG ADULT SURVIVORS OF CHILDHOOD CANCER
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Frederick, Natasha; Bober, Sharon; Recklitis, Christopher; Blackmon, Jaime] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2015
VL 62
SU 2
BP 25
EP 25
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA CF9BD
UT WOS:000352855600019
ER
PT J
AU Whagbo, J
Kim, H
Dusenbury, K
Reynolds, C
Chammas, M
Haining, W
Agarwal, S
Hofmann, I
Pai, SY
Lee, M
Margossian, S
Duncan, C
Lehmann, L
Ritz, J
AF Whagbo, Jennifer
Kim, Haesook
Dusenbury, Katharine
Reynolds, Carol
Chammas, Marie
Haining, William
Agarwal, Suneet
Hofmann, Inga
Pai, Sung-Yun
Lee, Michelle
Margossian, Steven
Duncan, Christine
Lehmann, Leslie
Ritz, Jerome
TI A PROSPECTIVE ANALYSIS OF IMMUNE RECONSTITUTION IN PEDIATRIC PATIENTS
UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Whagbo, Jennifer; Kim, Haesook; Dusenbury, Katharine; Reynolds, Carol; Chammas, Marie; Haining, William; Agarwal, Suneet; Hofmann, Inga; Pai, Sung-Yun; Lee, Michelle; Margossian, Steven; Duncan, Christine; Lehmann, Leslie; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2015
VL 62
SU 2
MA 527
BP 37
EP 37
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA CF9BD
UT WOS:000352855600058
ER
PT J
AU Frederick, N
Recklitis, C
AF Frederick, Natasha
Recklitis, Christopher
TI FATIGUE IN CHILDHOOD CANCER SURVIVORS: A REPORT FROM PROJECT REACH
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Frederick, Natasha; Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2015
VL 62
SU 2
MA 589
BP 55
EP 56
PG 2
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA CF9BD
UT WOS:000352855600120
ER
PT J
AU Xie, Q
Wu, QL
Mack, SC
Yang, KL
Kim, L
Hubert, CG
Flavahan, WA
Chu, CW
Bao, SD
Rich, JN
AF Xie, Qi
Wu, Qiulian
Mack, Stephen C.
Yang, Kailin
Kim, Leo
Hubert, Christopher G.
Flavahan, William A.
Chu, Chengwei
Bao, Shideng
Rich, Jeremy N.
TI CDC20 maintains tumor initiating cells
SO ONCOTARGET
LA English
DT Article
DE cancer stem cell; glioblastoma; glioma; tumor initiating cell; CDC20
ID CANCER STEM-CELLS; SPINDLE ASSEMBLY CHECKPOINT; SELF-RENEWAL;
GENE-EXPRESSION; HUMAN GLIOBLASTOMA; THERAPEUTIC TARGET;
COLORECTAL-CANCER; SMALL-INTESTINE; GROWTH-FACTOR; GLIOMA
AB Glioblastoma is the most prevalent and lethal primary intrinsic brain tumor. Glioblastoma displays hierarchical arrangement with a population of self-renewing and tumorigenic glioma tumor initiating cells (TICs), or cancer stem cells. While non-neoplastic neural stem cells are generally quiescent, glioblastoma TICs are often proliferative with mitotic control offering a potential point of fragility. Here, we interrogate the role of cell-division cycle protein 20 (CDC20), an essential activator of anaphase-promoting complex (APC) E3 ubiquitination ligase, in the maintenance of TICs. By chromatin analysis and immunoblotting, CDC20 was preferentially expressed in TICs relative to matched non-TICs. Targeting CDC20 expression by RNA interference attenuated TIC proliferation, self-renewal and in vivo tumor growth. CDC20 disruption mediated its effects through induction of apoptosis and inhibition of cell cycle progression. CDC20 maintains TICs through degradation of p21(CIP1/WAF1), a critical negative regulator of TICs. Inhibiting CDC20 stabilized p21(CIP1/WAF1), resulting in repression of several genes critical to tumor growth and survival, including CDC25C, c-Myc and Survivin. Transcriptional control of CDC20 is mediated by FOXM1, a central transcription factor in TICs. These results suggest CDC20 is a critical regulator of TIC proliferation and survival, linking two key TIC nodes -FOXM1 and p21(CIP1/WAF1) - elucidating a potential point for therapeutic intervention.
C1 [Xie, Qi; Wu, Qiulian; Mack, Stephen C.; Yang, Kailin; Kim, Leo; Hubert, Christopher G.; Flavahan, William A.; Chu, Chengwei; Bao, Shideng; Rich, Jeremy N.] Cleveland Clin, Dept Stem Cell Biol & Regenerat Med, Lerner Res Inst, Cleveland, OH 44195 USA.
[Yang, Kailin; Bao, Shideng; Rich, Jeremy N.] Case Western Reserve Univ, Dept Mol Med, Cleveland Clin Lerner Coll Med, Cleveland, OH 44195 USA.
[Flavahan, William A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Flavahan, William A.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
[Flavahan, William A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Flavahan, William A.] Broad Inst Harvard, Cambridge, MA 02142 USA.
[Flavahan, William A.] MIT, Cambridge, MA 02142 USA.
[Flavahan, William A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Chu, Chengwei] Kaohsiung Med Univ Hosp, Divis Neurosurg, Dept Surg, Kaohsiung 80756, Taiwan.
RP Rich, JN (reprint author), Cleveland Clin, Dept Stem Cell Biol & Regenerat Med, Lerner Res Inst, Cleveland, OH 44195 USA.
EM drjeremyrich@gmail.com
OI Yang, Kailin/0000-0001-5968-6738
FU National Institutes of Health [CA154130, CA171652, CA169117, NS087913,
NS089272, CA155764, NS070315]; Research Programs Committees of Cleveland
Clinic; James S. McDonnell Foundation
FX We would like to thank our funding sources: The National Institutes of
Health grants CA154130, CA171652, CA169117, NS087913, NS089272 (J. N.
R), CA155764 (C.H.) and NS070315 (S.B.), Research Programs Committees of
Cleveland Clinic (J. N. R), and James S. McDonnell Foundation (J.N.R).
NR 66
TC 11
Z9 11
U1 2
U2 5
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 30
PY 2015
VL 6
IS 15
BP 13241
EP 13254
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CO2TL
UT WOS:000359009400029
PM 25938542
ER
PT J
AU Yeh, RW
Elmariah, S
Doros, G
Kereiakes, DJ
Mauri, L
AF Yeh, Robert W.
Elmariah, Sammy
Doros, Gheorghe
Kereiakes, Dean J.
Mauri, Laura
TI Dual antiplatelet therapy duration and mortality Reply
SO LANCET
LA English
DT Letter
ID METAANALYSIS
C1 [Yeh, Robert W.; Elmariah, Sammy] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA 02138 USA.
[Yeh, Robert W.; Elmariah, Sammy; Doros, Gheorghe; Mauri, Laura] Harvard Clin Res Inst, Boston, MA USA.
[Doros, Gheorghe] Boston Univ, Boston, MA 02215 USA.
[Kereiakes, Dean J.] Christ Hosp Heart & Vasc Ctr, Lindner Res Ctr, Cincinnati, OH USA.
[Mauri, Laura] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc Med, Boston, MA 02115 USA.
RP Yeh, RW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA 02138 USA.
EM ryeh@partners.org
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 30
PY 2015
VL 385
IS 9983
BP 2149
EP 2150
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ6DG
UT WOS:000355583000021
PM 26068262
ER
PT J
AU McKay, D
Sookman, D
Neziroglu, F
Wilhelm, S
Stein, DJ
Kyrios, M
Matthews, K
Veale, D
AF McKay, Dean
Sookman, Debbie
Neziroglu, Fugen
Wilhelm, Sabine
Stein, Dan J.
Kyrios, Michael
Matthews, Keith
Veale, David
TI Efficacy of cognitive-behavioral therapy for obsessive-compulsive
disorder
SO PSYCHIATRY RESEARCH
LA English
DT Review
DE Obsessive-compulsive disorder; Exposure with response prevention;
Cognitive therapy; Meta-analysis; Treatment adherence
ID COMORBID MAJOR DEPRESSION; OVERVALUED IDEAS SCALE; FOLLOW-UP; INTRUSIONS
INVENTORY; RESPONSE PREVENTION; PSYCHOMETRIC VALIDATION; BELIEFS
QUESTIONNAIRE; INDIVIDUAL TREATMENT; ANXIETY DISORDERS; PATIENT
ADHERENCE
AB Cognitive-behavioral therapy (CBT), which encompasses exposure with response prevention (ERP) and cognitive therapy (CT), has demonstrated efficacy in the treatment of obsessive-compulsive disorder (OCD). However, the samples studied (reflecting the heterogeneity of OCD), the interventions examined (reflecting the heterogeneity of CBT), and the definitions of treatment response vary considerably across studies. This review examined the meta-analyses conducted on ERP and cognitive therapy (CT) for OCD. Also examined was the available research on long-term outcome associated with ERP and CT. The available research indicates that ERP is the first line evidence based psychotherapeutic treatment for OCD and that concurrent administration of cognitive therapy that targets specific symptom-related difficulties characteristic of OCD may improve tolerance of distress, symptom-related dysfunctional beliefs, adherence to treatment, and reduce drop out. Recommendations are provided for treatment delivery for OCD in general practice and other service delivery settings. The literature suggests that ERP and CT may be delivered in a wide range of clinical settings. Although the data are not extensive, the available research suggests that treatment gains following ERP are durable. Suggestions for future research to refine therapeutic outcome are also considered. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [McKay, Dean] Fordham Univ, Bronx, NY 10458 USA.
[Sookman, Debbie] McGill Univ, Dept Psychol, Ctr Hlth, Obsess Compuls Disorder Clin, Montreal, PQ, Canada.
[Sookman, Debbie] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
[Neziroglu, Fugen] Biobehav Inst, Great Neck, NY USA.
[Wilhelm, Sabine] Harvard Univ, Boston, MA 02115 USA.
[Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stein, Dan J.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Kyrios, Michael] Univ Melbourne, Melbourne, Vic, Australia.
[Matthews, Keith] Univ Dundee, Dundee, Scotland.
[Veale, David] South London & Maudsley NHS Fdn Trust, NIHR Specialist Biomed Res Ctr Mental Hlth, London, England.
[Veale, David] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
RP McKay, D (reprint author), Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
EM mckay@fordham.edu
RI Stein, Dan/A-1752-2008
OI Stein, Dan/0000-0001-7218-7810
NR 101
TC 5
Z9 6
U1 8
U2 41
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAY 30
PY 2015
VL 227
IS 1
BP 104
EP 113
DI 10.1016/j.psychres.2015.02.004
PG 10
WC Psychiatry
SC Psychiatry
GA CI8QS
UT WOS:000355037400016
PM 25937054
ER
EF